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Abstract
Cancer and Parkinson’s disease (PD) are two disorders for which the final pathophysio-
logical mechanism is not fully defined. Epidemiological data indicate that PD patients
have a decreased risk of cancer, with the exception of malignant melanoma, skin, thyroid
and breast cancers, suggesting a functional linkage between PD and cancer. In favour
of this, misregulation of mitochondria homeostasis is considered an important hallmark
in the pathogenesis of both diseases. Recently, several genes associated to PD, including
Parkin, LRRK2, DJ-1, or PINK1, have been proposed as modulators of cancer processes.
Mutations on PINK1 gene are associated with hereditary early-onset PD. PINK1 is a
protein kinase whose mRNA is up-regulated in several carcinoma cell lines and in PTEN
over-expressing cells. PINK1 protects cells against mitochondrial-mediated apoptosis, con-
trolling mitochondrial homeostasis through electron transport chain, mitochondrial mem-
brane potential, calcium homeostasis and ROS generation. Moreover, PINK1 together
with Parkin, has been associated to mitochondrial dynamics and mitophagy.
To define the putative role of PINK1 in cancer and Parkinson’s disease in relation
with the mitochondrial homeostasis, we present the analysis of apoptosis, mitochondrial
function, mitophagy and survival/proliferation processes on SH-SY5Y (human dopamin-
ergic cells) and MCF-7 (human breast cancer cells) cells over-expressing PINK1 wild-type
(wt), and missense (catalytically inactive mutation (K219M), some PD-linked mutations
(A168P, G309D, L347P and W437X) and truncated (∆C, ∆N and ∆N-C) mutations of
PINK1. Moreover, we examine the mRNA expression of PINK1 and PINK1-related genes
in breast cancer samples.
Our results demonstrate that PINK1 wt, but not missense or truncated mutations,
controls mitochondrial function and has an anti-apoptotic role in mitochondrial-mediated
apoptosis. In addition, PINK1 wt blocks tumourigenic processes such as invasion, anchorage-
independent growth, proliferation and cell cycle progression.
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Resumen
El ca´ncer y la enfermedad de Parkinson (PD) son dos enfermedades en las que el mecan-
ismo pato-fisiolo´gico final no esta´ completamente definido. Datos epidemiolo´gicos indican
que los pacientes con PD poseen bajo riesgo de ca´ncer, con la excepcio´n de melanoma
maligno y ca´nceres de piel, tiroides y mama, lo que sugiere una conexio´n funcional entre
PD y ca´ncer. Apoyando esta conexio´n, la desregulacio´n de la homeostasis mitocondrial es
una caracter´ıstica importante en la patoge´nesis de ambas enfermedades. Recientemente,
varios genes asociados a PD, tales como Parkin, LRRK2, DJ-1, y PINK1, han sido prop-
uestos como moduladores de procesos cancer´ıgenos. Mutaciones en el gen de PINK1 esta´n
asociadas con PD hereditaria de comienzo temprano. PINK1 es una quinasa de prote´ınas
cuyo mRNA esta´ expresado a altos niveles en varias l´ıneas celulares de carcinoma y en
ce´lulas que sobre-expresan PTEN. PINK1 protege a las ce´lulas de la apoptosis mediada
por la mitocondria, controlando la homeostasis mitocondrial a trave´s de la cadena de
transporte electro´nico, el potencial de membrana mitocondrial, la homeostasis del calcio
y la produccio´n de ROS. Adema´s, PINK1, junto con Parkin, ha sido asociado a procesos
de dina´mica mitocondrial y mitofagia.
Con objeto de definir la funcio´n de PINK1 en ca´ncer y la enfermedad de Parkinson,
en relacio´n con la homeostasis mitocondrial, presentamos el ana´lisis de procesos de apop-
tosis, funcio´n mitocondrial, mitofagia y supervivencia/proliferacio´n en ce´lulas SH-SY5Y
(ce´lulas dopamine´rgicas humanas) y MCF-7 (ce´lulas de carcinoma mamario humano) que
sobre-expresan PINK1 wild-type (wt) o mutaciones de cambio de aminoa´cido (mutacio´n
cataliticamente inactiva (K219M), mutaciones asociadas a PD (A168P, G309D, L347P y
W437X) o formas truncadas (∆C, ∆N y ∆N-C)) de PINK1. Adema´s, examinamos la ex-
presio´n del mRNA de PINK1 y de genes relacionados con PINK1 en muestras de tumores
de mama.
Nuestros resultados demuestran que PINK1 wt, pero no las mutaciones de cambio
de aminoa´cido o formas truncadas, controla la funcio´n mitocondrial y posee una funcio´n
anti-apopto´tica en la apoptosis mediada por la mitocondria. Adema´s, PINK1 wt blo-
quea procesos tumoroge´nicos tales como invasio´n, crecimiento independiente de anclaje,
proliferacio´n y progresio´n del ciclo celular.
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Prologue
PINK1 world between cancer and Parkinson’s disease
Nowadays, cancer and Parkinson’s disease are two common disorders for which the
population is worried about and where the essential molecular mechanism impaired is
not yet well known. Parkinson’s disease, first described by James Parkinson in 1817, is
the second most common neurodegenerative disease in elderly, affecting approximately 4%
of the population beyond age above 65 years. The major clinical symptoms of Parkinson’s
disease patients include resting tremor, rigidity and bradykinesia. This disease is caused
by pathological changes in the brain that implicate massive cell death with neuronal loss
and degeneration in several midbrain areas (such as the substantia nigra pars compacta,
the brain stem, the autonomic nervous system, some regions in the basal ganglia and the
cortex) and, thereby loose of the connection to the striatal neurons, like a blocked road
without connection between important cities of the country. This impairment in neu-
ronal transmission produces significative changes in emotional and motivation aspects of
behaviour and in normal movement body. One more important hallmark of Parkinson’s
disease is the deposition of proteinaceous inclusions, known as Lewy bodies, in the neu-
rons and the dendrites at the substantia nigra, like potholes in the cells that are still alive
[Schapira, 2006; Cookson, 2005].
Cancer, known as malignant neoplasm, is a wide group of various diseases, all involving
up-regulated cell growth. The earliest written record concerning cancer was made by
egiptians 3000 BC about breast cancer. Cancer is a cause of misregulated “crazy” dividing
cells that do not respond to stop proliferation signals nor to inducing apoptosis/cell death
stimuli.
Back in 1954 Doshay claimed cancer is rare in “paralysis agitans” [Doshay, 1954], and
a growing body of several epidemiological studies suggests that people with Parkinson’s
disease have a decreased risk of almost all cancers. In contrast, Parkinson’s disease patients
have a significant increased risk of malignant melanoma, skin, breast, and thyroid cancer
occurrence [Bajaj et al., 2010; Inzelberg and Jankovic, 2007]. Indeed, a PUBMED search
using the keywords “cancer” and “Parkinson’s disease” revealed over 2000 articles studying
the link between these two diseases, for the period between 1970 and August 2012.
What may account for this association?
The general idea that Parkinson’s disease provide “biologic protection” against some types
of cancer recently become true because common molecular pathways and genes have shown
to be essential in the progression of both diseases [Inzelberg and Jankovic, 2007]. Never-
theless, they represent two opposite forces within the cell, because Parkinson’s disease is
due to cell death and cancer is due to uncontrolled cell proliferation [Gao et al., 2009].
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At first, cancer and Parkinson’s disease were described as sporadic diseases mainly
caused by some environmental exposures such as pesticides or solvents. The oxidative
stress produced by toxins has been widely associated as a main cause of both diseases
[Green et al., 2002].
In the last two decades, since some genes were described associated to both diseases,
cancer and Parkinson’s disease research has been focused on the study of the molecular
mechanism modulated by these genetic factors. Expression alterations or mutations of
Parkinson’s disease associated-genes such as α-synuclein, Parkin, LRRK2, DJ-1 or PINK1
have been identified in a number of human cancers. Some of those genes are involved in
common disease pathways like cell cycle, apoptosis, mitochondria and oxidative stress, pro-
tein aggregation and degradation within the cellular body, survival/proliferation pathways
(PI3K/Akt and MAPKs pathways), etc. Indeed, recent papers have already concluded
that several of these genes, such as Parkin have clear and defined functions in the balance
of proliferation and cell death [Devine et al., 2011; West et al., 2005].
Who is PINK1? Possible connection between cancer and
Parkinson’s disease
One of the genes linked to Parkinson’s disease, PINK1 (PTEN Induced Kinase 1), has been
associated to cancer processes. Mutations on PINK1 gene are associated with hereditary
early-onset Parkinson’s disease [West et al., 2005]. PINK1 gene was discovered in 2001 as
a protein kinase whose mRNA is expressed at high levels in several carcinoma cell lines
and in PTEN (one of the major tumour suppressor proteins in humans) over-expressing
cells [Nakajima et al., 2003; Unoki and Nakamura, 2001]. Besides, several groups pointed
out PINK1 as a marker of survival prognosis in adenocarcinomas [de Reynie`s et al., 2009;
Fragoso et al., 2012].
PINK1 protein is associated to mitochondria (the power energy source of the cell)
promoting the mitochondrial health and optimising its function [Valente et al., 2004a; Gegg
et al., 2009]. PINK1 protects cells against mitochondrial-mediated apoptosis produced by
several cell death inducing agents [Petit et al., 2005; Beilina et al., 2005]. Moreover, PINK1
has been associated to survival/proliferative pathways (PI3K/Akt and MAPKs pathways),
which could be linked to cancer progression [Murata et al., 2011a,b].
PINK1 protein is likely to have more than one function (in apoptosis, mitochondria
homeostasis, survival and proliferation processes) and could potentially play different roles
in different diseases. Furthermore, PINK1 could undergo differential regulation depending
on the tissue environment. The balance of the PINK1 functional read-out could lead to
neurodegeneration or cell transformation, which could be important for future therapies
to fight Parkinson’s disease or cancer. Further studies need to be done to understand the
differential role of PINK1 in cancer and Parkinson’s disease.
Chapters to come
During my PhD thesis, I have worked with experts in both fields: cancer and Parkinson’s
disease. This thesis is my personal effort to explain the recent advances in the understand-
ing of PINK1 functions and its relation to the pathogenesis of both diseases.
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In Chapter 1, first we recapitulate the main evidences found for cancer and Parkin-
son’s disease connection and introduce the findings on PINK1 identification, regulation and
function. Lately, we include the literature describing the PINK1 implication in different
diseases such as cancer, Parkinson’s disease, diabetes and Alzheimer’s disease.
In Chapter 2, we emphasise the main objective of this thesis: to investigate how
PINK1 may control cellular homeostasis through mitochondrial quality control and its
pivotal role in two relevant human diseases: cancer and Parkinson’s disease. It is followed
by the methods and materials (Chapter 3) used in our study in SH-SY5Y and MCF-7
cultured cells and in human tissues. At the end of Chapter 3, we introduce the scheme
with all the missense and truncated mutations used in this study.
In Chapter 4, we present the study of PINK1 functions in SH-SY5Y cells as a Parkin-
son’s disease model. In particular, we show the implication of wild type PINK1 in mi-
tochondrial function through the ATP production by the electron transport chain, the
maintenance of the mitochondrial membrane potential, and control of oxidative stress.
Furthermore, we explore these processes with different PINK1 missense and truncated
mutations, showing disruption of these functions.
In Chapter 5, we study the possible implications of PINK1 on important tumourigenic
cancer processes such as invasion, adhesion, anchorage-independent cell growth, prolifera-
tion and cell cycle progression using MCF-7 breast cancer cells. We outline the control of
these processes by PINK1 and how PINK1 mutations or truncations affect them.
To follow with the possible cancer and Parkinson’s disease connection through PINK1
protein and other PINK1-related genes, we examine the expression of these genes in nor-
mal and neoplastic tissues in Chapter 6. Moreover, the cellular distribution of PINK1
is examined in these cultured cell models (i.e. SH-SY5Y and MCF-7) and in tissues
(Chapters 4, 5, and 6).
Finally we end up with the discussion of the results and future perspectives (Chapter 7)
as well as with the conclusions (Chapter 8) that come out from this thesis.
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Pro´logo
El mundo de PINK1 entre el ca´ncer y la enfermedad de
Parkinson
Hoy en d´ıa el ca´ncer y la enfermedad de Parkinson son dos enfermedades frecuentes que
preocupan a la poblacio´n y donde el mecanismo molecular esencial dan˜ado es desconocido.
La enfermedad de Parkinson se describio´ por primera vez por James Parkinson en 1817,
es la segunda enfermedad neurodegenerativa ma´s comu´n en edad avanzada, afectando
aproximadamente a un 4% de la poblacio´n por encima de los 65 an˜os de edad. Los prin-
cipales s´ıntomas de los pacientes con la enfermedad de Parkinson incluyen temblor en
posicio´n de reposo, rigidez y bradiquines´ıa o inestabilidad postural. La enfermedad es
causada por cambios patolo´gicos en el cerebro que implican la muerte masiva de neuronas
y la degeneracio´n de a´reas mesencefa´licas (como la parte compacta de la sustancia negra,
el tallo cerebral, el sistema nervioso auto´nomo, regiones en los ganglios basales y en la
corteza) y, por ello, la perdida de conexio´n con las neuronas del estriado, como una car-
retera bloqueada sin conexio´n entre ciudades importantes de un pa´ıs. Esta deficiencia en
la transmisio´n neuronal produce cambios significativos en los aspectos emocionales y de
motivacio´n del comportamiento, y en el movimiento normal del cuerpo.
Una caracter´ıstica ma´s importante de la enfermedad de Parkinson es la deposicio´n de
inclusiones proteicas, conocidas como cuerpos de Lewy, en las neuronas y dendritas de la
sustancia negra, como baches en las ce´lulas que au´n esta´n vivas [Schapira, 2006; Cookson,
2005].
El ca´ncer, conocido como neoplasia maligna, es un amplio grupo de enfermedades
diversas, que involucran todas ellas el aumento del crecimiento celular. El registro escrito
ma´s antiguo sobre ca´ncer fue hecho por los egipcios en el 3000 aC, en concreto sobre el
ca´ncer de mama. El ca´ncer es la causa de la divisio´n descontrolada “ loca” de las ce´lulas,
que no responden a las sen˜ales de parada de proliferacio´n ni a est´ımulos de induccio´n de
la apoptosis/muerte celular.
En 1954 Doshay afirmo´ que el ca´ncer es poco frecuente en “para´lisis agitante” [Doshay,
1954], y un nu´mero creciente de varios estudios epidemiolo´gicos sugieren que las personas
con enfermedad de Parkinson tienen un menor riesgo de casi todos los tipos de ca´ncer. Por
el contrario, los pacientes con enfermedad de Parkinson tienen un riesgo significativamente
mayor de incidencia de melanoma maligno, y de ca´ncer de mama, piel, y tiroides [Bajaj
et al., 2010; Inzelberg and Jankovic, 2007]. De hecho, una bu´squeda en PUBMED usando
las palabras clave “ ca´ncer” y “enfermedad de Parkinson” revelo´ ma´s de 2000 art´ıculos
que estudian la relacio´n entre estas dos enfermedades, para el per´ıodo comprendido entre
1970 y agosto de 2012.
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¿Que´ puede explicar esta asociacio´n?
La idea general de que la enfermedad de Parkinson puede proporcionar “proteccio´n biolo´gica”
contra algunos tipos de ca´ncer recientemente se ha convertido en un hecho cierto porque
se ha demostrado la existencia de v´ıas moleculares y genes comunes que son esenciales en
la progresio´n de ambas enfermedades [Inzelberg and Jankovic, 2007]. Sin embargo, rep-
resentan dos fuerzas alejadas opuestas dentro de la ce´lula debido a que la enfermedad de
Parkinson se debe a la muerte celular y el ca´ncer se debe a la proliferacio´n y supervivencia
celular descontrolada [Gao et al., 2009].
En un principio, el ca´ncer y la enfermedad de Parkinson se describieron como enfer-
medades espora´dicas causadas principalmente por algunas exposiciones ambientales como
pesticidas o disolventes. El estre´s oxidativo producido por toxinas ha sido ampliamente
asociado como una causa principal en ambas enfermedades [Green et al., 2002].
En las dos u´ltimas de´cadas, ya que algunos genes se han descrito asociados a ambas
enfermedades, la investigacio´n en ca´ncer y en la enfermedad de Parkinson se ha centrado en
el estudio del mecanismo molecular modulado por estos factores gene´ticos. Alteraciones
de expresio´n o mutaciones de los genes asociados a la enfermedad de Parkinson tales
como α-sinucle´ına, Parkina, LRRK2, DJ-1 o PINK1 se han identificado en un nu´mero
de ca´nceres humanos. Algunos de estos genes esta´n implicados en v´ıas comunes de la
enfermedad como ciclo celular, apoptosis, mitocondria y estre´s oxidativo, agregacio´n y
degradacio´n de prote´ınas dentro de la ce´lula, v´ıas de supervivencia/proliferacio´n (v´ıas
PI3K/Akt y MAPKs), etc.
De hecho, estudios recientes ya han concluido que varios de estos genes, como Parkina
tienen funciones claras y definidas en el equilibrio de la proliferacio´n y la muerte celular
[Devine et al., 2011; West et al., 2005].
¿Quie´n es PINK1? Posible conexio´n entre el ca´ncer y la
enfermedad de Parkinson
Uno de los genes ligados a la enfermedad de Parkinson, PINK1 (PTEN Induced Kinase
1), se ha asociado a los procesos de ca´ncer. Las mutaciones en el gen de PINK1 esta´n
asociadas con la enfermedad de Parkinson hereditario de comienzo temprano [West et al.,
2005]. El gen PINK1 fue descubierto en 2001, una quinasa de prote´ınas cuyo ARNm
se expresa en altos niveles en varias l´ıneas celulares de carcinoma y en ce´lulas que sobre
expresan PTEN (una de las principales prote´ınas supresoras de tumores en seres humanos)
[Nakajima et al., 2003; Unoki and Nakamura, 2001]. Adema´s, varios grupos han sen˜alado a
PINK1 como un marcador de prono´stico de supervivencia en adenocarcinomas [de Reynie`s
et al., 2009; Fragoso et al., 2012].
La prote´ına PINK1 esta´ asociada a la mitocondria (la fuente de energ´ıa de la ce´lula)
promoviendo la salud mitocondrial y optimizando su funcio´n [Gegg et al., 2009; Valente
et al., 2004a]. PINK1 protege a las ce´lulas contra la apoptosis mediada por la mitocondria
producida por varios agentes que inducen muerte celular [Petit et al., 2005; Beilina et al.,
2005]. Por otra parte, PINK1 se ha asociado a las v´ıas de supervivencia/proliferacio´n
(v´ıas PI3K/Akt y MAPKs), que podr´ıan estar relacionadas con la progresio´n del ca´ncer
[Murata et al., 2011a,b].
La prote´ına PINK1 probablemente tenga ma´s de una funcio´n (apoptosis, homeostasis
mitocondrial, supervivencia y procesos de proliferacio´n) y podr´ıa desempen˜ar diversas
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funciones en diferentes enfermedades. Adema´s, PINK1 podr´ıa regularse dependiendo del
entorno tisular. El balance de las funciones de PINK1 puede inducir neurodegeneracio´n o
transformacio´n celular, que podr´ıa ser importante para el desarrollo de futuras terapias,
para combatir la enfermedad de Parkinson o el ca´ncer. Nuevos estudios deben hacerse para
comprender el papel diferencial de PINK1 en el ca´ncer y la enfermedad de Parkinson.
Cap´ıtulos siguientes
Durante mi tesis doctoral, he trabajado con expertos en ambos campos: el ca´ncer y la
enfermedad de Parkinson. Esta tesis es mi esfuerzo personal para explicar los avances
recientes en la comprensio´n de la funciones de PINK1 y su relacio´n con la patoge´nesis de
ambas enfermedades.
En el cap´ıtulo 1, primero recapitulamos las principales evidencias encontradas para
la conexio´n entre el ca´ncer y la enfermedad de Parkinson e introducimos los hallazgos en
la identificacio´n, regulacio´n y funcio´n de PINK1. Por u´ltimo, se incluye la bibliograf´ıa
que describe la implicacio´n de PINK1 en diferentes enfermedades tales como el ca´ncer, la
enfermedad de Parkinson, la diabetes y la enfermedad de Alzheimer.
En el cap´ıtulo 2, hacemos hincapie´ en que el objetivo principal de esta tesis: la de in-
vestigar co´mo PINK1 puede controlar la homeostasis celular a trave´s del control de calidad
mitocondrial y su papel fundamental en dos enfermedades importantes: el ca´ncer humano
y la enfermedad de Parkinson. Le siguen los materiales y me´todos (cap´ıtulo 3) utilizados
en nuestro estudio en cultivos de ce´lulas SH-SY5Y y MCF-7 y en tejidos humanos. Al
final del cap´ıtulo 3, se presenta el esquema con todas las mutaciones puntuales y formas
truncadas de PINK1 utilizadas en este estudio.
En el cap´ıtulo 4, se presenta el estudio de las funciones de PINK1 en ce´lulas SH-SY5Y
como modelo de la enfermedad de Parkinson. En particular, se demuestra la implicacio´n
de PINK1 de tipo salvaje en la funcio´n mitocondrial a trave´s de la produccio´n de ATP
por la cadena de transporte de electrones, el mantenimiento del potencial de membrana
mitocondrial, y el control del estre´s oxidativo. Adema´s, se exploran estos procesos con
diferentes mutaciones puntuales y formas truncadas, mostrando alteracio´n de estas fun-
ciones.
En el cap´ıtulo 5 se estudian las posibles implicaciones de PINK1 en importantes
procesos de ca´ncer tumoroge´nesis como la invasio´n, adherencia, anclaje independiente de
crecimiento, proliferacio´n celular y la progresio´n del ciclo celular utilizando ce´lulas MCF-7
de ca´ncer de mama. Planteamos el control de estos procesos y co´mo las mutaciones
puntuales o formas truncadas pueden afectarlos.
Para seguir con la conexio´n entre el ca´ncer y la enfermedad de Parkinson, a trave´s de
la prote´ına PINK1 y de otros genes relacionados con PINK1, en el cap´ıtulo 6 se examina
la expresio´n de estos genes en los tejidos normales y neopla´sicos. Adema´s, la distribucio´n
celular de PINK1 se examina en estos modelos de cultivos celulares (es decir, SH-SY5Y y
MCF-7) y en los tejidos (cap´ıtulos 4, 5, y 6).
Por u´ltimo nos encontramos con la discusio´n de los resultados y perspectivas futuras
(cap´ıtulo 7), as´ı como con las conclusiones (cap´ıtulo 8) que se obtienen de esta tesis.
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1.1 Cancer and Parkinson’s disease
1.1.1 Parkison’s disease
Parkinson’s disease (PD, MIM 168600) is the second most common neurodegenerative
disorder of the elderly, affecting ∼4% of the population over the age of 65. It was first
described by James Parkinson in an 1817 monograph, “Essay on the Shaking Palsy”.
Patients typically present resting tremor, slow movements (bradykinesia), limb stiffness
(rigidity), and a shuﬄing gait. Many patients also suffer from autonomic, cognitive, and
psychiatric disturbances.
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1.1. Cancer and Parkinson’s disease
The major symptoms of PD result from the loss of monoaminergic neuron populations
in the brainstem, the most profound of which is a depletion of dopaminergic (DA) neurons
in the substantia nigra pars compacta (SNpc). Lewy bodies are intraneuronal inclusion
bodies composed of many proteins including heavily aggregated forms of a small protein,
α-synuclein.
Approximately 10-15% of patients with the typical clinical picture of PD have a positive
family history compatible with a Mendelian inheritance. In recent years, several new genes
and environmental factors have been implicated in PD, and their impact on DA neuronal
cell death is coming into focus. Table 1.1 shows the loci associated to PD described so
far [Cookson, 2005; Wood-Kaczmar et al., 2006; Lill et al., 2012].
The mutations of PD loci are present in proteins involved in protein quality control,
oxidative stress, and mitochondrial function, processes that are closely interlinked. Envi-
ronmental toxins used to model PD in animals similarly inhibit mitochondrial function,
increase formation of free radicals and, in some cases, cause protein aggregation. There-
fore, there is a strong link between mitochondrial dysfunction and PD pathology [Schapira,
2006, 2008; Kubo et al., 2006].
Mitochondria are essential organelles for aerobic metabolism present in all eukaryotic
cells. Mitochondria have a number of physiological roles within the cell including the gener-
ation of ATP through the electron transport chain, regulation of apoptosis, and the storage
and maintenance of intracellular calcium levels. Mitochondria are dynamic organelles and
via the processes of fission and fusion are capable of eliminate dysfunctional mitochondria
and remodel mitochondrial network within the cell. The mitochondria possess its own
genome (mtDNA) but is also dependent on proteins codified by nuclear genome. Mito-
chondria are composed of three structures: the outer mitochondrial membrane (OMM),
the inner mitochondrial membrane (IMM), and the matrix. The matrix contains the
mtDNA and the cristae protrude into it. The electron transport chain complexes are sit-
uated within the inner mitochondrial membrane. Electrons are transferred through these
complexes to the terminal electron acceptor O2. During this transfer a number of protons
are translocated across the inner mitochondrial membrane which establishes a proton gra-
dient and the mitochondrial membrane potential (∆Ψm). This potential is used by ATP
synthase to generate ATP and is also responsible for producing reactive oxygen species
(ROS) within the cell [Alberts et al., 2002b; Mathews et al., 2002].
Mitochondria are vulnerable organelles highly susceptible to damage from oxidative
phosphorylation, generation of ROS and damage to mtDNA. Therefore, neurons, which are
forced to high energy demands, are very susceptible to mitochondrial damage, connecting
to PD disease [Reeve et al., 2008].
1.1.2 Cancer
Cancer is a disease in which cells no longer respond to the environmental signals that
normally govern their behaviour in a tissue. Tumour cells grow and divide when they
should not, and fail to die when they should. They loose their attachments from the
tissue and spread to other tissues, a process known as metastasis. Cancer is a large and
complex group of related but distinct diseases, each with unique features that depends
on the biological characteristics of the cell type or tissue in which the disease originates
(Figure 1.1).
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Figure 1.1: Cancer is a complex disease. The intracellular signalling circuitry
and collaboration between cancer-associated genes are displayed here. The growth-
promoting, mitogenic circuit (light red), the circuit governing growth-inhibitory signal
(light brown), the circuit governing apoptosis (light green), and the circuit governing
invasiveness and metastasis (light blue) can be affected in cancer Source: Weinberg,
2007.
Cancer of all tissues share the same antisocial patterns of proliferative and invasive be-
haviour, which results from the gradual loss by mutation of the mechanisms that normally
limit these processes (Figure 1.1).
The plasma membrane is vulnerable to mechanical changes and it is required for in-
vasive and proliferative properties [Chen, 1981; Alberts et al., 2002a; Weinberg, 2007].
Pathological levels of mechanical stress such as cancer can exacerbate these constitutive
levels of cell wounding and contribute to tumour progression.
Regulation of the metazoan cell cycle is critical for processes such as proliferation,
differentiation, apoptosis and tumourigenesis. A tightly controlled interplay between in-
hibitory, activating and “checkpoint” factors ensures (1) the unidirectional progression
through G1, S, G2 and mitosis phases, (2) the exit from the cell cycle into the quiescent
G0 state, or (3) the re-entry into the cell cycle via G1. A complex network of regulatory
proteins governs progression through the steps of the cell cycle (Figure 1.2).
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Figure 1.2: The central governor of growth and proliferation. The term “cell
cycle clock” denotes a molecular circuitry operating in the cell nucleus that processes
and integrates a variety of afferent (incoming) signals originating from outside and
inside the cell, and decides whether or not the cell should enter into the active cell
cycle or retreat into a non-proliferating state. In the event that active proliferation is
decided upon, this circuitry proceeds to program the complex sequence of biochemical
changes that enable the cell to double its contents and to divide into two daughters.
Source: Weinberg, 2007.
Cell cycle progression is regulated by a group of cyclin-dependent kinases consisting
of catalytic subunits, designated Cdks, as well as activating subunits, designated cyclins.
Orderly progression through the cell cycle requires the activation and inactivation of dif-
ferent cyclin-Cdk complexes at appropriate times (Figure 1.3). Several proteins function
as mitotic inhibitors, such as p27, which interacts with D-type cyclins and Cdk4 and
subsequently promotes its degradation, allowing the G1 progression; or p21, which is de-
pendent of the p53 levels induced by DNA damage [Donovan and Slingerland, 2000]. The
cyclin D1 protein increases in G0/G1 phase, binds Cdk4 and p27, and, after p27 bind-
ing, its degradation is activated with G1 progression and the G1 phase progresses. The
expression of cyclin D has been associated with many forms of cancer and also plays a
critical role in mammary tissue maturation [Zwijsen et al., 1998; Dufourny et al., 2000;
Tashiro et al., 2007]. The cyclin A protein is involved in control of S phase and has been
associated to Cdk2. In addition, cyclin A has been implicated in cell transformation [Zer-
fass et al., 1995]. The cyclin B1 protein is required to activate the mitosis together with
maturation-promoting factor [Morgan, 2007] (Figure 1.3).
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Figure 1.3: The cell cycle scheme. 1) Cell cycle progression is governed by Cdks,
the activities of which are regulated by binding of cyclins, by phosphorylation and
by the Cdk inhibitors (the INK4 (inhibitors of Cdk4) family: p15, p16, p18 and p19;
and the kinase inhibitor protein (KIP) family: p21, p27 and p57). 2) Fluctuation
of cyclin levels during the cell cycle. These fluctuations are tightly coordinated with
the schedule of advances through the various cell cycle phases. The levels of cyclin-D
are highly regulated by extracellular signals and growth factors. Sources: Weinberg,
2007; Morgan, 2007.
1.1.3 Connection between cancer and Parkinson’s disease
Cancer and Parkinson’s disease (PD) are two common disorders for which the final patho-
physiological mechanism is not yet fully known. Several epidemiological and clinical studies
(Appendix 8) have illustrated that individuals with PD show lower occurrence of cancer
than expected, with the exception of higher risk of malignant melanoma, skin, breast and
thyroid cancers [Inzelberg and Jankovic, 2007].
In cancer, cell regulation mechanisms result in increased cell survival and/or prolif-
eration. Conversely, PD is associated with increased neuronal death, caused by, or con-
comitant with, accumulation of proteinaceous Lewy bodies. The possibility exists that
common perturbations of mechanisms involved in cell survival/death regulation could be
involved in both disorders [West et al., 2005].
The exact mechanisms underlying the observed cancer-PD association are not clear,
but different hypothesis have been raised for a positive or an inverse link between these
diseases. Oxidative stress and environmental exposition to pesticides or solvents have been
associated to both diseases [Checkoway and Nelson, 1999; Jenner and Olanow, 1996]. Also,
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the administration of levodopa to PD patients (a melanin precursor) increases suscepti-
bility to skin and melanoma cancers [Elbaz et al., 2005; Inzelberg and Israeli Korn, 2009].
On the other hand, epidemiological studies have reported an inverse relation between PD
and cancer, which can be dependent on the amount of potassium and detoxifying en-
zymes in the body [Jansson and Jankovic, 1985; Checkoway et al., 1998]. Furthermore,
the ubiquitin-proteasome system has been inversely linked to the pathogenesis of both
diseases [McNaught et al., 2001; Mitchell, 2003; Lim and Tan, 2007; Devoy et al., 2005].
In addition, the genes associated with familial forms of PD (the PARK loci) are now
somehow implicated in tumourigenesis and some of them have been found to be abnormally
expressed, inactivated, or deleted in several tumour types (Table 1.2) [Devine et al., 2011].
The effects of PARK mutations on tumourigenesis are unclear and, due to the un-
known functions of some of these PD-associated genes, conclusions about the nature of
the mutations (gain-of-function versus loss-of-function) are difficult to establish. For ex-
ample, α-synuclein (SNCA; PARK1, PARK4 ) expression is up-regulated in glioma cell
lines, schwannomas, medulloblastomas, and breast and ovarian carcinomas. Deletions of
Parkin (PARK2 ) have been identified in hepatocellular carcinomas and in breast, ovar-
ian and non-small-cell lung cancers. Finally, ubiquitin C-terminal hydrolase (UCHL1;
PARK5 ) is over-expressed in oesophageal and squamous cell carcinomas, and in pancre-
atic and colorectal cancers [West et al., 2005]. Moreover, loss/gain-of-function mutations
in PD-linked genes may have distinct effects on tumourigenesis. Nevertheless, genes as-
sociated with familial PD have been shown to regulate cell death and/or the cell cycle,
and several lines of evidence imply that malfunction of a shared biochemical pathway may
lead to PD or cancer [West et al., 2005].
1.2 PARK6, PTEN-induced kinase 1 (PINK1)
PINK1 (MIM 608309) (PTEN-induced kinase 1) was first identified as a protein associated
with cancer and PD. PINK1 isolation and identification came from two approaches: an
association study in a PD family, as a new locus linked to PD, and in tumour cell lines
where the tumour suppressor PTEN (Phosphatase and tensin homolog) was over-expressed
ectopically [Unoki and Nakamura, 2001; Valente et al., 2001].
1.2.1 PINK1 locus/gene
PINK1 gene (Enseml ID: ENSG00000158828), known as PARK6, is localised in a 3.7
cM region, 2.8Mb region of chromosome 1p36-p35 (1:20959948-20978004(1) strand). The
PINK1 gene contains eight exons spaning ∼ 1.8Kb.
1.2.2 PINK1 mRNA
PINK1 mRNA is expressed in all adult tissues from Mus musculus and Homo sapiens, with
more abundant expression in the brain, heart, testis and skeletal muscle, and low levels
in ovary, thymus and colon tissues (Table 1.3) [Unoki and Nakamura, 2001; Nakajima
et al., 2003; Chiba et al., 2009; Berthier et al., 2011]. The brain distribution of PINK1
mRNA in mouse and rat is homogeneous throughout the tissue, including PD relevant
structures such as SNpc, caudate-putamen, cortex and hippocampus [Taymans et al.,
2006; Blackinton et al., 2007].
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Table 1.2: Parkinson’s disease genes related to cancer.
Gene
(protein)
Alteration and putative role in:
Implicated cancers
PD Cancer
PARK1
PARK4
(SNCA)
•Heterozygous muta-
tions or over-expression Unknown
Over-expressed in brain tumours with
neuronal differentiation [Kawashima
et al., 2000]
•Synaptic dysfunction Expressed in malignant and benign
melanocytic lesions but not in normal
skin [Matsuo and Kamitani, 2010]
•Mitochondrial
dysfunction
Expressed in ovarian cancer but not in
normal ovarian tissue [Bruening et al.,
2000]
PARK2
(Parkin)
•Homozygous mutations
and deletions
E3 ubiquitin
ligase targeting
cyclin E
Inactivating mutations and deletions in
glioblastoma, and colon and lung cancers
[Veeriah et al., 2009]•E3 ubiquitin ligase tar-
gets Mfn, VDAC1 and
cyclin E
•Transcriptional
repression of p53
PARK5
(UCHL1)
•Heterozygous
mutations
Deubiquitylates
p53
Silenced (via CpG methylation) in na-
sopharyngeal carcinoma [Li et al., 2010],
•Role unknown colorectal and ovarian cancers [Okochi-
Takada et al., 2006], and renal cell car-
cinoma [Kagara et al., 2008]
PARK6
(PINK1)
•Homo-heterozygous
mutations Unknown
Heterozygous mutations in ovarian cancer
(627G>A, P209P; 1444G>A, V482M)
and glioma (644C>T, P215L)*•PI3K/Akt/mTOR
pathway
•Mitophagy
PARK7
(DJ-1)
•Homozygous mutations •PI3K/Akt/mTOR
pathway
Over-expressed in NSCLC [MacKeigan
et al., 2003] and prostate cancer cell lines
[Hod, 2004]
•PI3K/Akt/mTOR
pathway
•Response to oxidative
stress
•Modulation of
p53
•Mitophagy
PARK8
(LRRK2)
•Heterozygous
mutations
•PI3K/Akt/mTOR
pathway
Amplification or over-expression in
papillary renal cell carcinoma and thyroid
cancer [Looyenga et al., 2011]•PI3K/Akt/mTOR
pathway
•MicroRNA regulation
(let-7)
•MicroRNA
regulation (let-7)
PARK9
(ATP13A2)
•Heterozygous
mutations
Unknown
Missense mutations in ovarian cancer,
melanoma and glioma
•Lysosomal
dysfunctional
GBA
•Homozygous mutations •Decreased immune
surveillance of
tumours
Homozygous deficiency in haematological
malignancies (especially multiple
myeloma) and hepatocellular carcinoma
[De Fost et al., 2006]
•Microglial activation
•Lysosomal dysfunction
•UPS dysfunction •Cytokine release
PARK15
(FBXO7)
•Homozygous mutations Inhibition of
cIAP1
Over-expression in lung and colon cancer
[Laman et al., 2005]•Stabilization of cyclin
D-Cdk6 complexes
*Data source: COSMIC database http://www.sanger.ac.uk [Bamford et al., 2004].
See Appendix8. Modified from Devine et al., 2011.
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In Drosophila melanogaster, PINK1 mRNA is expressed throughout the lifespan, with
the highest levels in pupal stages and slightly reduced levels in adults, and is highly
abundant in brain and in the retina [Wang et al., 2006]. In Danio rerio, PINK1 mRNA is
distributed uniformly in larvae stage with increased intensity in muscle and in the nervous
system, where many DA neurons exist [Anichtchik et al., 2008; Sallinen et al., 2010], and
in Oryzias latipes increased expression was detected in telencephalon, diencephalon and
optic tectum [Matsui et al., 2010].
1.2.3 PINK1 protein
PINK1 is a 581 amino acid protein (63 kDa) composed of a mitochondrial localisation
sequence (MLS), a transmembrane domain (TM), a highly conserved Serine/Threonine
(Ser/Thr) kinase domain, and a regulatory C-terminal region (Figure 1.4). Noticeably,
PINK1 is the first kinase that exhibits a canonical mitochondrial targeting sequence with
several cleavage sites defined. PINK1 full length (FL, 63 kDa) leads to the generation of
at least three forms, suggesting the presence of mutiple cleavage sites: PINK1 FL, PINK1-
∆1 cleaved form upon entry into the mitochondria (54 kDa), and PINK1-∆2 cleaved form
(45 kDa). In addition, a third PINK1 protein of 60 kDa has been recently described [Sim
et al., 2012; Jin et al., 2010; Greene et al., 2012]. The specific functional role and the
topology of these PINK1 protein fragments are not yet well characterised (see below).
Figure 1.4: PINK1 domain organization. PINK1 is composed of a mitochondrial
localisation sequence (MLS, residues 1-77), a transmembrane domain (TM, residues
101-107), a Ser/Thr kinase domain (residues 150-510), and a regulatory C-terminal
domain (residues 510-581).
In humans, PINK1 protein is highly expressed in liver and epithelial tissues including
adrenal gland, mammary gland, prostate, pancreas, kidney tubules, stomach, intestine and
hypophysis. PINK1 protein expression is weak or absent in bladder and skin epidermis.
Moreover, PINK1 protein is widely expressed in the brain, including grey matter, but not
white matter. PINK1 is also expressed in cortex, striatum, and brainstem with cortical
neurons and Purkinje cells [Berthier et al., 2011]. Additional studies have shown that
PINK1 is expressed at low levels in white matter and in all cell types, including glia,
endothelial cells, and blood vessel smooth muscle cells (Table 1.3) [Gandhi et al., 2006;
Murakami et al., 2007].
In Danio rerio, PINK1 is expressed within the paraventricular regions of the adult,
including the hypothalamus and the deep layers of the optic tectum, and in dopaminergic
tyrosine hydroxylase positive neurons [Anichtchik et al., 2008].
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1.2. PARK6, PTEN-induced kinase 1 (PINK1)
1.2.4 PINK1 homology
PINK1 protein is highly conserved in evolution and it is present in metazoans, from ne-
matodes to mammals (Figure 1.5) [Nakajima et al., 2003; Valente et al., 2004a; Rogaeva
et al., 2004; Petit et al., 2005; Marongiu et al., 2007; Cardona et al., 2011]. The whole
PINK1 protein and, in particular, the kinase domain is highly conserved between PINK1
orthologues, as Table 1.4 shows.
Table 1.4: Identity of PINK1 and domains in differents organisms.
Organism
Percentage of identity
Total Kinase domain MLS C-terminal tail
H. sapiens 100 100 100 100
M. mulatta 97 96 98 99
M. musculus 81 82 80 86
M. domestica 77 81 66 75
G. gallus 64 66 41 62
D. rerio 54 63 45 38
A. gambiae 45 45 — —
D. melanogaster 43 45 — —
C. quinquefasciatus 41 45 — —
A. aegypti 40 42 — —
C. elegans 32 36 — —
Percentage of identity compared to PINK1 H.sapiens amino acid sequence;
—: below 30% of identity.
1.2.5 PINK1 Ser/Thr kinase and phosphorylation
The terciary structure of protein kinases is highly conserved and contains different sub-
domains, according to the classification of Hanks and Hunter, 1995 [Hanks and Hunter,
1995] (Figure 1.6). The N-terminal part comprises the subdomains I-IV and it is involved
in ATP binding and orientation. This contains the AIK motif where the lysine involved
in ATP orientation is localised (subdomain II). The C-terminal part of kinase domain
is composed of catalytic loop and activation loop and contains subdomains VIa-XI. The
catalytic loop (subdomain VI) is characterised by HRD motif (HRDLKxxN). The activa-
tion loop is composed of the highly conserved DFG motif that orients the γ-phosphate of
ATP and chelates Mg2+ (subdomain VII) and the APE motif which stabilises the kinase
catalytic domain (subdomain VIII). The rest of the subdomains are structurally important
(subdomains IV-V) and are involved in substrate recognition (subdomains IX-X).
PINK1 conserves the typical Ser/Thr kinase subdomains wiht high homology to Ca2+/
calmodulin family kinases. The PINK1-related high homology kinases are STK1 (sero-
logical thymidine kinase 1) [Nakajima et al., 2003; Silvestri et al., 2005], CLIK1 (CLP-36
interacting kinase) and PKA (protein kinase A) [Sim et al., 2006]. PINK1 has been classi-
fied in the NSKs family (nervous system function and development kinase with a partially
conserved putative calcium-binding site) [Cardona et al., 2011].
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1.2. PARK6, PTEN-induced kinase 1 (PINK1)
Figure 1.6: Ser/Thr kinase domain of PINK1. Schematic diagram of the
Ser/Thr kinase domain, with conserved functional motifs boxed, and predicted loca-
tions of insert regions marked. Dotted lines indicate some of the interactions between
specific residues, the substrate, ATP, and the cofactor Mg2+. Modified from Mills
et al., 2008.
The primary human sequence of PINK1 includes the three conserved Ser/Thr kinase
motifs: AIK (amino acids 216-219), HRD (amino acids 236-362), and DFG (amino acids
384-386) described above (Figure 1.7) [Albanese et al., 2005; Beilina et al., 2005; Silvestri
et al., 2005; Sim et al., 2006; Wang et al., 2006; Mills et al., 2008; Cardona et al., 2011]. A
special feature of PINK1 is the presence of three insertions in the N-terminal lobe of the
kinase domain which may modify the kinase activity (Figure 1.6 and 1.7) [Mills et al.,
2008; Cardona et al., 2011; Sim et al., 2012], and can cause the decrease of the intrinsic
kinase activity, as several authors have postulated [Pridgeon et al., 2007; Plun-Favreau
et al., 2007; Plun-Favreau and Hardy, 2008].
Phosphorylation of artificial substrates and auto-phosphorylation of PINK1 have been
described in PINK1 over-expressing cultured cells or using PINK1 protein purified from
bacteria [Nakajima et al., 2003; Silvestri et al., 2005; Beilina et al., 2005; Liu et al., 2009].
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Figure 1.7: Amino acid sequence of PINK1 protein. The MLS (residues 1-77)
with the cleavage sites (1st and 2nd), TM region (grey) with the 3rd cleavage site, the
kinase domain (pink) with the kinase subdomains (green brackets), and the secondary
structure (β-sheet in blue and α-helix orange) are indicated. There is a putative 4th
cleavage site after TM. The AIK, HRD and DFG motifs within the kinase domain
are shadowed in green and the three insertions indicated. The C-terminal tail is after
the kinase domain. Based on Petit et al., 2005; Beilina et al., 2005.
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Nevertheless, PINK1 exhibits low kinase activity, and only PINK1 insect ortologue
presents significant kinase activity [Woodroof et al., 2011]. PINK1 undergoes auto-
phosphorylation in multiple Ser and Thr residues. Auto-phosphorylation of Thr 257 oc-
curs upon CCCP (carbonyl cyanide m-chloro phenyl hydrazone) treatment and increases
the PINK1 phosphorylation activity over Parkin [Kondapalli et al., 2012]. Recently, the
PINKtide (WIpYRRSPRRR), which is the peptide able to be phosphorilated by insect
PINK1, and the consensus phosphorylation sequence (S/T E L/M) have been determined
[Woodroof et al., 2011; Sim et al., 2012; Wang et al., 2012]. The C-terminus of PINK1
regulates its kinase activity and both positive and negative regulations have been reported
[Sim et al., 2006; Silvestri et al., 2005]. Most of the PINK1 mutations analysed (K219A,
G309D, L347P, D362A, D386A, G409D, E417G) are associated with reduced kinase ac-
tivity [Beilina et al., 2005; Silvestri et al., 2005; Sim et al., 2006; Pridgeon et al., 2007].
The microtubule affinity-regulating kinase 2 (MARK2) has been described to phos-
phorylate PINK1 at Thr 313, in the third insertion region, and, subsequently, in other
residues. This cooperates with MARK2 function, which regulates mitochondrial traffick-
ing in neurons [Matenia et al., 2012].
PINK1 is involved in the phosphorylation of the mitochondrial chaperone TRAP1
(TNF receptor-associated protein 1) in hydrogen peroxide-treated PC12 cells, which can
modulate mitochondrial protection [Pridgeon et al., 2007]. Cytosolic substrates such as
Parkin and Miro are directly phosphorylated by PINK1. Parkin is phosphorylated at Thr
175 (in the linker region), which promotes its translocation to the mitochondria [Kim
et al., 2008; Sha et al., 2010]. Upon CCCP treatment, another Parkin residue (Ser 63) is
phosphorylated by insect PINK1, which is important for Parkin E3-ubiquitin ligase acti-
vation [Kondapalli et al., 2012]. Miro is directly phosphorylated by PINK1 at the Ser 156
and Thr 299 [Wang et al., 2012], which regulates mitochondrial trafficking. PINK1 modu-
lates the phosphorylation status of the mitochondrial protein Htra2 (5-hydroxytryptamine
(serotonin) receptor 2a)/omi by an indirect mechanism involving stress-activated kinase
p38 [Plun-Favreau et al., 2007, 2008]. Finally, PINK1 induces phosphorylation of Rictor
and thereby activates mTOR2 (mammalian target of rapamycin complex 2) [Murata et al.,
2011a].
1.3 PINK1 localisation and import
The subcellular and submitochondrial locations of PINK1 remain controversial. PINK1
has been reported to be located in the inner mitochondrial membrane (IMM) [Silvestri
et al., 2005; Gandhi et al., 2006; Muqit et al., 2006; Beilina et al., 2005; Pridgeon et al.,
2007; Weihofen et al., 2008; Marongiu et al., 2009], in the mitochondrial intermembrane
space (IMS) [Silvestri et al., 2005; Plun-Favreau et al., 2007; Pridgeon et al., 2007; Meiss-
ner et al., 2011] and in the outer mitochondrial membrane (OMM) [Zhou et al., 2008b;
Narendra et al., 2010] (Figure 1.8).
The PINK1 positive charged MLS presents, by bioinformatic prediction, several cleav-
age sites which could be targeted by distinct proteases during mitochondrial import
(Figure 1.7). The cleavage sites described include residues at 34, 76 and 103 (within
the TM) positions [Silvestri et al., 2005; Deas et al., 2010; Jin et al., 2010]. Indeed, the
first 34 or 93 amino acids of PINK1 suffice to target fused-GFP to the IMM via TOM/-
TIM23 complexes [Silvestri et al., 2005; Muqit et al., 2006; Jin et al., 2010; Jin and Youle,
2012]. Keeping with this notion, studies using various PINK1 N-terminal deletions (at
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Figure 1.8: Localisation of PINK1 in the mitochondria. PINK1 localises
at the IMS with the kinase domain facing this compartment and interacting with
mitochondrial substrates, like TRAP1 or Htra2/omi; or at the OMM, facing the
cytosol and binding to proteins such as Parkin, Rictor and Miro.
residues 35, 108, 111 and 150) concluded that the deleted PINK1 can not be imported to
the mitochondria [Haque et al., 2008; Takatori et al., 2008; Wang et al., 2007; Zhou et al.,
2008b]. However, PINK1 without MLS is still associated to the OMM, which could be due
to binding to others protein like Miro/Milton in an MLS-independent fashion [Weihofen
et al., 2009; Kane and Youle, 2012; Liu et al., 2012].
Experimental data on PD-linked PINK1 mutations show no effects on the localisation
of PINK1, suggesting that the topology of the kinase alone can not explain the pathology
due to mutation [Valente et al., 2004a; Silvestri et al., 2005; Beilina et al., 2005; Petit et al.,
2005; Muqit et al., 2006; Pridgeon et al., 2007; Wang et al., 2007; Zhou et al., 2008b; Becker
et al., 2012]. Only in the case of C-terminal truncated mutations, the localisation seems
to be more mitochondrial than in PINK1 wt [Becker et al., 2012].
Recent studies have shed light on the mechanism of PINK1 mitochondria import and
cleavage. PINK1 imported into the mitochondria is first cleaved by the mitochondrial
processing protease (MPP), at an unknown cleavage site, to form a 60 kDa intermediate
spanning the IMM [Sim et al., 2012]. Presenilin-associated rhomboid-like protein (PARL)
and/or matrix-AAA protease (m-AAA), and ClnXP proteases then cleave this 60 kDa in-
termediate to generate a 54 kDa processed form of PINK1 attached to the IMM (Figure
1.9) [Whitworth et al., 2008; Deas et al., 2010; Becker et al., 2012; Jin et al., 2010; Meiss-
ner et al., 2011; Greene et al., 2012]. Findings from D. melanogaster and cultured cells
concluded the role of Rhomboid-7 (human PARL homologue) in PINK1 cleavage at Ala
residue 103, generating PINK1-∆1, which is dependent on mitochondrial membrane po-
tential (∆Ψm) [Whitworth et al., 2008; Deas et al., 2010; Meissner et al., 2011]. Another
important determinant on PINK1 topology is its TM sequence, that acts as a hydrophobic
“stop transfer” signal of the MLS of PINK1 into the IMM. Indeed, deletion of the trans-
membrane domain leads to PINK1 accumulation within the matrix [Deas et al., 2010; Jin
et al., 2010].
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1.4. PINK1 regulation
The ∆Ψm dissipation upon valinomycin or CCCP treatment blocks PINK1 cleavage
and import inside the mitochondria, retaining PINK1 FL at the OMM through direct bind-
ing to TOM20 where it participates in regulating mitochondrial fission/fusion processes
and mitophagy [Lin and Kang, 2008; Zhou et al., 2008b; Lazarou et al., 2012].
PINK1 does not only localise to mitochondrial fractions, as cytosolic and microsomal
fractions were found to contain all cleaved forms of PINK1 [Petit et al., 2005; Gandhi
et al., 2006; Zhou et al., 2008b; Haque et al., 2008; Beilina et al., 2005; Weihofen et al.,
2008; Narendra et al., 2010]. Moreover, PINK1 has been found in aggresomes and in Lewy
bodies [Samaranch et al., 2010].
Figure 1.9: Model of PINK1 import and processing in the mitochondria.
PINK1 precursor proteins are imported into the mitochondria via the TOM complex
in a ∆Ψm-dependent manner, accompanied by maturation, likely by the MPP. Newly
imported PINK1 is degraded in the IMM by PARL. A dysfunction of mitochondria
(low ∆Ψm) impairs import but not mitochondrial targeting of PINK1, resulting in its
accumulation at the mitochondrial surface. Modified from Rugarli and Langer, 2012.
1.4 PINK1 regulation
1.4.1 PINK1 locus regulation
PINK1 mRNA expression was originally associated to PTEN regulation and expression
[Unoki and Nakamura, 2001]. Indeed, PINK1 mRNA expression correlates inversely with
PI3K/Akt activation status. Activated Akt translocates out of the nucleus and inactivates
transcription function of FOXO3a. FOXO3a up-regulates PINK1 mRNA expression and
thus, up-regulates the expression of downstream genes involved in the protection against
cellular stress [Mei et al., 2009].
17
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PINK1 mRNA levels are up-regulated during differentiation of human NSCs into neu-
rons and localise to soma and neurites of post-mitotic DA cells, suggesting a possible
function in differentiated neurons [Wood-Kaczmar et al., 2008].
Intriguingly, it has been described in human and mouse that the PINK1 gene locus
originates a cis-transcribed non-coding natural antisense (ncNAT), and a predicted novel
short splice variant protein (svPINK1) which represents the C-terminal portion of PINK1
[Scheele et al., 2007; Chiba et al., 2009]. The ncNAT displays near complete sequence
overlap with the svPINK1 and only partial overlap with PINK1 at the 3’ end (Figure
1.10). The functional role and regulation of these variants are still open questions.
Figure 1.10: Scheme of the exon-intron organization and regulation of hu-
man PINK1 locus. Exons (red boxes) and introns (lines) are drawn to scale in
PINK1 gene. The PINK1 protein corresponding to the exons is indicated: MLS (or-
ange), TM (green) and kinase domain (purple). The PD-linked mutations used in
this study are indicated with red arrows. The bottom diagram represents the chro-
mosomal coordinates for the PINK1 gene annotated in the Ensembl database ver.67
May, 2012 (20,832,535–20,850,591, chromosome 1). Black arrows indicate direction of
transcription: PINK1 and svPINK1 are transcribed from left to right, while naPINK1
is transcribed from right to left. Modified from Scheele et al., 2007.
1.4.2 PINK1 protein levels regulation
PINK1 protein is a multiple form protein which is transcribed in the nucleus as full length
(FL), translated in the cytoplasm, and imported intact into the mitochondria, with sub-
sequent processing and intra-mitochondrial or cytosolic sorting.
As we previously mentioned, it has been described that PINK1 FL (63 kDa) is depen-
dent on PARP-cleavage under basal conditions, producing PINK1-∆1 [Muqit et al., 2006;
Lin and Kang, 2008; Weihofen et al., 2008; Petit et al., 2005; Takatori et al., 2008]. The
other form, PINK1-∆2 is from unclear origin, and it has been proposed to be generated
18
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from ans alternative translation initiation site or by another cleavage event [Jin et al.,
2010; Becker et al., 2012] . Conversion of the FL protein to these two cleavage products is
rapid, occuring within 3 min after PINK1 FL protein synthesis and being dependent on
the mitochondrial integrity [Lin and Kang, 2008].
PINK1 is a short-life protein of only 30 min half-life under basal conditions, and is
mainly degraded via the proteasomal pathway [Muqit et al., 2006; Lin and Kang, 2008;
Um et al., 2009]. The three PINK1 forms are accumulated upon proteasomal inhibition
by MG132 or epoxomicin, although the PINK1-∆1 form of 54 kDa is prominent [Tang
et al., 2006; Takatori et al., 2008]. It has been described that PINK1 FL and PINK1-∆2,
but not PINK1-∆1, are stabilised by binding to hsp90/cdc37 chaperones [Lin and Kang,
2008].
The levels of PINK1 are directly related to Parkin protein, which inhibits PINK1
ubiquitination upon binding through its RING2 domain [Um et al., 2009]. Binding to
DJ-1 also stabilised PINK1 [Xiong et al., 2009].
Recent evidence indicates that PINK1 protein levels are kept low through instant
shedding of the protein during or shortly after mitochondrial import. However, when
the mitochondrial membrane potential is dissipated or the mitochondrial integrity is lost,
PINK1 processing is inhibited and PINK1 FL is stabilised at the OMM [Jin and Youle,
2012; Narendra and Youle, 2011].
Finally, PINK1 protein is also regulated through dimers formation via the region at
residues 246-509, as well as through association to the mitochondrial membranes and
mitochondrial protein complexes, as a highly hydrophobic protein [Silvestri et al., 2005;
Liu et al., 2009].
1.5 Animals models to study PINK1 function
The PINK1 functions described are mainly based on PINK1 relation to PD where PINK1
is inactivated.
Flies deficient for PINK1 show progressive degeneration of a subset of dopamine neu-
rons in the brain, degeneration of flight muscle tissue, and defective sperm cell develop-
ment. PINK1 deficiency leads to fragmented mitochondrial cristae and hypersensitivity
to oxidative stress [Park et al., 2006; Clark et al., 2006]. This deficiency can be rescued
by Parkin and the fission factors Drp1 and Fis1, suggesting a physiological role for PINK1
in dynamics and/or degradation of damaged mitochondria [Deng et al., 2008; Yang et al.,
2008; Poole et al., 2008] (see Section 1.6.3 and 1.6.4).
By contrast, knock-out PINK1 mice have a mild phenotype and do not recapitulate
the dopamine neuron loss observed in humans. Nevertheless, these mice have nigrostriatal
physiological defects, suggesting a role for PINK1 in dopamine transmission [Kitada et al.,
2007].
Other brain phenotypes of PINK1 knock-out (KO)/ knock-down (KD) mice include
[Kitada et al., 2007; Zhou et al., 2007; Gautier et al., 2008; Gispert et al., 2009; Martella
et al., 2009; Akundi et al., 2011; Gautier et al., 2012; Wang et al., 2011]:
• Elevated susceptibility to H2O2 or heat-shock stress, with decreased activities of the
oxidative-stress vulnerable respiratory complexes as well as of aconitase activity.
• Increased calcium levels and vulnerability with subsequent excess of ROS production,
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decreased glucose availability and loss of ∆Ψm, causing pathological opening of the
mitochondrial permeability transition pore.
• Reduced synaptic dopamine release and plasticity in the striatum.
• Sensitization to activation of group II metabotropic glutamate receptors at corticos-
triatal synapses.
• Reduced viability of cortical neurons.
Finally, Billia et al. also reported in a PINK1 KD mouse model higher degree of
cardiomyocyte apoptosis with greater levels of oxidative stress, suggesting that PINK1 is
indispensable for normal heart function [Billia et al., 2011].
Additional PINK1 mutant models have been generated in C. elegans, where increased
susceptibility to oxidative stress and mitochondrial morphology defects were observed
[Samann et al., 2009], as well as in D. rerio, which exhibited a decrease in dopamine-
producing cells and reduced mitochondrial activity [Sallinen et al., 2010].
These models have limitations as their phenotypes do not recapitulate well the PD
phenotype observed in humans. Others models such as culture cells are needed to throw
light on PINK1 functions linked to human disease.
1.6 Functions of PINK1
1.6.1 Mitochondrial-mediated apoptosis
The programmed cell death, known as apoptosis, encompasses various pathways. The
mitochondrial pathway begins with the permeabilization of the OMM and the subsequent
release from the IMS to the cytosol of several apoptogenic proteins such as apoptosis-
inducing factor (AIF) or cytochrome c (cyt c). In the cytosol, cyt c forms a complex
with apoptotic protease activating factor 1 (Apaf-1) and pro-caspase 9 (the apoptosome),
which activated caspase 9 and induces the activation of downstream executioner caspases,
including caspase 3 [Nijhawan et al., 2000; Green and Kroemer, 2004].
During mitochondrial apoptotic cascade, the opening of mitochondrial permeability
transition pore (mPTP) is believed to cause mitochondrial membrane permeabilization
and cyt c release [Kinnally and Antonsson, 2007]. Proteosome inhibitors like MG132,
electron transport chain inhibitors like rotenone, and increased production of ROS, activate
mitochondrial apoptotic pathways and cause the mitochondrial release of cyt c.
PINK1 was first described as a mitochondrial-mediated anti-apoptotic protein [Valente
et al., 2004a]. PINK1 deficient cells are more susceptible to apoptosis after exposure to
mitochondrial toxins like MPP+, staurosporine or rotenone [Deng et al., 2005; Wang et al.,
2006; Pridgeon et al., 2007; Haque et al., 2008; Wood-Kaczmar et al., 2008]. In addition,
over-expression of PINK1 wt, but not PINK1 kinase inactive or PD-linked mutations,
protects against cell death mediated by chemical insults such as MPTP, MG132 or stau-
rosporine [Valente et al., 2004a; Petit et al., 2005; Wang et al., 2006; Tang et al., 2006;
Pridgeon et al., 2007; Wang et al., 2007; Haque et al., 2008; Chu, 2009] (Figure 1.11).
PINK1 over-expression blocks the release of cyt c and the cleavage and activation of
the pro-caspase 3 (Figure 1.11). Surprinsingly, over-expression experiments using PINK1
with N-terminal mutation (R68P) or deletion (first 111 aa) revealed protection against cell
death, even in the asbsence of the MLS [Haque et al., 2008; Tan et al., 2009; Tan, 2009].
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Figure 1.11: PINK1 protects against mitochondrial-mediated apoptosis.
In the absence of PINK1, upon stress stimuli (staurosporine, rotenone, MPP+,
paraquat), cytosolic Bax (Bcl-2–associated X protein) is recruited to the mitochon-
dria, followed by release of intermembrane space proteins (such as cyt c) to the cy-
tosol and activation of caspases cascade with increased cell death. Over-expression of
PINK1 wt blocks the activation of apoptosis and cell death.
However, the deletion of the first 34 aa does not prevent the mPTP opening [Wang et al.,
2007].
It has been proposed that the PINK1 mediated protection in response to mitochon-
drial stressors is due to the interaction with substrates (Figure 1.12). PINK1 might
provide protection against oxidative stress-induced apoptosis by the phosphorylation and
the activation of the mitochondrial chaperone TRAP1 [Pridgeon et al., 2007], and by the
modulation of the phosphorylation of the protease Htra2/omi [Plun-Favreau et al., 2007,
2008]. Moreover, PINK1 phosphorylates Parkin, which increases E3-ubiquitin ligase and
favours the K63-linked polyubiquitination of IKKγ. Degradation of IKKγ is a critical step
in the activation of NF-κβ, a ubiquitously expressed transcription factor of pro-survival
genes [Sha et al., 2010]. Parkin activation by PINK1 enhances mitophagy, which recently
has been proposed as a protective cell death pathway. It has been demonstrated that
PINK1 activates phosphorylation of Rictor, a component of mTOR2, promoting cell sur-
vival mediated by Akt activation in neurons [Deas et al., 2010; Murata et al., 2011a]
(Figure 1.12).
1.6.2 Mitochondrial function
In mitochondria, electrons travel through the electron transport chain (complexes I-IV)
to generate energy by the respiration process.
Reactive oxygen species (ROS, such as oxygen ions, free radicals and peroxides) are
formed as a natural byproduct of oxygen metabolism, where roughly 1-5% of the oxygen
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Figure 1.12: PINK1 protection is mediated by its substrates. Phosphory-
lation of mitochondrial PINK1 associated proteins TRAP1 and Htra2/omi can block
activation of apoptosis and clearance of damaged proteins by proteolysis. Moreover,
phosphorylation of cytosolic PINK1 associated proteins such as Parkin and Rictor
favours the expression and activation of pro-survival effects. Arrows indicate PINK1
substrates and dotted arrows indicate PINK1-associated proteins.
consumed is converted into ROS [Westermann, 2008]. ROS can be useful to the immune
system and also involved in cell signalling events, but if the levels overcome the cell’s
ability to neutralize and eliminate them, ROS can inflict damages on DNA, lipids and
proteins [Zhou et al., 2008a]. This situation is known as oxidative stress and is caused by
reduced antioxidant capacity or by the over-production of ROS.
There are many findings indicating that the mitochondria in PINK1 deficient models
are vulnerable and unhealthy. Gegg et al. have shown that PINK1-silenced SH-SY5Y cells
resulted in a decrease in mtDNA levels and synthesis, impairment of respiratory chain, and
complex IV deficiency [Gegg et al., 2009]. Primary cultured neurons and mouse embryonic
fibroblasts (MEFs) derived from PINK1 deficient mice showed loss of ∆Ψm and defects of
complex I and oxygen consumption, causing pathological opening of the mPTP [Gandhi
et al., 2009; Gautier et al., 2012; Amo et al., 2010; Samann et al., 2009; Wang et al.,
2011]. Moreover, PINK1 deficiency increased intracellular calcium levels and vulnerability,
decreased glucose availability and excess in ROS production in the mitochondria and the
cytosol [Gandhi et al., 2009] (Figure 1.13).
Patient fibroblasts and immortalized lymphoblasts from individuals carrying a PINK1
mutation (G309D) have also been reported to display mid decrease of complex I activity,
induced antioxidant defence and enhanced lipid peroxidation [Hoepken et al., 2007, 2008].
Fibroblasts from a patient with W437X mutation displayed significant decrease in the
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respiratory activity and ATP, accompanied by ROS accumulation [Piccoli et al., 2008].
Other patient fibroblasts studies (V170G and Q456X mutations) have described decrease
in ∆Ψm and altered redox state, but normal glutathione levels and no increase in cytosolic
oxydation [Gru¨newald et al., 2009; Abramov et al., 2012]. PINK1 mutations over-expressed
in SH-SY5Y cells showed defects in oxygen consumption [Liu et al., 2009].
Mitochondrial PKA and inhibition of mTOR pathway by rapamycin or 4E-BP over-
expression can suppress the mitochondrial defects of PINK1 loss in D. melanogaster, maybe
through activation of pro-survival genes and increased mitochondrial electron transport
chain activity, but the molecular mechanism underlying this process needs to be clarified
[Tain et al., 2009; Dagda et al., 2011].
Figure 1.13: PINK1 in mitochondrial function. Loss of PINK1 impairs mito-
chondrial respiration, decreases complex I activity and reduces ATP production, ac-
companied by increased mitochondrial and cytoplasmic ROS, which produces mtDNA
damage. Also, PINK1 deficiency decreases calcium capacity, blocking the Na+/Ca2+
exchanger and increasing cytosolic Ca2+ levels, which favours the opening of mPTP.
Opening of the mPTP releases pro-apoptotic factors such as cyt c from the mitochon-
dria and induces apoptosis.
1.6.3 Mitochondrial dynamics
Mitochondrial fission and fusion are membrane-remodeling processes that control in vivo
dynamics, distribution, and structure of the mitochondrial network. These processes re-
spond to the cell energy status and are necessary for proper mitochondrial function. Dys-
function of mitochondrial fission/fusion has been linked to the pathogenesis of neurode-
generative [Twig et al., 2008; Westermann, 2008].
A role for PINK1 in the regulation of mitochondrial fission/fusion dynamics has re-
cently been proposed [Deng et al., 2008; Park et al., 2006; Poole et al., 2008; Yang et al.,
2008]. D. melanogaster PINK1 (dPINK1) RNAi, or dPINK1 mutant flies, display altered
mitochondrial morphology with mitochondrial aggregates, swollen or enlarged mitochon-
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dria, and the presence of a tubular mitochondrial network in high-energy demand tissues,
such as flight muscle and DA neurons. This phenotype can be modified by genetic com-
plementation of the flies with either an extra copy of the fission promoting gene Drp-1
or removal of a copy of the fusion promoting gene Opa-1 [Poole et al., 2008; Yang et al.,
2008]. Overall, the combined results from flies studies suggest that dPINK1 is involved
in promoting mitochondrial fission and/or inhibiting mitochondrial fusion. In support of
this, Morais et al. reported similar defects in PINK1 knockout flies to those observed
in Drp-1 deficient cell lines [Morais et al., 2009]. However, the PINK1/Parkin pathway
directly promotes degradation of mitofusin (Mfn) which leads to mitochondrial fragmenta-
tion [Poole et al., 2008; Ziviani et al., 2010]. Recently, it has been described that PGAM5
is a PINK1 binding protein, which can modulate the defects in mitochondrial dynamics
upon PINK1 loss, but without contribution to PINK1/Parkin pathway in fission/fusion
[Imai et al., 2011].
Nevertheless, in mammalian cells, PINK1 is thought to function as a pro-fusion pro-
tein, since PINK1 KD, G309D or Q126P human cells showed increase in fragmented
mitochondria with abnormal morphology [Exner et al., 2007; Wood-Kaczmar et al., 2008].
Contrary to fly results, Drp1 loss or dominant negative over-expression rescued the frag-
mented and abnormal mitochondrial, but not the ROS production associated with PINK1
loss. This suggests that mitochondrial dysfunction is the direct impairment, and fission/-
fusion processes are secondary effects in PINK1 deficiency. Indeed, Sandebring et al. have
proposed that accumulation of damaged mitochondria by PINK1 inactivation results in
mitochondrial calcium eﬄux, which activates Drp1 in human cells through calcineurin-
mediated dephosphorylation [Sandebring et al., 2009] In line with this, studies in PINK1
KO mice showed increased of mitochondrial size [Gautier et al., 2008] and in mammalian
cells PINK1 over-expression leads to aggregation and fragmentation [Lutz et al., 2009].
Opposite to these results, it has been recently described that PINK1 and/or Parkin over-
expression leads to increase fission in post-mitotic mammalian cells (hippocampal and DA
neurons) [Yu et al., 2011; Liu et al., 2012].
PINK1 is associated with another aspect of mitochondrial dynamics: mitochondrial
trafficking. Mitochondrial trafficking is a vital aspect of cellular homeostasis, especially in
large cells such as neurons, where trafficking allows the redistribution of mitochondria to
regions of high-energy demand such as synapses and areas of neuronal outgrowth. PINK1
forms a complex with Miro, an atypical GTPase of the mitochondrial outer membrane,
and Milton, a cytoplasmic adaptor protein [Weihofen et al., 2009]. This protein complex
is responsible for the anterograde movement of mitochondria along microtubules, which
is thought to involve the attachment of mitochondria to microtubules via an interaction
between Milton and the kinesin heavy chain I. This allows the transport of mitochondria
to regions of high intracellular calcium (Figure 1.14) [Wang et al., 2012; Liu et al., 2012].
Without the formation of this complex, mitochondria are no longer transported and can
not efficiently meet the energy demands of the cells. Moreover, PINK1 is activated by
MARK2, an important regulator of cell polarity through phosphorylation and inactivation
of several microtubule-associating proteins. The activation of PINK1 by MARK2 regulates
the mitochondrial trafficking in neurons [Matenia et al., 2012]. Together, these findings
indicate that PINK1 may influence both short- and long-range mitochondrial dynamics.
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Figure 1.14: PINK1 and mitochondrial trafficking. PINK1 interacts with Miro
and Milton and may play a role in anterograde mitochondrial transport within cells.
1.6.4 Mitophagy
Autophagy is a tightly regulated process which involves the degradation of cellular com-
ponents. Autophagy can be divided into three types of pathways depending of the cargo:
macroautophagy, microautophagy, and chaperone-mediated autophagy. Autophagy is of-
ten considered to be a nonselective pathway for the degradation of bulk cytoplasmic com-
ponents. However, in some cases autophagy displays substrate specificity like the selective
degradation of mitochondria, also known as mitophagy [Lynch-Day et al., 2012].
The term ”mitophagy”, coined by Lemasters in 2005, defines how damaged mitochon-
dria are removed from the cell via a form of selective macroautophagy. This process has
been linked to mitochondrial dynamics, whereby mitochondria are selectively fragmented
depending on ∆Ψm, a marker of mitochondrial health [Lemasters, 2005; Twig et al., 2008].
Dysfunctional mitochondria undergo fragmentation, and these mitochondria, which can
not be recovered through fission/fusion processes, are subsequently eliminated from the
network by components of autophagy machinery, and are degraded via the lysosomal
pathway.
Mitophagy can be induced in cultured cells by toxic agents such as the mitochondrial
membrane uncoupling agents CCCP and valinomycin, and the ROS-producing herbicide
paraquat. Prolonged treatment with these toxins has been shown to lead to a complete
removal of mitochondria from the cell, a phenomenon exclusively dependent on autophagy
[Ziviani et al., 2010; Narendra et al., 2008].
Although the complete mechanism mediating mitophagy is not yet fully understood,
recent studies have shown that PINK1 accumulates in the outer membrane of dysfunctional
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mitochondria, and recruits Parkin, which activates the clearance of damaged mitochondria
by mitophagy [Narendra et al., 2010; Vives-Bauza et al., 2010a; Matsuda et al., 2010;
Dagda et al., 2009; Geisler et al., 2010]. Reduced ∆Ψm inhibits PINK1 cleavage and
stabilises PINK1 FL at the OMM, triggering Parkin relocalisation from the cytosol to
the mitochondria and activating mitophagy. However, the question of how PINK1/Parkin
communicate each other and how the Parkin recruitment occurs is still opened. One
hypothesis involves Parkin phosphorylation by PINK1 and subsequent activation of Parkin
E3 ubiquitin ligase needed for mitophagy activation [Kim et al., 2008; Moore, 2006; Um
et al., 2009; Shiba et al., 2009; Kondapalli et al., 2012]. In fact, the kinase activity of
PINK1 is essential for Parkin recruitment and mitophagy activation [Vives-Bauza and
Przedborski, 2010].
Figure 1.15: Model of PINK1 role in mitophagy. Upon mitochondrial mem-
brane depolarization, PINK1 FL accumulates at the OMM. Parkin is recruited and
phosphorylated by PINK1, which facilitates ubiquitination of VDAC1 and Mfn. Sub-
sequently, NIX, GABARAP, p62 and LC3 are recruited for autophagosome formation
and depolarized mitochondria are removed by mitophagy.
Recent studies have added further insight into the mechanism of PINK1/Parkin -
mediated mitophagy by revealing downstream targets of Parkin ubiquitination. Reports
in D. melanogaster and human cells found that the pro-fusion protein Mfn is ubiquitinated
in a Parkin-dependent manner [Ziviani et al., 2010; Poole et al., 2008; Gegg et al., 2010].
In addition, a separate study using human cells reported that the voltage-dependent anion
channel 1 (VDAC1), a proposed component of the mPTP, was also ubiquitinated by Parkin
[Geisler et al., 2010]. The consequences of the ubiquitination may be the blockage of fusion
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processes and of the release of pro-apoptotic factors, triggering the mitochondrial removal
(Figure 1.15).
Prior to mitophagic degradation, mitochondria need to be clustered to the perinuclear
area, a process occurring in PINK1 over-expressing cells upon stress conditions [Narendra
et al., 2010]. In addition, under basal conditions, PINK1-silenced cells showed increased
autophagosome number and autophagy with mitochondrial localised close to the perin-
uclear area [Chu, 2009, 2010]. Thus, in the case of PINK1 loss, protective autophagic
pathways can be activated to clean up damaged mitochondria.
Finally, PINK1 FL interacts physically with Beclin-1 (Coiled-coil, moesin-like Bcl-2
interacting protein), a protein that regulates the initiation of autophagosome formation,
increasing basal levels of autophagy [Michiorri et al., 2010]. This suggests that PINK1 not
only plays a role in recruitment of Parkin but also in recruitment of autophagy machinery
components to mitochondria.
1.7 PINK1 and human disease
1.7.1 PINK1 and PD
PINK1 (PARK6 ) represents the second most frequent cause of early-onset juvenile Parkin-
son’s disease (EOJP) after Parkin, accounting for approximately 4-5% of autosomal re-
cessive and 1-2% of sporadic cases. The initial report described three pedigrees with a
G309D point substitution in one family and a truncation mutation W437X in two ad-
ditional families [Valente et al., 2004a]. So far, more than 100 homozygous mutations
(missense mutations, genomic rearrangements, truncating mutations) throughout PINK1
gene have been identified [Deas et al., 2009] (Appendix 8) and linked to autosomal-
recessive PD in diverse populations. Many heterozygous mutations of PINK1 have been
noted in late-onset PD patients and rarely in recessive families, suggesting a possible role
of PINK1 mutations as a susceptibility factor (Figure 1.16) [Valente et al., 2004b; Boni-
fati et al., 2005; Abou-Sleiman et al., 2006; Ibanez et al., 2006; Tang et al., 2006; Gandhi
et al., 2006; Klein and Schlossmacher, 2007].
The missense mutations of PINK1 are distributed through the different PINK1 do-
mains. However, the majority of the missense mutations are localised in the Ser/Thr
kinase domain, suggesting that loss of kinase activity plays a crucial role in the pathogen-
esis of PINK1-linked PD. Moreover, several nonsense mutations in the C-terminal region
of the kinase domain and in the tail of PINK1 have been found in PD patients [Bonifati
et al., 2005; Sim et al., 2012].
1.7.1.1 Clinical features
PINK1-related disease is clinically similar to idiopathic PD. The PINK1-associated phe-
notype is characterised by a wider range of ages at onset than the Parkin-associated
phenotype, and responds well to dopamine replacement therapies.
The consistent features in the PINK1 phenotype include [Gispert et al., 2009; Sama-
ranch et al., 2010]:
• Onset in most cases before age 40.
• A much more benign course despite decades of Parkinsonism.
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• Symptoms primarily referable to DA substrates with well-preserved levodopa re-
sponsiveness (but with levodopa dyskinesias and motor fluctuations).
• No substantial cognitive decline (although psychiatric symptoms may occur).
• Minimal dysautonomia (confined to urinary urgency, male impotence and autonomic
symptoms attributable to medications).
• Some cases of Lewy bodies presence.
Although the genotype-phenotype correlation has not been confirmed, the mean age
at onset in patients with single heterozygous mutations is higher than that in patients
with homozygous mutations [Kumazawa et al., 2008]. Homozygous mutations in PINK1
invariably cause PINK1-linked PD, whereas heterozygous mutations have been suggested
to be a susceptibility factor for sporadic PD [Klein et al., 2007; Klein and Schlossmacher,
2007].
Figure 1.16: Some of the PINK1 mutations reported in PD patients. Mis-
sense and truncated mutations are depicted on top and at the bottom of the protein
bar, respectively. Mutations found in homozygous or compound heterozygous states
are in black. Mutations found in heterozygous state are in grey. Data from Va-
lente et al.; Valente et al.; Hatano et al.; Healy et al.; Rogaeva et al.; Bonifati et al..
Modified from Bonifati et al., 2005.
1.7.1.2 PINK1 interaction with other PD-linked genes
As previously mentioned, PINK1 has been functionally associated to Parkin. It has been
described in D. melanogaster and in mammalian cultured cells that Parkin over-expression
rescues the phenotype of PINK1 deficiency, but not viceversa. Parkin stabilises PINK1
through direct interaction, and it was concluded that PINK1 functions upstream of Parkin
in a common pathway [Park et al., 2006; Clark et al., 2006; Yun et al., 2008].
Parkin, PINK1 and DJ-1 form a ubiquitin E3 ligase complex that promotes the degra-
dation of unfolded proteins [Xiong et al., 2009]. In D. melanogaster, DJ-1 can revert the
consequences of PINK1 loss (except for infertility), but not the consequences of Parkin
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loss. Moreover, Parkin can not rescue DJ-1 loss, suggesting that DJ-1 may not be a direct
downstream effector of PINK1 [Hao et al., 2010]. In human neuroblastoma cells, PINK1
and Parkin protect against the loss of DJ-1, and, although DJ-1 does not alter PINK1 de-
ficient mitochondrial phenotypes, DJ-1 protects against rotenone-induced damage in the
absence of PINK1 [Kim and Son, 2010; Thomas et al., 2010]. These findings suggest that
DJ-1 works in parallel to the PINK1/Parkin pathway to maintain mitochondrial function.
PINK1 KD causes proteasome dysfunction, accompanied by increased α-synuclein ag-
gregation [Liu et al., 2009], and α-synuclein over-expression leads to increased mitochon-
drial fragmentation and dysfunction, which can be rescued by Parkin, PINK1 or DJ-1
co-expression [Kamp et al., 2010].
PINK1 has been associated to LRRK2. In C.elegans, the mitochondrial and axonal
dysfunction caused by PINK1 deficiency can be rescued by the absence of LRRK2 [Samann
et al., 2009]. In flies, over-expression of LRRK2 promotes the phenotype associated to
PINK1 deficiency [Venderova et al., 2009]. Moreover, Parkin protects against LRRK2-
induced neurotoxicity in vivo [Ng et al., 2009]. These evidences suggest that dysfunction
of several PD causative gene products might contribute to pathogenesis of PD and may
be linked through common pathways.
1.7.2 PINK1 association to cancer
First genomic analysis showed that PINK1 lies next to chromosome 1p31.1-34.3 region,
where losses of heterozygosity (LOH) are frequently observed in endometrial cancers [Arlt
et al., 1996].
The first description of PINK1 related to cancer disease was done by Unoki and Naka-
mura in 2001. They showed PINK1 mRNA up-regulation in cancer cells(HEC-151 and
Ishikawa3-H12 endometrial cells) with exogenous PTEN over-expression but this was not
linked to changes in colony-formation assay or tumour suppression. The PTEN gene is a
tumour suppressor gene encoding a multifunctional phosphatase, which plays an impor-
tant role in inhibiting the PI3K/Akt pathway, and PTEN mutations have been found in
many human cancers. In addition, PINK1 (also named as BRPK) showed increased ex-
pression in mouse cancer cell lines with higher metastatic potential [Nakajima et al., 2003].
Also, PINK1 has been identified in a sensitized siRNA kinome and phosphatome screen
as a protein essential for survival, making PINK1 important as a potential anti-cancer
target [MacKeigan et al., 2003]. Finally, PINK1 has been identified in a microarray study
as a strong predictor, together with Dlg7 and Bub1, of overall survival and disease-free
survival in adenocarcinomas [de Reynie`s et al., 2009], and the prognostic value of the
combined expression of these three genes has been validated in different samples of adult
adenocarcinomas [Fragoso et al., 2011, 2012].
Recently, down-regulation of PINK1 has been shown to sensitise bladder cancer cells
that are resistant to adenovirus carrying Reic/dkk-3. This sensitisation was associated
with increasing production of ROS, down-regulation of Bcl-xL and TRAP1 proteins, and
up-regulation of Bax protein [Jin et al., 2012].
1.7.3 PINK1 and other human diseases
PINK1 has also been reported to be linked with Alzheimer disease and multiple sclerosis
lesions [Wilhelmus et al., 2011]. Interestingly, PINK1 immunostaining was observed in
both diseases predominantly in reactive astrocytes associated with these lesions, and in
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classic senile plaques and vascular amyloid depositions, suggesting that the increase in
astrocytic PINK1 protein might be an intrinsic protective mechanism to limit cellular
injury [Wilhelmus et al., 2011].
PINK1 has been associated to type 2 diabetes, obesity and impairment in glucose
transport. In skeletal muscle cells of type 2 diabetes patients, transcripts from the PINK1
locus were down-regulated and the gene expression correlated with diabetic status, since
aerobic training increased PINK1 transcript abundance. RNA interference of PINK1 im-
paired basal glucose uptake of human neuronal cell lines, and PINK1 abundance correlated
with plasma glucose levels [Scheele et al., 2007; Franks et al., 2008].
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Objectives
The main objectives of this study have been:
• To investigate how PINK1 may control cellular homeostasis through mitochondrial
quality control.
• To elucidate PINK1 pivotal interplay in two relevant human diseases: cancer and
Parkison’s disease.
1. To investigate PINK1 role in Parkinson’s disease:
• We analyse the functional role of PINK1 in a human neuroblastoma model (SH-
SY5Y cell line), in terms of mitochondrial function, homeostasis and mitophagy
processes.
2. To investigate PINK1 role in cancer:
• We explore the functional role of PINK1 in a human breast cancer model (MCF-
7 cell line), in terms of growth, survival, apoptotic and transformation features.
• We examine the level of expression of PINK1 in human breast cancer tumours
and in human cancer cell lines.
3. To investigate the functional properties of PINK1 catalytically inactive, PINK1 PD-
associated mutations and PINK1 truncations.
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3.1 Sequence alignment
PINK1 amino acids sequences from different organisms were obtained from Uniprot Knowl-
edgebase database http://www.uniprot.org/ [Consortium et al., 2011]. Alignments
were done with ClustalX [Larkin et al., 2007] http://www.ch.embnet.org/software/
ClustalW.html or Bioedit http/www.mbio.ncsu.edu/BioEdit/biioedit/html [Hall,
1999]. The UniprotKB codes of the sequences used were: Homo sapiens, Q9BXM7;
Gorilla gorilla, G3RF52; Bos Taurus, A5PJP5;Rattus norvegicus, B5DFG1; Mus mus-
culus, Q99MQ3; Monodelphis domestica, F7FR77; Canis familiaris, E2RCD1; Sus
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scrofa, F1SU10; Danio rerio, B5TXD9; Salmo salar, B5X237; Drosophila melanogaster,
QOKHV6; Caenorhabditis elegans, QO9298; Pediculus humanus, EOW1I1; Ascaris suum,
F1LON5.
3.2 cDNAs, plasmids and mutagenesis
The cDNA encoding full length human PINK1 (pCMV-sport6-hPINK1) was provided from
GeneService (Mammalian Gene Collection, IMAGE ID 5214483; GeneService, Cambridge,
United Kingdom). As this cDNA contained the mutation P209A, the original cDNA clone
was changed by site-directed mutagenesis to reconstitute the wild-type (wt) Pro209.
The mammalian expression plasmids to generate stable non-inducible human SH-
SY5Y cell lines, pcDNA3.1-PINK1 wt and mutations, were obtained by PCR and cloning
(BamHI/EcoRI) into pcDNA3.1.
The mammalian expression plasmids to generate inducible double stable Tet-On MCF-
7 human cell lines, pTRE2hyg-PINK1wt and mutations, were obtained by PCR, cloning
into pBluescript and subcloning (BamHI/ClaI) into pTRE2hygromicine. For all vectors,
a 5’ primer containing a Kozak sequence for the initiation of translation was used.
All sequences were verified by DNA sequencing. Preparative PCR contained 25 ng
template, 0.2 mM dNTPs, 0.3 µM of each primer, and 0.2 µl of the termostable DNA
polymerase G-C rich (Roche Diagnostics), in a total volume of 50 µl. PCR conditions
included an initial denaturation step at 95oC for 5 minutes (min), followed by 30 cycles of
94oC denaturation for 2 min, 60oC annealing for 2 min, 72oC extension for 1 min and a
last 72oC step of final elongation for 10 min. Table 3.1 shows the primers used for cloning
and mutagenesis. T4 DNA ligase (Invitrogen) and restriction endonucleases (Roche Diag-
nostics and Fermentas) were used according to the manufacturer’s instructions.
3.3 DNAs and bacterial methods
3.3.1 Plasmid DNA purification
Plasmid DNA was extracted from Escherichia coli (E. coli) DH5α strain (a recombination
deficient strain) transformants by two methods based on alcaline lysis.
• Small-scale purification of plasmid DNA (miniprep) was carried out to identify pos-
itive transformants.
• Large-scale purification of plasmid DNA (maxiprep) was done using an alkaline lysis
based maxiprep kit (Plasmid DNA Purification, Machery-Nagel).
For mini- and maxiprep, cells were grown in 3 ml and 100 ml LBA media, respectively (10
g.l−1 peptone, 5 g.l−1 yeast extract, 0.17 M NaCl, 50 µg.ml−1 ampicillin) 16 hours (h) on
a shaker at 37oC.
3.3.2 Agarose gel electrophoresis and purification of DNA fragments
Agarose gel electrophoresis (1-2%) was used to separate, identify and/or purify DNA frag-
ments according to size. Gels, containing 0.6 µg.ml−1 EtBr to visualise DNA fragments,
were run at 100-120 V in 1X TAE buffer (40 mM Tris-acetate, 1 mM EDTA). To obtain
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Table 3.1: Primers used for cloning and mutagenesis.
Primer name Sequence
PINK1 forward (pBluescript) AAAGGATCCCGGCCGGCCGCCACCATGGCGGTGCGAC
AGGCGC
PINK1 reverse (pBluescript) CCGGAATTCCTCGAGTCACAGGGCTGCCCTCCATG
PINK1 forward (pcDNA3.1) GCTCTAGAGGCCGCCACCATGGCGGTGCGACAGGCGC
PINK1 reverse (pcDNA3.1) CCCAAGCTTTCAGAGGCTAGCATAATCAGGAACATCAT
ACTCGAGCAGGGCTGCCCTCCATGAGCA
P209A forward AGCGAGCTCCGGGGGCC
P209A reverse GGCCCCCGGAGCTCGCT
A168P forward GGCTGCAGTCCTGCTGTGTAT
A168P reverse ATACACAGCAGGATCGCAGCC
K219M forward TTGGCCATCATGATGATGTGG
K219M reverse CCACATCATCATGATGGCCAA
G309D forward AAGGCCTGGACCATGGCCG
G309D reverse CGGCCATGGTCCAGGCCTT
L347P forward TGCAGCTGCCGGAAGGCGT
L347P reverse ACGCCTTCCGGCAGCTGCA
W437X (pBluescript) CCCGAATTCAAGCTTTCAGGCATCAGCCTTGCTGTAGT
W437X (pcDNA3.1) CCCGAATTCAAGCTTTCAGAGGCTAGCATAATCAGGAA
CATCATAGGCATCAGCCTTGCTGTAGT
510 reverse (pBluescript) CCCGAATTCCTCGAGTCAGCTTAGATGAAGCACATTTG
CG
510 reverse (pcDNA3.1) CCCAAGCTTTCAGAGGCTAGCATAATCAGGAACATCAT
AGCTTAGATGAAGCACATTTGCG
150 forward (pBluescript) AAAGGATCCCGGCCGGCCGCCACCATGGGCTTTCGGCT
GGAG
150 forward (pcDNA3.1) GCTCTAGAGGCCGCCACCATGGGCTTTCGGCTGGAG
DNA fragments for ligation, samples were run on low melting agarose gels and gel slices
containing the DNA were melted and added directly to the ligation mix. For PCR re-
striction products, DNA samples were separated on agarose gels and DNA fragments were
purified using the QIAEX II Gel Extraction Kit (Qiagen).
3.3.3 Bacterial methods
Cells from E. coli DH5α strain were made competent by treatment with CaCl2. E. coli
cells were transformed with the suitable plasmid by the heat shock method (30 min at
4oC, 50 seconds at 42oC and 2 min at 4oC) and incubated on a shaker (1 h at 37oC) with
LB before plating. To select single transformant colonies, bacteria were plated on LBA
plates containing the appropriate selection marker (LBA media with 5 g.l−1 agar) and
incubated for 16 h at 37oC. Cultures of positive E. coli colonies were grown overnight in
LBA media on a shaker at 37oC.
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3.4 Cell culture, treatments, stable transfections and
siRNA
3.4.1 Cell culture
All parental cell lines were obtained from American Type Culture Collection (ATTC), and
were grown at 37oC in a 5% CO2 humidified atmosphere.
The human dopaminergic neuroblastoma SH-SY5Y cell line (Figure 3.1) was cultured
in 1:1 (v/v) DMEM (Dulbecco’s Modified Eagle Medium):Ham’s F12 (Nutrient mixture
F-12 Ham medium) media (Gibco, Invitrogen) containing 3.6 g.l−1 glucose and supple-
mented with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 1 mM non-essential
aminoacids, 100 U.ml−1 penicillin and 100 µg.ml−1 streptomycin. SH-SY5Y stable cells
were grown in SH-SY5Y cell medium supplemented with 200 µg.ml−1 G418 (Fisher BioRe-
agents).
The human breast carcinoma MCF-7 cell line (Figure 3.1) was cultured in Roswell
Park Memorial Institute medium (RPMI) 1640 (Gibco, Invitrogen) supplemented with
10% FBS, 2 mM L-glutamine, 100 U.ml−1 penicillin and 100 µg.ml−1 streptomycin. MCF-
7 stable Tet-On cell line containing Tet-On plasmid was provided by R.P. Shiu [Gonza´lez
et al., 2006; Venditti et al., 2002]. MCF-7 Tet-On double-stable cells were grown in MCF-7
cell medium, supplemented with 200 µg.ml−1 G418 (Gibco, Invitrogen) and 100 µg.ml−1
hygromycin (Sigma-Aldrich).
The human breast MDA-MB-231 cell line was cultured in DMEM (Gibco, Invitrogen)
supplemented with 10% FBS, 2 mM L-glutamine, 100 U.ml−1 penicillin and 100 µg.ml−1
streptomycin.
Figure 3.1: MCF-7 and SH-SY5Y cells.
3.4.2 Stable transfections
For the generation of the different PINK1 over-expressing SH-SY5Y stable cell lines, SH-
SY5Y cells were stably transfected with pcDNA3.1 vector (Invitrogen) using Fugene HD
(Roche Diagnostics) (Figure 3.2). For selection of positive transformants, the optimal
drug concentration was determined at 200 µg.ml−1. To select stable cells, single colonies
were isolated using 3 mm cloning discs or cloning cylinders (Sigma-Aldrich), and trans-
ferred to 24-well plates. From 24-well plates, half of the cells were tested for expression
of ectopic proteins, and half of the cells were transferred to 12-well plates. From 12-well
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plates the clones were expanded to 6-well plates, and then to 10 cm plates. Stocks of each
clone were frozen after expanding the cell cultures.
To generate double-stable cell lines, MCF-7 Tet-On cell line was transfected with the
pTRE2hyg plasmid (Clontech) using FuGENE 6TM (Roche Diagnostics) (Figure 3.2).
Pilot experiments to generate the double-stable MCF-7 Tet-On cell lines, with inducible
expression of the different PINK1 cDNAs, were done according to the Tet-On R© Advanced
Inducible Gene Expression System User Manual (Clontech) (Figure 3.2). For selection
of double-stable transformants, the optimal drug concentration was determined at 100
µg.ml−1 hygromycin, and the optimal plating density of cells was determined at 1x106
cells/10 cm dish containing 10 ml of the appropriate selective media. To select double-
stable cells, single colonies were isolated as above. To induce PINK1 expression in MCF-7
Tet-On double-stable cells, the cell lines were pre-treated with 100-500 ng.ml−1 doxycycline
(Dox) for 24 h before processing or analysis.
Figure 3.2: Generation of PINK1 stable over-expressing MCF-7 and
SH-SY5Y cells. 1) Scheme of pcDNA3.1(-) vector used to clone the differ-
ent PINK1 cDNAs and to transfect SH-SY5Y to generate stable clones (Modified
from http://xlaevis.cpsc.ucalgary.ca/other/static/methods/vector-info/
maps/pcdna3_1p-_map.jpg). 2) Scheme of pTRE2hyg vector used to clone the
different PINK1 cDNAs and to transfect MCF-7 to generate stable clones (mod-
ified from http://www.clas.ufl.edu/jur/200308/images/piacenti_1.gif). 3)
Scheme of the Tet-On Advanced System: rtTA-Advanced binds TRE-Tight and fully
activates transcription in the presence of low concentrations of doxycycline. Source:
http://www.clontech.com.
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3.4.3 siRNA
Silencing of MCF-7 and MDA-MB-231 cells was performed by transfection with Lipofec-
tamine RNAiMAX or Lipofectamine 2000 (Invitrogen), respectively, of validated scram-
bled, GAPDH and PINK1 siRNAs (Ambion Applied Biosystems), following manufac-
turer’s instructions. Silencing of SH-SY5Y cells was performed by transfection of scram-
bled, or PINK1 siRNAs as above, using HiPerfect Transfection (Qiagen), following man-
ufacturer’s instructions. Cells were processed 48 h after transfection.
3.4.4 Cellular treatments
The cellular treatments used are displayed in Table 3.2.
Table 3.2: Cellular treatments.
Treatment Cellular effect Use Supplier
SH-SY5Y cells
Oligomycin ATP synthase inhibitor 2 µg.ml−1 Sigma-Aldrich
O4876
Rotenone Inhibitor of mitochondrial electron
transport
5 µM Sigma-Aldrich
R8875
CCCP (carbonyl
cyanide m-chloro
phenyl hydrazone)
Mitochondrial uncoupler 10µM Sigma-Aldrich
C2759
FCCP
(carbonylcyanide-4-
trifluoromethoxyphenylhydrazone)
Mitochondrial uncoupler 100 µM Sigma-Aldrich
C2920
MCF-7 cells
H2O2 (hydrogen per-
oxide)
Apoptosis inductor by increasing ROS 0.15 mM Merck 107209
3.5 Semiquantitative PCR and real-time quantitative PCR
analysis
Semiquantitative PCR was performed from a human normal tissue cDNA collection (Prime-
Express II, PrimeGen, USA), using GC-Rich PCR kit (Roche). Total RNA was extracted
from MCF-7 and SH-SY5Y cells using illustra RNAspin Mini RNA Isolation Kit (GE
Healthcare). Human brain, breast and thyroid total RNA were provided from Ambion
Applied Biosystems. Breast cancer tissue samples were provided by Dr. Jaime Fer-
rrer, Biobanco FIHCUV-INCLIVA, Valencia. Total RNA from 10-15 breast cancer tis-
sue slides (10 µm each) was extracted with RNeasy Universal Plus Mini kit (Qiagen).
Then, RNA was quantified by spectrometry and measured the RIN quality (Nano Drop
ND1000, NanoDrop Technologies, Wilminton, Delaware USA). 1 µg total RNA was re-
verse transcribed using RevertAidTM reverse transcriptase, oligo(dT)18 primers and Ri-
boLock RNase inhibitor (all from Fermentas). The primer conditions and the cDNA
amount were optimized, getting efficiency values between 1.9 to 2.1. Each qPCR reac-
tion contained 100 ng cDNA template, 0.5 µM of each primer, and 5 µl SYBRGreenI
Master (Roche) and was performed in Lightcycler 480 (Roche) in a total volume of
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Table 3.3: Primers used for semiquantitave and quantitative PCR.
mRNA Forward Primer Reverse Primer Amplified
fragment
Semiquantitative PCR
PINK1 AGTGATTGACTACAGCAAG
GCTGAT
ATCTTGTCTAACTTCAGATT
CTTCAGG
300 bp
β-actin CCAAGGCCAACCGCGAGAA
GATGAC
AGGGTACATGGTGGTGCCG
CCAGAC
350 bp
qPCR of cells and normal tissues
PINK1 Validated (Qiagen) 112 bp
HPRT GACCAGTCAACAGGGACAT GTGTCAATTATATCTTCCACA
ATCAAG
90 bp
qPCR of breast cancer tissues
PINK1 GCCTCATCGAGGAAAAACAGG GTCTCGTGTCCAACGGGTC 114 bp
Parkin TCCAAACCGGATGAGTGGTG TTGCGATCAGGTGCAAAGCTA 128 bp
SNCA AAGAGGGTGTTCTCTATGTAGGC GCTCCTCCAACATTTGTCACTT 106 bp
SNCAIP GAAGCCCCTGAATACCTTGATTT CGTATCACATCTTCGGCACAGT 108 bp
LRRK2 AGGAAAACAGATAGAAACGCTGG GTGCTCGGAGTACGTGAACAC 67 bp
DJ-1 GAGCTGGGATTAAGGTCACCG GACCACATCACGGCTACACT 71 bp
UCHL1 CCTGTGGCACAATCGGACTTA CATCTACCCGACATTGGCCTT 201 bp
GBA CTGGCGATGTAGCTTGTGG GAAGCGGTAATGAGTCAATCCAA 86 bp
ATP13A2 GTGCTGCGGTATTACCTCTTC TGGGTCTCGATCCAGATATAGC 53 bp
Htra2/omi ACCTGGTGAGTGAGACATCCT GCTCAGAAACTTGACCAAACATC 104 bp
PTEN TGGATTCGACTTAGACTTGACCT TGGCGGTGTCATAATGTCTTTC 182 bp
TRAP1 AGGACGACTGTTCAGCACG CCGGGCAACAATGTCCAAAAG 145 bp
MTP18 GTGTGCTGCCTCTCTCTATGT GCCAGGGTCTTTGGACACC 299 bp
ER AATGTGCCTGGCTAGAGATCC CTGTCCAAGAGCAAGTTAGGAG 97 bp
PGR TCAACTAGGCGAGAGGCAACT GCCACATGGTAAGGCATAATGA 251 bp
HER2 TGACACCTAGCGGAGCGAT GGGGGATGTGTTTTCCCTCAA 185 bp
Ki67 ACGCCTGGTTACTATCAAAAGG CAGACCCATTTACTTGTGTTGGA 209 bp
HPRT GAAAAGGACCCCACGAAGTGT AGTCAAGGGCATATCCTACAACA 89 bp
10 µl. Relative quantifications were performed using the comparative method ∆∆Ct and
HPRT (Hypoxanthinephophoribosyl-transferase) as a reference gene with the mathemat-
ical method described in Pfaﬄ, 2001 [Pfaﬄ, 2001].
The set of genes analysed was selected from STRING software (http://string-db.
org/) [Von Mering et al., 2007] and from PDgene database (http://www.pdgene.org/)
[Lill et al., 2012]database. The sets of specific primers used to analyse expression in
breast cancer samples were designed by PrimerBank (http://pga.mgh.harvard.edu/
primerbank/) [Spandidos et al., 2010]. All the primers used are displayed in Table 3.3.
3.6 Immunoperoxidase staining of tissue sections
Immunohistochemistry (IHC) was performed as previously described [Torres et al., 2001],
with some modifications. Briefly, home-made tumour microarrays were created from tu-
mour tissue samples obtained by standard surgical procedures, fixed in buffered 10%
formaldehyde and embedded in paraffin. 5 µm-sections were quenched for 15 min in
3% hydrogen peroxide in methanol, washed with phosphate-buffered saline (PBS), and
incubated with 20% horse serum for 20 min. Then, sections were incubated with anti-
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PINK1 89B mAb (culture supernatant; 10 µg.ml−1 approximately) for 45 min at 20oC,
followed by washing and incubation with the secondary streptavidin-conjugated antibody
and avidin-biotin for 30 min at 20oC. Samples were washed and developed using an au-
tomated processor (Autostainer, Dako; Envision Plus, Dako, Glostrup, Denmark). As a
control of specificity, incubation of the samples in the presence of an excess of recombi-
nant GST-PINK1 150-510 blocked the reactivity of the anti-PINK1 89B mAb. As negative
controls, anti-PINK1 89B mAb was substituted for a non-reactive Ig from mouse ascites.
Immunostaining of human normal tissues was performed on a multi-tissue control block
(Biomeda Corporation); tissue sections stained included brain and breast.
3.7 Protein expression analysis
3.7.1 Cellular extracts
Whole cell protein extracts from mammalian cells were prepared as follows: cells were
harvested and lysed on ice in lysis buffer A (0.25% Triton X-100 in PBS, supplemented with
protease inhibitors (1 mM PMSF (phenylmethanesulfonyl fluoride), 1 µg.ml−1 pepstatin
A, 1 µg.ml−1 leupeptin) and 1 nM Na3VO4) or lysis buffer B (50 mM Tris-HCl pH 7.5,
150 mM NaCl, 1% Igepal (Nonidet P-40), 2 mM Na3VO4, 100 mM NaF, 1 mM PMSF,
1 µg.ml−1 aprotinine, 20 mM Na4P2O7, 0.25% Triton X-100) for 30 min, followed by
centrifugation at 16000xg for 10 min. The supernatant (soluble fraction) was collected
and stored at −20oC before processing for immunoblot (IB).
3.7.2 Immunoblot
For immunoblot (IB), the soluble fraction (25-50 µg of protein) was resolved in 9% (PINK1
blots), 15% (p27 and LC3 blots) or 10% SDS-PAGE under reducing conditions. Pro-
tein concentrations were determined using the Bradford (Biorad) method or BCA (bicin-
choninic acid, Pierce). Prestained molecular weight markers (Sigma-Aldrich) were used
to estimate protein sizes. The proteins were transferred to a Hybond-P PVDF membrane
(Amersham, GE Healthcare) activated with methanol. The membrane was blocked for
at least 1 h prior to incubation with primary antibody (Table 3.4), 16 h at 4oC or 2 h
at 20oC . Blocking and washing of the membranes were done in NET-gelatine (NET-gel)
buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl, 5 mM EDTA, 0.05% Triton X-100, 0.25%
gelatine), 0.1% Tween-PBS (T-PBS), or 0.1% Tween-TBS (T-TBS) (see Table 3.4). The
blocking was done with 5% non-fat dry milk and antibodies incubation with 3% BSA in
the case of T-TBS and P-PBS conditions, except for anti-DNP with 1% BSA for blocking
and antibody incubation. After membrane incubation with the appropriate horseradish
peroxidase-linked secondary antibody, blots were developed with enhanced chemilumines-
cence reagent (Roche Diagnostics and Pierce) and exposed to X-ray film (Kodak BioMax
MS). In some cases, in order to probe a second primary antibody, the membranes were
stripped twice for 5 min with stripping solution (0.2 N NaOH, 1% SDS). Quantification
of the immunoblots was done using the Image J (v1.44, Wayne Rasband, NIH, Bethesda,
USA).
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Table 3.4: Antibodies.
Antibody name IB use IF use Condition Source Reference
Primary antibodies
α-PINK1 Ag 1:1000 1:100 T-TBS Mouse Abgent
α-PINK1 108-200 1:500 1:50 NET-gel Rabbit
Generation in our
group
α-PINK1 89B culture
supernatant (89B
mAb)
1:1 or 1:2 1:1 or 1:2 NET-gel Mouse
Generation in our
group[Berthier et al.,
2011]
α-PINK1 BC100-494 1:500 — T-TBS Rabbit Novus Biologicals
α-TOM20 (FL-145) 1:2000 1:500 T-PBS Rabbit
SC Biotechnology,
Inc. Sc-11415
α-SDHA 1:1000 — T-PBS Rabbit Abcam (ab 66484)
α-β-actin 1:1000 — T-PBS Rabbit Sigma-Aldrich A2066
α-GAPDH (6C5) 1:10000 — T-PBS Mouse Abcam (clone 6C5)
α-GAPDH 1:1000 — NET-gel Mouse
SC Biotechnology,
Inc. Sc-32233
α-LC3 1:1000 — T-PBS Rabbit Cell signaling 2775
α-p62 1:1000 — T-PBS Mouse
BS Transduction
Lab. 610833
α-DNP 1:150 — T-PBS Rabbit Millipore 90451
α-Click iT R© Alexa
Fluor 488EdU
Manufacturer’s conditions Invitrogen C35002
α-cyclin D1 (DCS6) 1:1000 — NET-gel Mouse Cell signaling 2926
α-cyclin A (C19) 1:1000 — NET-gel Goat
SC Biotechnology,
Inc. Sc-596G
α-cyclin B1 (GNS1) 1:1000 — NET-gel Mouse
SC Biotechnology,
Inc. SC-245
α-p27 (N20) 1:500 — NET-gel Rabbit
SC Biotechnology,
Inc. Sc-527
α-p27 (C19) 1:500 — NET-gel Rabbit
SC Biotechnology,
Inc. Sc-5286
Secondary antibodies
α-Rabbit (SH-SY5Y) 1:5000 — — Goat Calbiochem DC03L
α-Rabbit (SH-SY5Y,
oxyblot)
1:300 — — Goat Millipore 90452
α-Mouse (SH-SY5Y) 1:5000 — — Goat Calbiochem DC02L
α-Rabbit (MCF-7) 1:5000 — — Goat Oncogene
α-Mouse (MCF-7) 1:5000 — — Goat Promega
α-Sheep 1:20000 — — Donkey Sigma-Aldrich A2066
α-Rabbit Alexa Fluor
544
— 1:100 — Goat Invitrogen A11001
α-Mouse Alexa Fluor
488
— 1:100 — Goat Invitrogen A11006
3.7.3 Immunofluorescence
For immunofluorescence (IF) analysis, the different cell lines were grown onto glass cover-
slips in 24-well or 6-well plates at approximate density 0.9x105 cells/coverslip. Then, cells
were washed with PBS, fixed in 4% paraformaldehyde (PFA)-PBS for 20 min at 20oC and
washed three times with PBS. Staining of mitochondrial network was done with a prein-
cubation step of 1 h with 0.5 µM Mitotracker CMXROS red (λexmax : 579nm λemmax :
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597nm, Invitrogen) in living cells. PINK1 over-expressing SH-SY5Y cells kept untreated
or treated with carbonyl cyanide m-chloro phenyl hydrazone (CCCP, 3 hours) were fixed
and washed as above. Then, cells were treated with 10 mM Sodium Citrate pH6, 20 min,
95oC, and permeabilised with methanol for 15 min at −20oC. Cells were blocked with 5%
goat serum in PBS, and incubated with antibodies against PINK1 (AM6406a, Abgent) and
TOM20 (sc-11415 Santa Cruz Biotechnology) followed by goat anti-mouse and anti-rabbit
secondary antibodies conjugated to the fluorophore alexa-488 and alexa-594 (alexa-488:
λexmax : 495nm λemmax : 519nm; alexa-594:λexmax : 590nm λemmax : 617nm, Invitro-
gen), respectively. Coverslips were mounted on slides with Citifluor supplemented with
4’-6-diamidino-2-phenylindole (DAPI, λexmax : 350nm λemmax : 470nm). Images were
taken using a Zeiss 710 UV-visible CLSM confocal microscope and fluorescence microscope.
PINK1 over-expressing MCF-7 Tet-On cells were fixed as above, permeabilized with 0.5%
Triton X-100-PBS for 5 min at 20oC and blocked with 3% bovine serum albumin (BSA)-
PBS 1 h at 20oC. Cells were incubated for 2 h at 37oC in wet-chamber with anti-PINK1
108-200 or anti-PINK1 89B mAb primary antibodies diluted in 3% BSA-PBS, followed
by incubation with goat anti-mouse or anti-rabbit secondary antibodies conjugated to the
fluorophore alexa-488 for 1 h. Nuclei were stained with Hoechst 33258 (λexmax : 352nm
λemmax : 461nm, Sigma-Aldrich). Coverslips were mounted onto microscope slides using
fluorescence mounting medium. Images were obtained with a DM2000 fluorescence mi-
croscope (Leica Microsystems, Wetzlar, Germany) equipped with a Leica DFC420 camera
and analyzed by ImageJ software.
3.7.4 Cellular subfractionation and mitochondrial isolation
PINK1 over-expressing SH-SY5Y cells were harvested by trypsinisation, washed in PBS
supplemented with 50 mM dithiothreitol (DTT), protease (1 mM PMSF, 1 µg.ml−1 pep-
statin A and 1 µg.ml−1 leupeptin) and phosphatase (1 nM Na3VO4 and 1 mM NaF)
inhibitors, and homogenised with a glass-teflon homogeniser in isolation medium (250
mM sucrose, 1 mM EDTA, 10 mM Tris, pH7.4 supplemented with 50 mM DTT, protease
(1 mM PMSF, 1 µg.ml−1 pepstatin A and 1 µg.ml−1 leupeptin) and phosphatase (1 nM
Na3VO4 and 1 mM NaF) inhibitors). Nuclei were removed by centrifugation (1500xg),
and mitochondrial were obtained by further centrifugation at 11800xg (pellet fraction)
and resuspended in isolation medium. Cytosolic fractions were concentrated with Am-
icon Ultra-4 10 K columns (Millipore). Antibodies against mitochondrial (TOM20 and
SDHA) and cytosolic (GAPDH (6C5) and β-actin) proteins were used as markers of these
compartments.
3.8 Cellular assay methods
3.8.0.1 Cell viability
SH-SY5Y cells were plated at a density of 4000 cells per well and incubated from 2 to
5 days. Cells were stained with 20 µl Cell Titer Blue Reagent (CellTiter-Blue R© Cell
Viability Assay (Promega)) for 4 h, and fluorescence (560/590nm) was measured. Data
are presented as the average fluorescence corrected for background.
MCF-7 cells were plated at a density of 3000 cells per well and incubated from 2 to
6 days. Cells were washed with PBS and fixed with 4% PFA-PBS for 20 min. Subse-
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quently, cells were stained with crystal violet solution, and after three washes, the stain-
ing was solubilized with 1% SDS. The absorbance (580nm) was measured with VICTOR3
(PerkinElmar) plate reader, using Wallac 1420 Workstation software. Data are presented
as the average absorbance corrected for background.
3.8.1 Neuroblastoma cell lines
3.8.1.1 ATP synthesis
PINK1 over-expressing SH-SY5Y cells were trypsinized and washed three times with
ice-cold PBS. Cells were resuspended at 2.5x105 cells.ml−1 in incubation medium (25
mM Tris, 150 mM KCl, 2 mM K+-EDTA, 10mM K2HPO4, pH7.4). An aliquot of cells
(2.5x104 cells) was mixed with an equal volume of incubation buffer containing 1 mg.ml−1
of BSA, 1 mM ADP and substrates (complexes I, III, IV: glutamate+malate (10 mM);
complexes II, III, IV: succinate (10 mM)+rotenone (10 µM); complex IV: ascorbate (2
mM)+N,N,N’,N’-tetramethyl-p-phenylenediamine (TMPD; 50 µM)), permeabilized with
digitonin (30 µg.ml−1), and incubated at 37oC for 30 min. The reaction was stopped with
perchloric acid, and samples neutralized with 3 M K2CO3/0.5 M triethanolamine. Debris
was removed by centrifugation and ATP measured with the ATP Bioluminesence Assay
kit HSII (Roche). Data were expressed as pmoles ATP synthesized.minute−1.mgprotein−1.
ATP synthesised in cells in the absence of substrates was substracted from the data.
3.8.1.2 Confocal imaging of mitochondrial membrane potential, reactive
oxygen species and glutathione
For measurements of ∆Ψm, cells were loaded with 25 nM tetramethylrhodamine
methylester (TMRM, λexmax : 548nm λemmax : 573nm, Invitrogen) in a HEPES-
buffered salt solution (HBSS, 156 mM NaCl, 3 mM KCl, 2 mM MgSO4, 1.25 mM
KH2PO2, 2 mM CaCl2, 10 mM glucose, 10 mM HEPES pH7.35) for 30 min at 20
oC,
and the dye was present throughout the experiment. In these experiments, TMRM
is used in the redistribution mode [Duchen et al., 2003] to assess ∆Ψm and therefore
a reduction in mitochondrial localised TMRM fluorescence represents ∆Ψm depolariza-
tion. Oligomycin (2 µg.ml−1), rotenone (5 µM) and FCCP (100 µM, carbonylcyanide-4-
trifluoromethoxyphenylhydrazone) were added after basal TMRM measurements to assess
changes of ∆Ψm. Confocal images were obtained using a Zeiss 710 UV-visible CLSM
microscope equipped with a META detection system and a 63x oil immersion objective.
The 543nm argon laser line was used to excite TMRM and fluorescence measured using a
560nm long-pass filter.
To measure cytosolic ROS (cROS) production, 2 µM dihydroethidium (HEt, λexmax :
543nm λemmax : 560nm, Invitrogen) was present in the solution during the experiment
(the absence of previous loading step limited the intracellular accumulation of oxidised
products). HEt is a non-fluorescent derivative of the red fluorescent ethidium, and an
increase in red fluorescence gives a measure of the rate of oxidation. The ratio between
the oxidised and reduced species was considered as the measurement of ROS generation.
For GSH measurement, cells were incubated with 50 µM monochlorobinane (MCB,
λexmax : 351nm λemmax : 430 − 480nm, Invitrogen) for 30 min. Non-fluorescent MCB
undergoes a reaction with glutathione catalysed by glutathione-transferase, to yield a
fluorescent adduct which gives a measure of GSH content [Keelan et al., 2001].
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HEt and GSH fluorescence measurements were obtained on an epifluorescence inverted
microscope equipped with an 20x fluorite objective. Emitted fluorescence light was re-
flected to a cooled CCD camera. All data presented were obtained from at least three
coverslips from different cell preparations.
3.8.1.3 Oxyblot: detection of protein carbonyls
Protein carbonyl levels were measured in PINK1 over-expressing SH-SY5Y cells using the
Oxyblot R© protein oxidation detection kit (Millipore). Briefly, cells were lysed with 0.25%
Triton X-100-PBS supplemented with 50 mM DTT and protease inhibitors (1 mM PMSF,
1 µg.ml−1 pepstatin A and 1 µg.ml−1 leupeptin). Following removal of insoluble material,
protein carbonyls were derivatized to 2,4-dinitrophenylhydrazone (DNP) by reaction with
2,4-dinitrophenylhydrazine. The DNP-derivatized protein samples were then separated
by SDS-PAGE followed by immunoblot (section 3.7.2). Carbonyls were detected by
incubation with an antibody specific to DNP. Note that protein samples which were not
derivatized to DNP were not detected by the DNP antibody. Equal loading was determined
by reprobing the same blot with anti-GAPDH (6C5) antibody.
3.8.1.4 Mitochondrial DNA copy number
To measure mitochondrial DNA (mtDNA) copy number, total cellular DNA
was isolated with E.N.Z.A genome DNA kit (Omega Bio-tek, Doraville, GA).
qPCR analysis of the mtDNA copy number was performed using primers in the
D-loop of mitochondria: forward 5’-CATCTGGTTCCTACTTCAGGG-3’ and re-
verse 5’-TGAGTGGTTAATAGGGTGATAGA-3’ and in the nuclear thymidine ki-
nase 2 (TK2), exon 5: forward 5’-TCCTGCAGA TGCCACTTTGA-3’ and reverse
5’-CCCCAAGTCTGAAGAAAACG-3’. Amplification of the D-loop of mitochondria was
measured using the QuantiTect SYBR Green kit, and was expressed relative to the single
copy nuclear gene. Relative expression was calculated using the ∆∆Ct method.
3.8.1.5 Mitophagy analysis and citrate synthase activity
Following treatment with 10 µM CCCP, cells were washed once with PBS and lysed
(Buffer A) as in section 3.7.1. Supernatant was used for immunoblot analysis to check
LC3 and p62 expression and to measure citrate synthase activity by following the oxida-
tion of 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB or Ellman’s reagent). Oxydation was
measured over time in a spectrophotometer (absorbance at 412nm) at 30oC in the pres-
ence of Acetyl Co-A and oxaloacetate [Coore et al., 1971; Shepherd and Garland, 1969].
Protein concentration from the same aliquot was measured using the BCA protein assay
(Pierce). Enzyme activity was expressed as nmol.min−1.mgprotein−1.
3.8.2 Breast cancer cell lines
3.8.2.1 Apoptosis
MCF-7 inducible cell lines were plated at density 2.5x105 cells per well in 6-well plates
24 h before treatment with 0.15 mM hydrogen peroxide (H2O2) for 24 h, to induce
mitochondrial-mediated apoptosis through mitochondrial release of cyt c-dependent path-
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way [Brookes et al., 2002]. Cellular viability and mitochondrial membrane potential
(∆Ψm) were measured by flow cytometry (FACS).
Cell death was determined by 5 min incubation with propidium iodide (PI; λexmax :
493nm λemmax : 617nm; Sigma-Aldrich), a membrane impermeable nucleic acid dye which
enters the cells upon cell death due to loss of membrane integrity.
∆Ψm was measured upon 30 min incubation with 40 nM 3,30-dihexylo-xacarbocyanine
iodide (DiOC6(3)), λexmax : 484nm λemmax : 511nm, Invitrogen). DiOC6 is a membrane-
permeable lipophilic cationic dye that stains mitochondria of live cells at physiologic ∆Ψm
because of its affinity to cardiolipines [O¨zgen et al., 2000].
Fluorescence was quantified on a Cytomomics FC 500 flow cytometer (Beckton-
Dickinson). For each sample, 10000 cells were acquired.
3.8.2.2 Adhesion assay
Cells were pretreated with Dox and plated at a density of 1x105 cells per well in 96-well
plates pre-coated with 1:20 diluted BD Matrigel (Basement Membrane Matrix, BD Bio-
science), 10 µg.ml−1 fibronectin (Sigma-Aldrich), 10 µg.ml−1 colagen IV (BD Pharmigen)
or 1 µg.ml−1 gelatine (Merck) in PBS for at least 16 h. Before plating the cells, plates
were pre-coated for 1 h with 0.1% BSA. Cells were plated with MCF-7 medium with or
without Dox, containing 0.1% BSA, and were incubated 3 h for attachment. Non-attached
cells were washed with PBS, and the attached cells were fixed with 4% PFA-PBS, stained
with 0.1% crystal violet, and re-solubilised with 10% acetic acid. The absorbance was
measured at 570nm with VICTOR3 (PerkinElmar) plate reader, and data are presented
as the average absorbance corrected for background.
3.8.2.3 Invasion assay
Cells were plated at a density of 1.8x105 cells per well in 24-well plates and grown with
or without Dox for 48 h. Subsequently, the cell monolayers were scratched with a sterile
micropipette tip and incubated for another 24 h. For each sample, the scratch boundary
area was monitored during this period. The photographs were taken every 30 min during
24 h at 5x magnification with an automatised time-lapse Leica DMI6000 microscope. The
analysis of the photographs was done with Image J as followed (Figure 3.3):
• Separation of the different positions stored in single files in one file per position using
the automation “separate-time series” and saving as *.tif files.
• Open a *.tif file in Image J and process it as follows: Process→ Find Edges; Process
→ Sharpen.
• Make threshold. Image → Adjust → Threshold; Select Black/White. Upper slider
to 0 (left). Set lower slider in such a way that it is clear where the cells are.
• Second process to count particles. Process → Find Edges; Image → Look up Tables
→ Invert LUT
• Analyse Particles. Size: select a number between 50000-50000000. Circularity: 0.00-
1.00. Show: Outlines. Flag: Summarise. Save both the summarised data file and
the file with outlines. The data file will show the percentage of wound area in the
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image on every time point. Initial and final photographs were analysed with Image
J and invasion index (i) area were represented as:
i =
areatf − areat0
areat0
Figure 3.3: Image processing of invasion time lapse photographs. A) and
B) Example of images taken by time lapse: initial (A) and final photographs (B).
After first image processing (C), threshold selected (D), and selection of Invert-LUT
(E), and the output outline (F).
3.8.2.4 Colony-formation assay
Soft agar growth assays of PINK1 over-expressing MCF-7 Tet-On cells were carried out in
12-well plates (Modified from Koleske et al., 1995). In each well, a 0.75 ml top layer con-
taining the cell suspension (2500 cells in 0.38% cell culture tested agar (Sigma-Aldrich),
10% FBS, 100 U.ml−1 penicillin, 100 µg.ml−1 streptomycin, 200 µg.ml−1 G418, 100
µg.ml−1 hygromycin B, 100 ng.ml−1 Dox) was added to a hardened bottom layer (0.75
ml previous medium, 0.45% agar). Cells were cultured for two weeks and colonies were
stained with 0.05% crystal violet (Sigma-Aldrich) and were photographed at 40x magni-
fication. The culture was analysed in five independent experiments, and colonies larger
than 100 µm in diameter were counted. Number of colonies was quantified with ImageJ
software as followed (Figure 3.4):
• Open a *.tif file in Image J and duplicate as follows: Image → Duplicate; Image →
Adjust → Brightness/Contrast → Auto → Apply.
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• Obtain the background: Image → Duplicate (duplicate original image). Process →
Filters → Maximum. Select Radious 10 pixeles.
• Substract the background to the image of interest: Process → Image Calculator.
Image 1: image with colony to quantify; Select Substract; Image 2: image with
background created previously. Create a new window; 32-bit result.
• Count and analyse the colonies: Image → Adjust → Threshold (Select the same for
all the images in which all the colonies are selected) → Apply. Analyse → Analyse
Particles. Options selected: Size 100-Infinity; Circularity 0.00-1.00; Show masks;
Display results; Summarise.
The number of colonies counted was normalised and represented as 100% in control cells.
Figure 3.4: Image processing of colony formation in soft agar photographs.
A) Example of image of colony formation in soft agar. B) After the first adjustment.
(C) Background generation of the same image. (D) Result of the original image
original after background substraction.(E) Last processed step with threshold ad-
justment.
3.8.2.5 Cell cycle and EdU proliferation
Cells were plated at a density of 2.5x105 cells per well in 6-well plates, grown and incubated
for 24 h. Then, cells were arrested in G0/G1 by FBS starvation for 18 h [Kehn et al., 2007],
and cells were re-entered to cell cycle by adding FBS, and were harvested at 12, 24 and
48 h. Subsequently, cells were trypsinised, washed with PBS and resuspended in 300 µl
cell-cycle buffer (100 mg Na3C6H5O7, 100 µl Triton X-100, 5 mg PI, 10 mg RNase A). PI
binds to DNA by intercalating between the bases with a stoichiometry of one dye per 45
base pairs of DNA, allowing the quantification of DNA content.
The FACS cell cycle analysis was represented as fluorescence intensity histograms of the
three characteristic cell cycle populations: two Gaussian curves corresponding to G0/G1
(2N) and G2/M (4N), and an inter-region representing the S phase population (Figure
3.5). WinMDI 2.8 software (J. Trotter, Purdue University, USA) was used to adjust the
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histograms with correct mathematical models, and representation was done in Cylchred
software (Cardiff University, UK).
Figure 3.5: Example of cell cycle FACS graphic. Fluorescence intensity his-
togram with the three characteristic cell cycle phases: G1 phase, S phase and G2/M
phase.
.
Sincronised cells were lysed (Buffer B) at different times and cell cycle protein expres-
sion (cyclin D1, cyclin A, cyclin B1 and inhibitor p27) was analysed by immunoblot.
For the analysis of cells in S phase (proliferating cells), cells were plated and starved
as in cell cycle experiments. The EdU compound (5-ethynyl-2’-deoxyuridine, an analog
to BrdU, λexmax : 360nm λemmax : 449nm) was added at starvation point and kept
for 18 h. Then, the Click-iT TM EdU Flow Cytometry assay kit protocol was followed,
which is based on the detection of EdU by antibodies after its incorporation to the DNA
during S phase. Percentages of cellular proliferation events, proliferating cells in G0/G1
and proliferating cells in G2/M were represented.
3.9 Statistical Analysis
Statistical analysis was performed with PRISM software (GraphPad Software, San Diego,
CA) by using the Newman’s Keuls multiple comparison test for one-way analysis of vari-
ance ANOVA. Student t-test was performed for mtDNA, adhesion and cell cycle/prolifer-
ation experiments. Data are expressed as the mean ± standard error of the mean (S.E.M)
of separate experiments (n).
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3.10 Mutations used in this study
We have functionally studied PINK1 missense and truncated mutations in the context of
human neuronal (SH-SY5Y cells) and breast cancer (MCF-7 cells) models. Table 3.5 and
Figure 3.6 summarize the PINK1 mutations analysed.
Table 3.5: PINK1 mutations used in this study.
Name Mutations References
PINK1 wt — Unoki and Nakamura,
2001; Valente et al.,
2001
K219M Catalytically inactive mutation. Lysine proposed to bind
ATP.
Petit et al., 2005
A168P Missense PD-linked mutation. Decreased kinase activity,
localised inside the putative ATP binding site
Valente et al., 2004b
G309D Missense PD-linked mutation. Decreased kinase activity,
localised in the kinase subdomain V
Valente et al., 2004a
L347P Missense PD-linked mutation. Decreased stabilisation,
localised in the kinase subdomain VI
Hatano et al., 2004; Ro-
gaeva et al., 2004
W437X Nonsense PD-linked mutation. Increased/decreased ki-
nase activity
Valente et al., 2004a
∆C PINK1 1-510 (deletion of C-terminal tail) Silvestri et al., 2005
∆N PINK1 150-581 (deletion of N-terminal tail) Takatori et al., 2008;
Wang et al., 2007;
Haque et al., 2008
∆N-C PINK1 150-510 (deletion of N- and C-terminal tails) Sim et al., 2006;
Berthier et al., 2011
All mutations have been over-expressed in SH-SY5Y and MCF-7 cells, except for K219M
(only in SH-SY5Y cells) and ∆N-C (only in MCF-7 cells).
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Figure 3.6: PINK1 domain organisation and schematic of the PINK1 mu-
tations and truncations used in this study. Missense and truncated mutations
are indicated with amino acid numbering. See Table 3.5 for further details.
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4.1 PINK1 over-expressing SH-SY5Y cells
Recent reports have determined the mitochondrial dysfunction underlying PINK1 loss of
function (see Section 1.6). However, little is known regarding how PD-linked PINK1
mutations, as well as PINK1 subdomains, affect PINK1 function in physiological settings.
To investigate the role of PINK1 in neuronal mitochondrial function and mitophagy,
as well as the functional consequences of missense or truncated mutations on the PINK1
protein, we generated SH-SY5Y human neuroblastoma cells stably over-expressing wild
type, mutated or truncated PINK1 proteins. The scheme and the features of the PINK1
over-expressing cells generated are displayed in Chapter 3, Table 3.5 and Figure 3.6.
4.1.1 PINK1 expression and cell viability
PINK1 mRNA expression levels in the SH-SY5Y cell lines were measured by qPCR, com-
pared to HPRT as a reference gene. Over-expression of PINK1 mRNA in all cell lines was
similar, compared to control cells (Figure 4.1-1). PINK1 protein was undetectable in
parental SH-SY5Y cells, probably due to low endogenous PINK1 expression levels.
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Figure 4.1: PINK1 expression levels and cell viability were similar in all
PINK1 over-expressing SH-SY5Y cells generated. 1) qPCR analysis of PINK1
mRNA levels. Total RNA was subjected to reverse transcription. qPCR was per-
formed and quantification was normalized to HPRT as a reference gene. 2) PINK1
protein expression levels detected by immunoblot with anti-PINK1 BC100 antibody.
GAPDH (6C5) was used as a loading control. Red arrows indicate the unprocessed
PINK1 full length protein. Green head arrows indicate the processed PINK1 proteins.
3) Cell viability, measured by CellTiter-Blue R©, of SH-SY5Y cells over-expressing
missense (A and B) and truncated (C) PINK1 mutations, compared to control and
PINK1 wt over-expressing cells.
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PINK1 protein expression levels were similar in all PINK1 over-expressing cells gener-
ated (Figure 4.1-2). Cell lysates were analysed with anti-PINK1 BC100 antibody which
detects three PINK1 protein forms: the unprocessed form (or full length (FL), 63 kDa);
and two processed forms: PINK1-∆1 and PINK1-∆2 (54 kDa and 45 kDa, respectively),
as indicated in Figure 4.1-2.
The cellular viability under normal growth conditions of PINK1 over-expressing cells
was analysed to rule out deleterious effects. The cellular growth of PINK1 over-expressing
cells did not show differences compared to control cells (Figure 4.1-3).
4.1.2 PINK1 localisation
PINK1 is localised in mitochondria and cytosol compartments in cultured cells (see Sec-
tion 1.3). Thus, we analysed PINK1 localisation in our over-expressing cells by im-
munofluorescence. Ectopic expression of PINK1 resulted in increased green staining com-
pared to control cells. PINK1 wt overlapped with the staining of the outer mitochondrial
membrane protein TOM20 in over-expressing SH-SY5Y cells (Figure 4.2-1). The PINK1
missense and C-terminal truncated mutations (PINK1 PD-linked W437X, ∆C: residues
1-510) co-localised with TOM20 as PINK1 wt, and in the case of C-terminal truncations
the mitochondrial localisation was higher than PINK1. The N-terminal truncation (∆N:
residues 150-581) mostly localised to the cytosol, but still slightly associated to mitochon-
dria compartment.
We also verified the PINK1 localisation by subcellular fractionation. PINK1 over-
expressing cells were fractionated by differential centrifugation, and the mitochondrial
and cytosolic fractions were analysed. As shown, PINK1 forms were present in both com-
partments (Figure 4.2-2). In PINK1 wt cells, the three PINK1 forms (PINK1 FL, ∆1 and
∆2) were detected in the cytosol fraction, but PINK1 FL was mostly in the mitochondrial
fraction. PINK1 K219M and G309D over-expressing cells showed the same distribution
pattern of the protein compared to PINK1 wt cells. Besides, in PINK1 missense mutation
cells, PINK1 ∆1 form was detected in the mitochondrial fraction. Curiously, in the PINK1
C-terminal truncated over-expressing cells the three PINK1 forms were localised in both
compartments, but with higher detection in the mitochondrial compartment. The PINK1
∆N over-expressing cells presented two PINK1 protein forms, mainly but not exclusively,
localised in the cytosolic fraction (Figure 4.2-2).
In summary, we demonstrate that PINK1 is localised in both compartments and that
the localisation is unaffected by missense mutations, whereas truncated mutations partially
affected the distribution of PINK1 protein.
4.2 Mitochondrial function
PINK1 deficiency leads to an impairment in ATP production through the mitochondrial
electron transport chain, decreases mitochondrial membrane potential (∆Ψm), increases
reactive oxygen species (ROS) production, and decreases the mtDNA content (see Section
1.6.2). Thus, we analysed the phenotypes of the different PINK1 over-expressing SH-
SY5Y cells for those mitochondrial functional parameters.
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Figure 4.2: PINK1 wt, PD-linked mutations, and C-terminal truncated
mutation are distributed in mitochondria and cytosolic compartments.
The N-terminal truncated mutation is mostly localised in cytosol. 1) Con-
trol (a-d), PINK1 wt (e-h), K219M (i-l), A168P (m-p), G309D (q-t), L347P (u-x),
W437X (A-D), ∆C (E-H), and ∆N (I-L) over-expressing SH-SY5Y cells were studied.
Immunofluorescence was carried out with anti-PINK1 Ag antibody [green] (a, e, i, m,
q, u, A, E, I), anti-TOM20 [red] (b, f, j, n, r, v, B, F, J), DAPI [blue] (c, g, k, o, s,
w, C, G, K). In panels d, h, l, p, t, x, D, H, and L, the overlay of the three colours is
shown. 2) Subcellular fractionation of control, PINK1 wt, K219M, G309D, W437X,
∆C, and ∆N over-expressing SH-SY5Y cells. C: cytosolic fraction, M: mitochondrial
fraction. GAPDH (6C5) was used as cytosolic marker, and SDHA and TOM20 as
mitochondrial markers.
4.2.1 ATP production through the mitochondrial electron transport
chain
We measured ATP production through the mitochondrial electron transport chain, using
PINK1 over-expressing SH-SY5Y cells permeabilized with digitonin, and supplemented
with the different mitochondrial electron transport chain substrates for complex I: gluta-
mate+malate, complex II/III: succinate+rotenone or complex IV: ascorbate and TMPD
(Figure 4.3).
Over-expression of PINK1 wt had no effect on ATP synthesis produced through com-
plexes I, II/III, or IV, compared to control cells (Figure 4.3). ATP synthesis was sig-
nificantly inhibited in the PINK1 K219M over-expressing cells via complexes II/III and
complex IV (Figure 4.3-1). The cells over-expressing C-terminal truncated mutations
(PINK1 W437X and ∆C) also showed an inhibition in ATP synthesis, as well as the
cells over-expressing the PD-linked mutations A168P, G309D and L347P (Figure 4.3).
The PINK1 ∆N over-expressing cells did not show impaired ATP production, but rather
a slight increase in ATP production. Therefore, the PINK1 kinase activity and the C-
terminal domain are important to maintain ATP production through the electron trans-
port chain.
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Figure 4.3: PINK1 kinase activity and C-terminal domain modulate
mitochondrial ATP synthesis. PINK1 over-expressing SH-SY5Y cells were
permeabilised and ATP synthesis was measured following incubation with gluta-
mate+malate (panels A), succinate+rotenone (panels B) or ascorbate+TMPD
(panels C) for 30 minutes. ATP was measured by luciferase assay. Data are shown as
the mean±SEM from five independent experiments. Statistical significance *p<0.05
and **p<0.01 versus control cells.
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4.2.2 Mitochondrial membrane potential
The impairment of ATP synthesis mediated by PINK1 missense and C-terminal truncated
mutation can be due to a decrease in ∆Ψm (see Section 1.6.2). Thus, we monitored the
∆Ψm in our cellular model using tetramethylrhodamine methylester (TMRM) staining.
PINK1 wt over-expressing SH-SY5Y cells showed two-fold increase in basal ∆Ψm, com-
pared to control cells (Figure 4.4-1). PINK1 K219M, A168P, L347P, W437X and ∆C
over-expressing SH-SY5Y cells showed decreased in ∆Ψm compared to PINK1 wt over-
expressing cells. In some of the mutations the decrease was below the control cells value,
suggesting a dominant negative effect. We included silenced PINK1 SH-SY5Y cells to
confirm the reported decrease in ∆Ψm [Gandhi et al., 2009].
PINK1 wt over-expressing cells displayed a mitochondrial network more intercon-
nected, with mitochondria scattered through the whole cytoplasm. In the case of PINK1
K219M, A168P, L347P, W437X and ∆C over-expressing cells, the mitochondrial net-
work is less interconnected, compared to PINK1 wt cells. Interestingly, PINK1 G309D
over-expressing cells, with no changes in ∆Ψm, displayed ring-like and more fragmented
mitochondrial network (Figure 4.4-2), compared to the rest of the mutations. PINK1
∆N did not show significant changes in ∆Ψm nor mitochondria morphology changes in
comparison to control cells (Figure 4.4-1 and -2).
In summary, we conclude that PINK1 controls ∆Ψm and ATP production through
the electron transport chain. PINK1 catalytic activity and C-terminus are important to
maintain the mitochondrial function and mitochondrial morphology.
To test the maintenance of ∆Ψm in those cells, we analysed the TMRM staining in the
presence of various mitochondrial inhibitors: oligomycin (complex V inhibitor), rotenone
(complex I inhibitor) and FCCP (mitochondrial uncoupling agent). Control, PINK1 wt,
A168P, G309D, L347P and ∆N cells showed either no response or slight hyperpolarization
upon oligomycin treatment. However, PINK1 K219M, W437X and ∆C cells showed depo-
larization in response to ATP synthase inhibition by oligomycin. Subsequent inhibition of
complex I by rotenone, and whole mitochondrial depolarization by FCCP, caused a rapid
loss of mitochondrial potential in all the PINK1 over-expressing cells analysed (Figure
4.5). In the case of PINK1 wt and ∆N over-expressing cells, the addition of rotenone
caused less decrease in mitochondrial membrane potential compared to the rest of the
cells.
Therefore, the low ∆Ψm is largely maintained by the hydrolysis of ATP by complex
V, rather than by respiration, in the K219M catalytically inactive mutant and in the C-
terminal truncated mutants, whereas in the rest of the cells analysed ∆Ψm is not affected
by blocking complex V.
4.3 Oxidative Status
PINK1-silenced cells and fibroblasts from PD patients display an increase in oxidative
stress linked to an increase in reactive oxigen species (ROS) and a decrease in antioxidant
capacity (see Section 1.6.2). However, the exact defect of PINK1 mutations and trunca-
tions in these processes are still unclear. Thus, we determined the oxidative stress status
and the sensitivity to free radical generators of PINK1 over-expressing SH-SY5Y cells.
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Figure 4.4: Most of PINK1 mutations over-expressing SH-SY5Y cells dis-
play mitochondrial membrane potential dissipation and less interconnected
mitochondria network. The measurements of inner mitochondrial membrane po-
tential (∆Ψm) were made using confocal imaging of TMRM fluorescence. The signal
intensity was quantified per pixel in a confocal slice after thresholding to remove back-
ground signal. 1) Relative TMRM fluorescence intensity is expressed as the percent-
age of the signal from control cells in arbitrary units (A. U.). Data are the mean±SEM
from five independent experiments (*p<0.05, **p<0.01 and ***p<0.001). PINK1 si-
lenced cells were included as a control of the experiment. 2) Confocal overlapped
images of TMRM staining in the different SH-SY5Y cells. Note the more intercon-
nected mitochondrial network in PINK1 wt, and the ring-like and more fragmented
mitochondrial network in PINK1 G309D over-expressing SH-SY5Y cells.
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Figure 4.5: The mitochondrial membrane potential in PINK1 K219M,
W437X and ∆C over-expressing SH-SY5Y cells is maintained by the hy-
drolysis of ATP by complex V. Kinetic changes in TMRM measurements after
oligomycin, rotenone and FCCP treatments in the different PINK1 over-expressing
cells.
4.3.1 Free radical species generation
To evaluate the level of oxidative stress in our model, we measured by kinetic confocal
imaging the rates of intracellular cROS generation using dihydroethidium (HEt), a non-
fluorescent derivative of ethidium which is oxidised to a fluorescent product by in situ
superoxide production. Under basal conditions, in PINK1 K219M, A168P, G309D, L347P
and W437X cells, the rate of cROS production was significantly higher compared to PINK1
wt over-expressing cells (Figure 4.6-2). Upon rotenone treatment, control cells increased
cROS production as expected, as well as cells over-expressing PINK1 missense and C-
terminal truncated mutations. Over-expressing PINK1 wt and ∆N cells did not display
increased cROS generation rates compared to untreated conditions. Thereby, PINK1
wt and ∆N protect against generation of oxidative stress, but not PINK1 missense or
truncated mutations (Figure 4.6).
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Figure 4.6: PINK1 missense and C-terminal truncated mutations increase
ROS generation. The measurement of cROS production was made using imag-
ing of HEt fluorescence. 1) The traces represent changes of HEt fluorescence over
the time before and after rotenone treatment. 2) The mean rates of HEt fluo-
rescence change per minute, obtained from plot in 1) are shown. Results are ex-
pressed as percentage changes with regard to control cells. Silenced PINK1 SH-SY5Y
cells were used as a positive control. Grey stars: compared to untreated control
cells (*p<0.05; **p<0.01). Black stars: compared to rotenone-treated control cells
(*p<0.05; **p<0.01; ***p<0.001). Data are the mean±SEM of five independent
experiments.
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4.3.2 Glutathione measurements
To analyse the antioxidant defense in our model, we measured the levels of the antioxidant
glutathione (GSH) in basal conditions, using monochlorobimane (MCB), which forms a
fluorescent adduct following an enzyme catalysed reaction with GSH. In parallel with
the increase in ROS, GSH was significantly depleted in PINK1 K219M, A168P, G309D
and L347P over-expressing cells, when compared with control cells or PINK1 wt over-
expressing cells (Figure 4.7-1). The C-terminal truncated mutations displayed a trend
of GSH decreased but it was no significant.
4.3.3 Oxyblot
To assess if the increase in ROS and decrease in GSH are related to increase in mitochon-
dria oxidated species, we analysed the carbonylation of proteins by oxidizing species in
isolated mitochondria of PINK1 over-expressing cells, using the Oxyblot protein oxidation
detection kit. Oxyblot analysis showed increase in carbonylated proteins in SH-SY5Y cells
over-expressing PINK1 missense or truncated mutations but not in cells over-expressing
PINK1 wt (Figure 4.7-2).
4.3.4 mtDNA content
Alterations in the rates of intracellular ROS generation are associated with changes in mi-
tochondrial abundance and mitochondrial DNA (mtDNA) copy number. PINK1 K219M,
G309D and W437X cells displayed a significant decrease in their mtDNA content, as
compared with PINK1 wt cells (Figure 4.7-3).
4.4 Mitophagy/Autophagy processes
PINK1, together with Parkin, is involved in clearance of damaged mitochondria by se-
lective autophagy, known as mitophagy (see Section 1.6.4). PINK1 deficiency leads
to a decrease in Parkin recruitment to the mitochondria and produces accumulation of
damaged mitochondria. Next, we monitored the mitophagy/autophagy response of our
PINK1 over-expressing SH-SY5Y cells, in a CCCP-induced model, and in a starving model.
CCCP is a protonophore that pokes a hole in the mitochondrial membrane, making it more
permeable to the protons, which causes loss of mitochondrial membrane potential.
4.4.1 PINK1 activated mitophagy/autophagy
To monitor mitophagy/autophagy activation, we measured the cleavage of the protein
LC3 in control, PINK1 wt, K219M and W437X over-expressing cells (Figure 4.8). LC3
has two isoforms, cytosolic LC3-I (18 kDa), and its processed and lipidated form LC3-II
(16 kDa), which is recruited to autophagosomes and can be used as an autophagosome
formation marker [Cuervo, 2004]. Under CCCP-induced mitophagy or starvation, LC3-II
levels increased compared to untreated control SH-SY5Y cells, and were further increased
in PINK1 wt over-expressing cells. The levels of LC3-II in the two PD-linked mutations
(K219M and W437X) over-expressing cells were lower than in control or PINK1 wt over-
expressing cells (Figure 4.8).
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Figure 4.7: PINK1 mutations decrease GSH status and mtDNA, and in-
crease carbonylated proteins. 1) Intracellular glutathione containing was mea-
sured by MCB. Relative intensity of MCB fluorescence is expressed in A. U. as the
mean±SEM from four independent experiments. 2) The protein carbonylation was
determined by Oxyblot. Loading was assessed by re-probing the immunoblot with
anti-TOM20 and anti-SDHA antibodies. 3) Relative abundance of mtDNA, compared
to nDNA, was analysed by qPCR. (Statistical significance: *p<0.05; **p<0.01, com-
pared to control cells).
We analysed other PINK1 mutations in the CCCP-induced mitophagy model, in
parallel with measurement of mitochondrial content using the citrate synthase assay
and TOM20 protein (mitochondrial marker), and p62 (autophagy marker) levels. All
tested mutations displayed reduced LC3-II levels, compared to control or PINK1 wt over-
expressing cells (Figure 4.9-1). Cells over-expressing PINK1 wt, but not PINK1 muta-
tions, displayed diminished mitochondrial content. Furthermore, PINK1 wt expression,
but not K219M expression, increased the levels of p62, a protein that connects ubiq-
uitinated proteins with LC3 for autophagic degradation [Pankiv et al., 2007] (Figure
4.9-2,3).
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Figure 4.8: PINK1 wt activates mitophagy and autophagy processes
through increasing LC3 cleavage. 1) Immunoblot analysis, using anti-LC3 an-
tibody, of PINK1 wt, K219M and W437X SH-SY5Y cells, untreated (φ), treated 3
h with CCCP or incubated 4 h in free nutrient medium (starving conditions). LC3
cleavage was detected as a 16 kDa band (LC3-II). β-actin was used as a loading
control. 2) Quantification of LC3-II bands with respect to β-actin.
These results indicate that PINK1 wt, but not PINK1 mutations or truncations, in-
creases mitophagy in SH-SY5Y cells.
4.4.2 PINK1 localisation
PINK1 mitochondrial localisation and accumulation upon CCCP treatment is necessary
to activate clearance of damaged mitochondria (see Section 1.6.4). To investigate the
possible defects on mitophagy in the PINK1 mutations and truncations over-expressing
cells, we analysed by immunofluorescence and by subcellular fractionation whether PINK1
localisation is altered upon CCCP treatment. PINK1 wt cells treated with CCCP for 3 h
showed clear PINK1 mitochondria localisation (co-localisation index: 0.93) (Figure 4.10-
1), as previously reported [Narendra et al., 2010]. The PINK1 mutations K219M, A168P,
G309D and L347P cells showed diminished mitochondria localisation of PINK1 protein
upon 3 h of CCCP treatment, whereas in the C-terminal PINK1 W437X and ∆C and
N-terminal truncated cells, PINK1 protein did not accumulate in the mitochondria after
CCCP treatment. In untreated conditions, control cells showed low co-localisation index
between PINK1 and TOM20 proteins, perhaps due to the detection threshold of the anti-
PINK1 Ag antibody, while PINK1 over-expressing cells presented higher co-localisation
index.
Subcellular fractionation after 18 h of CCCP treatment in PINK1 over-expressing SH-
SY5Y cells showed high mitochondrial localisation of the PINK1 protein, even in the case
of PINK1 ∆N cells (Figure 4.10-2). In conclusion, upon CCCP treatment, initial PINK1
localisation seems to be affected in cells over-expressing PINK1 mutations or truncations,
although subfractionation analysis of long term CCCP treatment was not altered in the
different PINK1 over-expressing cells analysed.
63
Chapter 4. Results I: PINK1 function in SH-SY5Y cells
Figure 4.9: PINK1 wt, but not PINK1 mutations and truncations, in-
creases LC3 cleavage and decreases mitochondria content. 1) Immunoblot
analysis, using anti-LC3 antibody, of PINK1 over-expressing SH-SY5Y cells, un-
treated (φ) or treated for 3 h or 18 h with CCCP. β-actin was used as a loading
control. Quantification of LC3-II bands with respect to β-actin is indicated as the
ratio at 3 h of CCCP treatment. 2) Citrate synthase assay, as a measurement of the
mitochondria content (Statistical significance: **p<0.01 compared to control cells).
3) Immunoblot analysis of PINK1 wt and K219M over-expressing cells, using anti-
PINK1 BC100, anti-LC3 and anti-p62 antibodies (autophagy markers), and anti-
TOM20 antibody (mitochondria marker) from cells untreated (φ) or treated for 3 h
or 18 h with CCCP. β-actin was used as loading control.
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Figure 4.10: PINK1 wt cells, but not PINK1 mutations and truncations,
co-localised with mitochondria after short period of CCCP treatment
whereas, after long times of CCCP treatment, PINK1 co-localised to mi-
tochondrial compartment in all PINK1 over-expressing SH-SY5Y cells.
1) A) Immunofluorescence of control, PINK1 wt, K219M, A168P, G309D, L347P,
W437X, ∆C and ∆N over-expressing SH-SY5Y cells was performed in untreated and
3 h CCCP-treated conditions, and co-localisation indexes are indicated. Immunofluo-
rescence was carried out with anti-PINK1 Ag antibody [green], anti-TOM20 antibody
[red], and DAPI [blue]. The overlay of the three colours is shown in all panels. B)
PINK1 mitochondrial levels in CCCP-treated conditions related to basal conditions
in PINK1 over-expressing cells were analysed. 2) Cellular subfractionation of control,
PINK1 wt, K219M, G309D, W437X, ∆C and ∆N over-expressing cells, after 18 h of
CCCP treatment. C: cytosolic fraction, M: mitochondrial fraction. β-actin was used
as cytosolic marker and SDHA and TOM20 as mitochondrial markers.
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Figure 4.11: PINK1 mutations and truncations displayed defects in PINK1
protein accumulation after CCCP treatment. In PINK1 wt over-expressing
cells (1), PINK1 protein is accumulated at short term and over the time of CCCP
treatment. Protein accumulation in PINK1 missense (2) and C-terminal truncation
(3) mutations is lower than in PINK1 wt. PINK1 accumulation does not occur in
PINK1 ∆N over-expressing cells. PINK1 protein expression levels were detected by
immunoblot using anti-PINK1 BC100 antibody. β-actin was used as a loading control.
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4.4.3 PINK1 accumulation or expression upon CCCP
It has been reported that PINK1 is accumulated upon CCCP and localised to the mito-
chondria [Narendra et al., 2010]. To know how the accumulation occurs in the PINK1
over-expressing cells, we performed immunoblot analysis upon a time course of CCCP
treatment. Upon long term of CCCP treatment, endogenous PINK1 FL is accumulated
in parental SH-SY5Y cells, suggesting a stabilization and/or new synthesis of the protein
(Figure 4.11). In PINK1 wt over-expressing cells, the levels of PINK1 increased after
3 h of CCCP incubation and accumulated during time of CCCP treatment, suggesting
stabilization of the protein. The accumulation in the cells with PINK1 mutations K219M,
A168P, G309D and L347P showed a similar trend, but it was lower compared to PINK1
wt cells, whereas the cells with truncated mutations did not show a clear accumulation
of PINK1 over the time with CCCP. In the case of PINK1 W437X and ∆C cells, the
protein accumulation at short time was disrupted, but at long times of CCCP treatment
the accumulation was observed. Remarkably, PINK1 protein levels, in PINK1 ∆N cells
did not change (Figure 4.11) upon CCCP treatment.
In conclusion, PINK1 wt, but not mutated or truncated PINK1, is accumulated in
the mitochondria upon CCCP treatment, with a concomitant increase in autophagosome
formation and mitophagy, and decrease in mitochondria mass.
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5.1 PINK1 inducible over-expressing MCF-7 cells
MCF-7 breast cancer cell line is an epithelial-like estrogen receptor α (ERα) positive cell
line. Stable MCF-7 cells were generated to over-express, upon induction with doxycycline
(Dox), PINK1 wt, and different PINK1 missense or truncated mutations (Chapter 3,
Figure 3.6 and Table 3.5).
5.1.1 PINK1 expression and cell viability
In all MCF-7 stable cell lines, PINK1 mRNA and protein were efficiently induced upon
Dox treatment (Figure 5.1-1 and 5.1-2). PINK1 protein expression was analysed with
two different polyclonal antibodies: anti-PINK1 108-200 and anti-PINK1 BC100 (Figure
5.1-2.A-B). PINK1 protein levels were comparable in the different cell lines. The PINK1
full length (FL, 63 kDa), and the PINK1-∆1 cleaved form (54 kDa) were detected in
the PINK1 inducible over-expressing cells. However, the PINK1-∆2 cleaved form (45
kDa) was weakly detected or undetectable (only with anti-PINK1 108-200 antibody) in
the PINK1 over-expressing cells (Figure 5.1-2). Leakage expression was very low in the
absence of Dox but PINK1 antibodies in MCF-7 displayed several nonspecific bands, and
perhaps the sensitivity is limited (Figure 5.1-2). Next, cell viability was tested to discard
some deleterious effects of the induced PINK1 over-expression. As shown, the induction
of PINK1 over-expression in MCF-7 cells did not cause significant changes in cell viability,
and all cells displayed similar growth rate profiles (Figure 5.1-3).
5.1.2 PINK1 localisation
We have previously described that PINK1 is localised in mitochondrial and cytosolic com-
partments (Figure 4.2.)
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Figure 5.1: PINK1 expression levels and cell viability were similar in all
PINK1 over-expressing MCF-7 cells generated. 1) qPCR analysis of PINK1
mRNA levels in the presence of Dox. Total RNA was subjected to reverse transcrip-
tion. qPCR was performed and quantification was normalized to HPRT as a reference
gene. 2) PINK1 protein expression levels in the presence and absence of Dox, de-
tected by immunoblot with anti-PINK1 polyclonal antibodies (anti-PINK1 BC100
(A) and a home-made anti-PINK1 108-200 (B)). GAPDH was used as a loading
control. Red arrows indicate the full length unprocessed PINK1 protein. Green head
arrows indicate the processed PINK1 proteins. 3) Cell viability, measured by crystal
violet method, of MCF-7 cells over-expressing missense (A) or truncated (B) PINK1
mutations, compared to control and PINK1 wt over-expressing cells in the presence
of Dox.
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5.2. Cell death and apoptosis upon H2O2 treatment
To monitor PINK1 localisation in our MCF-7 inducible over-expression system, we
analysed by immunofluorescence the localisation of PINK1, in comparison with the stain-
ing of the mitochondrial marker Mitotracker CMX-ROS (Figure 5.2). In control cells,
the PINK1 signal (green) was very weak and nonspecific (Figure 5.2 panel a), likely
due to low levels of endogenous PINK1 in MCF-7 cells (see Figure 5.1-2). Induction of
PINK1, in PINK1 wt cells, increased the green specific staining compared to the signal
of control cells, with a punctate pattern which co-localised with Mitotracker (Figure 5.2
panel e). The same punctate pattern and mitochondrial co-localisation of PINK1 pro-
tein were observed in the PINK1 A168P, G309D, L347P, W437X and ∆C cells (Figure
5.2 panels i, m, q, u, A). The PINK1 ∆N and PINK1 ∆N-C cells showed cytosolic
localisation of PINK1 with a diffuse cytosolic pattern, and little or no clear mitochondria
co-localisation (Figure 5.2 panels E, I).
The Mitotracker staining of the induced PINK1 over-expressing MCF-7 cells did not
reveal differences in terms of mitochondrial content, network or shape (Figure 5.2 Mi-
totracker panels).
5.2 Cell death and apoptosis upon H2O2 treatment
It has been previously reported the anti-apoptotic role of PINK1 in several cell lines, but it
is not known its role in breast cancer cells (see Section 1.6.1). Thus, we analysed the cell
death response in the PINK1 over-expressing MCF-7 cells treated with hydrogen peroxide
(H2O2) for 24 h. Upon H2O2 treatment, PINK1 wt cells displayed more protection to cell
death than control cells, as monitored by phase contrast microscopy (Figure 5.3). On
the other hand, PINK1 A168P, G309D, L347P and W437X cells showed less protection
to H2O2-induced cell death, whereas the truncated forms PINK1 ∆C, ∆N and ∆N-C
exhibited partial protection (Figure 5.3).
To study in more detail PINK1 anti-apoptotic function in MCF-7 cells, we performed
FACS analysis of cell death and mitochondrial membrane potential (∆Ψm). PI (propidium
iodide) nuclear staining was used as a measurement of cell death. As shown in Figure
5.4-1, PINK1 A168P, G309D, L347P and W437X cells exhibited increased permeability
to PI upon H2O2 treatment, compared to PINK1 wt cells. PINK1 wt cells showed a
trend of cell death protection, although this effect was not statistically significant. The
truncated forms PINK1 ∆C, ∆N and PINK1 ∆N-C cells showed no significant differences
with respect to PINK1 wt.
Next, the cell-permeant probe DiOC6(3) was used to monitor the ∆Ψm (Figure 5.4-
2). PINK1 wt and ∆N cells displayed significant protection against H2O2-induced mi-
tochondrial depolarization. This protection was not observed in PINK1 A168P, G309D
L347P, W437X, ∆C and ∆N-C over-expressing cells. All the PINK1 over-expressing cells
showed, under untreated conditions, comparable percentage of cells permeable to PI and
with depolarized mitochondria, suggesting that PINK1 mutations do not inducted basal
cell death.
Together, these results indicate that the N-terminus of PINK1 is not required for the
mitochondrial anti-apoptotic role of PINK1, whereas the intact PINK1 kinase domain and
C-terminus are relevant for this PINK1 anti-apoptotic function.
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Figure 5.2: PINK1 wt, PD-linked mutations and C-terminal truncations
are mostly localized at the mitochondria. The N-terminal truncations are
mostly localised in cytosol. Control (a-d), PINK1 wt (e-h), A168P (i-l), G309D
(m-p), L347P (q-t), W437X (u-x), ∆C (A-D), ∆N (E-H) and ∆N-C over-expressing
MCF-7 cells were studied. Immunofluorescence was carried out with anti-PINK1 108-
200 polyclonal antibody [green] (a, e, i, m, q, u, A, E, I), Mitotracker CMX ROS [red]
(b, f, j, n, r, v, B, F, J) and Hoescht 33258 [blue] (c, g, k, o, s, w, C, G, K). In panels
d, h, l, p, t, x, D, H and L, the overlay of the three colours is shown.
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Figure 5.3: Cell death sensitivity of PINK1 over-expressing MCF-7 cells
upon H2O2 treatment. Morphology studies of cells untreated (A, C, E, H, J, L,
N, P, R) or treated with 0.15 mM H2O2 for 24 h (B, D, F, I, K, M, O, Q, S). H2O2-
treated PINK1 wt over-expressing cells (D), but not the different PINK1 mutations
over-expressing cells (A168P (F), G309D (I), L347P (K), and W437X (M)) are more
resistant to H2O2-induced apoptosis. The truncated PINK1 forms (∆C (O), ∆N (Q),
and ∆N-C (S)) show a trend to resistance to apoptosis. Cells were photographed
after 24 h in culture in the presence of H2O2 and Dox.
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Figure 5.4: PINK1 wt and ∆N, but not the PD-linked mutations (PINK1
A168P, G309D and L347P) nor PINK1 ∆C and ∆N-C, protect against
H2O2-induced apoptosis in PINK1 over-expressing MCF-7 cells. Apoptosis
and cell death were measured by FACS analysis of cells untreated (black) or treated
with 0.15 mM H2O2 (pink) for 24 h. Percentage of cells that present permeability to PI
(1) and of cells with depolarized mitochondria membrane (2) are shown. (Statistical
significance: **p<0.01 PINK1 wt and *p<0.05 PINK1 ∆N, versus control cells; and
*p<0.05 PINK1 mutations and PINK1 C-terminal truncations, versus PINK1 wt.
To confirm the anti-apoptotic role of PINK1 in breast cancer cells, we silenced PINK1
in two breast cancer cell lines, MCF-7 and MB-MDA-231. Quantification of the decrease
in PINK1 mRNA after transfection with validated siPINK1 (siGAPDH as a control) was
performed by qPCR analysis. As shown in Figure 5.5-1, almost 50% reduction of PINK1
mRNA (65% reduction of GAPDH mRNA) was observed in both MCF-7 and MB-MDA-
231 cells upon PINK1 silencing. The analysis of cell growth in these cells revealed no
inhibitory effect, compared to control or siGAPDH cells (data not shown).
The percentage of cells permeable to PI was higher in siPINK1 MCF-7 and MB-MDA-
231 cells after H2O2 treatment, compared to control cells (Figure 5.5-2A). Also, PINK1
silencing in both breast cancer cell lines increased mitochondrial depolarization upon H2O2
treatment (Figure 5.5-2B).
In conclusion, we have demonstrated that PINK1 wt and ∆N, but not other mutations
or C-terminal truncations, decrease the cell death triggered by H2O2 in breast cancer cells.
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Figure 5.5: Apoptotic sensitivity of PINK1-silenced MCF-7 and MB-
MDA-231 breast cancer cells. 1) qPCR analysis of PINK1-silenced MCF-7 (A)
and MB-MDA-231 (B) cells. Total RNA was subjected to reverse transcription.
qPCR was performed and quantification was normalized to HPRT as a reference
gene. Silencing efficiency of PINK1-siRNA was approximately 50% at mRNA level.
2) FACS analysis of cells untreated (black) or treated with 0.15 mM H2O2 (pink)
for 24 h. Percentage of cells that present permeability to PI (A) and of cells with
depolarized mitochondria membrane (B) in PINK1-silenced MCF-7 and MB-MDA-
231 cells are shown. (Statistical significance: **p<0.01 and *p<0.05 versus control).
PINK1-silenced MCF-7 cells are more sensitive than MB-MDA-231 to H2O2-induced
apoptosis.
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Figure 5.6: Adhesion of PINK1 over-expressing MCF-7 cells to different
matrix substrates. After incubation for 24 h with Dox, cells were plated onto
gelatine- (2), matrigel- (3), colagen IV- (4) or fibronectin- (5) coated wells and
incubated for 4 h, allowing cell adhesion. Adherent cells were fixed and stained with
crystal violet. BSA was used as control of adhesion (1). Cell adhesion was quantified
by absorbance measuring. Results represent the mean±SEM of four independent
experiments.
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5.3 Adhesion capacity onto different substrates
Previous analysis of PINK1 expression in human tumours suggests a role for PINK1 in can-
cer (Section 1.7.2). Thus, we examined the role of PINK1 in adhesion, tumourigenicity
and proliferation properties of PINK1 over-expressing MCF-7 breast cancer cells.
To measure the adhesion capacity of PINK1 over-expressing cell lines, cells were plated
onto gelatine, matrigel, fibronectin or colagen IV-coated wells, and the attachment was
allowed for four hours. BSA-coated wells were used as control. As shown in Figure 5.6 no
significant differences were observed in the attachment of PINK1 over-expressing cells to
the distinct substrates, in comparison with control cells. In gelatine and matrigel-coated
wells, cell attachment was lower than in fibronectin and colagen IV-coated wells (Figure
5.6).
These results suggest that PINK1 does not affect the adhesion capacities of MCF-7
breast cancer cells.
5.4 Wound healing invasion
Next, wound healing invasion assays were performed. Confluent cells were scratched and
invasion of the cell-free area was measured. PINK1 wt cells migrated less into the scratch
area after 24 h of culture, compared to control cells, suggesting less invasive capacity.
However, PINK1 A168P, G309D and L347P cells occupied more of the free scratch area
after 24 h of growing, suggesting more invasive capacity than PINK1 wt cells. In PINK1 C-
terminal (W437X and ∆C) and N-terminal (∆N and ∆N-C) truncation cells, no differences
in invasion were observed with respect to control cells. In the absence of Dox, all cell lines
displayed similar invasion capacity (Figure 5.7).
These results suggest a negative role for PINK1 in the control of invasion processes.
5.5 Anchorage-independent growth and colony formation
in soft agar
To further study the role of PINK1 in tumourigenesis, we performed anchorage-independent
growth assays with the PINK1 over-expressing MCF-7 cell lines. Cells were plated in soft
agar with or without Dox, and colony formation was monitored after two weeks. MCF-7
control cells formed round and numerous large colonies after 2 weeks of growth in soft
agar, and were unaffected in the presence of Dox. In contrast, PINK1 wt cells (Figure
5.8) exhibited a reduced capacity for soft agar colony formation in the presence of Dox,
with lower number of colonies and reduced colony size. The PINK1 A168P, G309D, and
W437X over-expressing cells, and the PINK1 ∆C and ∆N-C over-expressing cells formed
similar number of colonies but larger than control cells. The PINK1 L347P and ∆N
over-expressing cells grew in soft agar similarly to PINK1 wt.
These results indicate that PINK1 attenuates anchorage-independent growth in MCF-7
cells, and suggest that PINK1 has a role in proliferation and tumour formation in vitro.
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Figure 5.7: PINK1 wt, but not PINK1 missense mutations, decreases
invasive capacity of PINK1 MCF-7 cells. 1) Confluent PINK1 over-expressing
cells were scratched and cell invasion over the cell-free area was photographed every
30 min for 24 h. Initial and final photographs are displayed in (A) and (B). 2)
Quantification of invasion assay was measured over the free area before and after
24 h of culture after scratching. Results represent the mean±SEM of the migration
index. (Statistical significance: **(pink)p<0.01 versus control; *<p0.05, **<0.01
versus PINK1 wt)
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Figure 5.8: PINK1 modulates the anchorage-independent growth in soft
agar of MCF-7 cells. PINK1 wt, ∆N and L347P, but not the other missense
mutations or truncations, inhibit colony formation in soft agar. Cells were grown for
2 weeks in soft agar allowing colony formation. Colonies were stained with crystal
violet and were photographed. 1) Photographs of PINK1 MCF-7 cells without or
with Dox, 5x and 40x. 2) Quantification of the colonies grown in soft agar of PINK1
MCF-7 cells without or with Dox, using by Image J. (Statistical significance: *p<0.05
**p<0.01 versus control).
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5.6 Cell cycle progression, study of cell cycle proteins, and
proliferation.
Finally, we analysed the cell cycle and proliferation properties of PINK1 wt and G309D
over-expressing MCF-7 cells.
Cells were synchronized at G0/G1 by 24 h growth in the absence of serum (FBS), and
cell cycle re-entry and proliferation were restored by addition of serum to the medium.
Samples were harvested at different times and analysed by FACS. Control, PINK1 wt and
G309D over-expressing MCF-7 cells were equally arrested in G0/G1 upon withdrawal of
serum. Interestingly, the S phase population was higher in PINK1 wt cells at 12 and 24 h
than in control cells, but at 48 h the G0/G1 population was recovered. The cells carrying
PINK1 G309D mutation showed the same profile as PINK1 wt cells at 12 h, with higher
S phase population, but at longer times, the G0/G1 population increased faster than in
control cells (Figure 5.9).
Figure 5.9: PINK1 alters the cell cycle progression of MCF-7 cells. PINK1
wt, but not G309D, blocks cell cycle in S phase and decreases the progres-
sion through the cell cycle in MCF-7 cells. Equal number of control, PINK1
wt and G309D over-expressing MCF-7 cells, were grown in the presence of Dox for
2 days, reaching 50% confluency. Then, cells were grown in FBS medium for 12 h,
24 h, or 48 h. 1) FACS analysis of the cells was carried out by standard cell cycle
protocol (fixation and PI staining). 2) Percentage of cells in each cell cycle phase is
shown in histograms.
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5.6. Cell cycle progression, study of cell cycle proteins, and proliferation.
Next, we checked by immunoblot the levels of several cell cycle proteins: cyclin D1
(G0/G1 phase), cyclin A (late S phase), cyclin B1 (G2/M phase) and p27 (inhibitor and
required progressor of G0/G1 phase). In the absence of serum, the levels of cyclins are
low in all the MCF-7 cells analysed, with the exception of cyclin D1 in PINK1 G309D
over-expressing cells which was highly expressed. In control, PINK1 wt, and G309D over-
expressing cells, the levels of p27 were higher in the absence of serum, likely due to cell
cycle arrest. In the parental MCF-7 cell line, the cells re-entered into cell cycle with
increased levels of cyclin D1 (at 12 and 24 h) and subsequently, higher levels in cyclin
A and B1 (at 24 and 48 h, respectively). The PINK1 wt over-expressing cells re-entered
into cell cycle with lower levels of D1, A and B1, compared to control cells. In PINK1
wt cells, the kinetics of cyclin A activation is shorter than in control cells, characterised
by a slight increase at 12 h (as control cells) and a decrease afterwards. PINK1 G309D
over-expressing cells presented higher levels of cyclin D1 at every time point compared
to control and PINK1 wt cells, and cyclin A levels were increased earlier (12 h) than in
control cells, and were higher than PINK1 wt cells. This suggests a more rapid progression
of cell cycle in the PD-linked missense mutation G309D over-expressing MCF-7 cells. It is
important to note that p27 protein is accumulated over the time in control cells because
the cells reached the G0/G1 restriction point, whereas in PINK1 wt over-expressing cells
the levels of p27 were low at long times, suggesting a delay in the progression of the cell
cycle. The p27 levels in PINK1 G309D over-expressing cells were lower than in control
cells, indicating cell cycle activation at later times of serum addition (Figure 5.10).
Figure 5.10: PINK1 modulates cyclin and p27 levels during the cell cy-
cle progression of MCF-7 cells. PINK1 wt cells, but not G309D cells, show
decrease cyclin D1, cyclin A and p27 levels. Protein expression analysis was made
by immunoblot using anti-cyclin D1 (phase G0/G1 cyclin), anti-cyclin A (phase late
S cyclin), and anti-cyclin B1 (phase G2/M cyclin), anti-p27 (inhibitor of G0/G1 pro-
gression), or anti-PINK1 BC100 antibodies. β-actin was used as a loading control.
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Finally, we measured, by EdU (5-ethynyl-2’-deoxyuridine, an analog to BrdU) assay,
the proliferation rate of the PINK1 over-expressing MCF-7 cells. Cells were synchronized
as above and incubated in the presence of serum and EdU for 18 h, followed by FACS anal-
ysis. PINK1 wt, but not PINK1 G309D, over-expressing MCF-7 cells, displayed 20% less
of total proliferating cells. Moreover, we detected in control cells an EdU positive popula-
tion in G0/G1 phase which corresponds to EdU incorporation (S phase, proliferating cells),
progression to G2/M phase and captured in G0/G1 phase (green circle). This population
is smaller in the case of PINK wt over-expressing cells but not in G309D cells (Figure
5.11). This suggests that PINK1 wt over-expressing MCF-7 cells proliferate slower and
the PD-linked missense mutation G309D over-expressing MCF-7 cells proliferate faster,
than control cells.
Figure 5.11: PINK1 alters proliferation of MCF-7 cells. PINK1 wt, but not
G309D over-expressing cells, showed lower percentage of total proliferating cells and a
decrease in G0/G1 phase proliferating cells. Equal number of PINK1 over-expressing
MCF-7 cells were grown in the presence of Dox, and FBS was removed for 24 h to
synchronize cells in G0/G1, followed by 18 h incubation in medium with FBS and EdU
compound (5-ethynyl-2’-deoxyuridine, incorporates in S phase: proliferation measure-
ment). 1) FACS analysis of EdU and PI in control (A), PINK1 wt (B) and G309D
(C) cells was carried out. 2) Percentage of total proliferating cells (cells above the
pink line), G0/G1 proliferating cells (green circle), and G2/M phase proliferating cells
(the rest of proliferating cells) are shown in the histogram. (Statistical significance:
***p<0.001 versus control; *p<0.05 versus PINK1 wt).
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6.1 PINK1 expression in normal and neoplastic tissues
PINK1 mRNA is expressed in a wide variety of human tissues (Figure 6.1-1), in agree-
ment with the northern blot analyses from mouse tissues performed by Nakajima et al.
[Nakajima et al., 2003]. Analysis of PINK1 mRNA by qPCR revealed high expression
in brain and breast tissues, while thyroid tissue showed low expression. We also tested
the expression of PINK1 mRNA in the cell lines used in this study and found that SH-
SY5Y cells displayed higher expression levels than MCF-7 cells, in acccordance with the
endogenous PINK1 protein levels found in these cell lines (Figure 6.1-2) [Berthier et al.,
2011].
PINK1 protein analysis was performed by immunoblot with the anti-PINK1 89B mAb
on several human and mouse tissue extracts (Figure 6.1-3). In mouse brain sample, the
89B mAb recognized a 55 kDa band that co-migrated with the mitochondrial-processed
form of PINK1. Human liver, a mitochondria-enriched tissue, revealed a noticeable band
that migrated at the molecular weight predicted for the processed PINK1 form, whereas in
human bladder a weak immunoreactive band was detected, likely representing low levels of
PINK1 expression in this tissue. Finally, in mice tissue samples, the 89B mAb recognized
a 55 kDa band, corresponding to processed PINK1, in testis and heart, but not in colon
(data not shown). Thus, the 89B antibody recognises both human and mouse PINK1,
which is in accordance with the high degree of amino acid sequence identity of PINK1
protein (82%) between these two species.
In summary, our biochemical results reveal that the 89B mAb is specific for PINK1
protein, and indicate a wide tissue distribution pattern for PINK1, not restricted to the
brain.
Next, immunohistochemical analysis of PINK1 was performed with the anti-PINK1
89B mAb in a multi-tissue array containing a wide representation of human tissues. A sum-
mary of 89B immunostaining of human tissue sections is shown in Berthier et al. [Berthier
et al., 2011]. In the brain, cortical neurons were highly positive for 89B immunoreactivity.
Conversely, glial cells and white matter were negative. Ventricular epithelium was strongly
stained by the 89B mAb. In the cerebellum, only Purkinje cells displayed staining (Figure
6.2). These findings are in agreement with PINK1 mRNA expression pattern in the brain
reported by Blackinton et al., but show differences with that reported by Gandhi et al.
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Figure 6.1: PINK1 mRNA and protein expression in human and mouse
tissues. 1) PINK1 mRNA expresion is widely expressed in human tissues. cDNA
samples from different normal human tissues were subjected to PCR using PINK1 and
β-actin primers. Amplified bands were visualised in agarose gels. 2) qPCR analysis
of PINK1 expression from total RNA from SH-SY5Y and MCF-7 cell lines, and from
brain, breast and thyroid human tissues. HPRT was used as a reference gene to
quantify the relative mRNA expression by comparative ∆∆Ct method (mean±SD
from two experiments is shown). 3) PINK1 protein expression in human and mouse
tissues. Lysates from transfected HEK293 cells (50 g) (lanes 1,2) or from tissue
samples (150 g) (lanes 3-5) were subjected to SDS-PAGE, followed by immunoblot
with the anti-PINK1 89B mAb or with the anti-β-actin antibody, as indicated.
using anti-PINK1 polyclonal antibodies, that showed PINK1 expression in all brain cell
types, including glial cells [Blackinton et al., 2007; Gandhi et al., 2009]. This difference is
likely due to the different nature and epitope specificity of the anti-PINK1 antibodies used
in Gandhi’s and in our study. Positive 89B reactivity was detected in epithelial tissues,
including adrenal gland, mammary gland, prostate, pancreas, kidney tubules, stomach,
intestine, and hypophysis (Figure 6.2) [Berthier et al., 2011].
Interestingly, the subcellular pattern of immunostaining with the 89B was variable,
depending on the tissues. In general, three distinct patterns were observed:
• Cytoplasmic granular pattern in brain neurons, Purkinje cells, stomach and liver,
suggesting mitochondrial localisation.
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• Cytoplasmic diffuse pattern in cardiac and striated muscles, and lymph node.
• Membrane-associated pattern: acini of the mammary gland.
Figure 6.2: Immunoperoxidase staining with the anti-PINK1 89B mAb
of human normal and neoplastic tissues. (A) Normal cortical brain. The
arrows indicate stained neurons. (B) Normal cerebellum. The arrows indicate stained
Purkinje cells. (C) Normal breast acini. The arrow indicates stained apical pole
of secretory cells. (D) Breast carcinoma. The arrows indicate the membrane-like
staining of cancer cells.
Analysis of human neoplastic tissues revealed that PINK1 expression was absent or very
weak in blastomas and sarcomas but very high in carcinomas. Breast carcinomas displayed
cytoplasmic diffuse staining, together with a prominent membrane staining, which differed
from the granular cytoplasmic pattern and the low membrane staining observed in normal
breast (Figure 6.2).
We further examined the expression of PINK1 mRNA in breast cancer. We analysed
PINK1 mRNA expression in 43 breast cancer samples, and found that 60% of the breast
tumours analysed displayed over-expression of PINK1 mRNA (Figure 6.3).
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6.2 Parkinson’s disease linked genes in normal and
neoplastic breast cancer
We selected a group of genes related to PD and PINK1 (including the variants naPINK1
and svPINK1), and analysed the mRNA expression pattern in the breast tumour sam-
ples collection. We used String software to identify PINK1-related proteins (http://
string-db.org/) [Von Mering et al., 2007], and we included in the analysis other PD
genes whose expression is regulated in cancer (Figure 1.2). Finally, we added markers
of proliferation and hormone growth factor receptors, which have been involved in breast
cancer progression. A list of the selected genes is showed in Table 6.1.
Table 6.1: Expression of PINK1 and PINK1-related genes in breast cancer.
mRNA
PINK1-/PD-/cancer- link Percentage of tumours (expression)*
Normal Low High
Htra2/omi PARK13-binding partner 5 0 95
ATP13A2 PARK9 7 2 91
LRRK2 PARK8-associated partner 9 2 89
GBA Associated protein 30 3 67
PINK1 PARK6 30 9 61
DJ1 PARK7-binding partner 40 2 58
TRAP1 Binding partner 49 2 49
MTP18 Associated protein 51 5 44
Parkin PARK2-binding partner 53 21 26
UCHL1 Associated protein 74 12 14
SNCA PARK1-4-associated partner 79 14 7
SNCAIP Associated protein 39 56 5
PTEN Associated protein 77 21 2
svPINK1 Variant 28 23 49
naPINK1 Variant 51 5 44
ER Breast cancer related receptor 19 7 74
PGR Breast cancer related receptor 39 28 33
HER2 Breast cancer related receptor 74 10 16
Ki67 Proliferation marker 40 9 51
*Expression is indicated in Figure 6.3
We detected high expression of LRRK2, DJ-1, GBA, ATP13A2, Htra2/omi, MTP18
and TRAP1 in many tumours, compared to normal breast tissue. Moreover, high per-
centage of tumours showed low expression of PTEN and SNCAIP. The PINK1 variants
naPINK1 and svPINK1 were highly expressed in half of the tumours (Table 6.1 and
Figure 6.3).
The high expression of PINK1 is associated with high expression of other PD-related
genes in the same breast cancer samples. For example, high expression of PINK1 is
associated in almost 50% of cases with high expression of LRRK2, DJ-1, GBA, ATP13A2,
Htra2/omi, TRAP1 and MTP18. Indeed, in 30% of the breast cancer samples all these
genes are associated, suggesting a common regulation of their expression linked to breast
cancer. On the other hand, high or low expression of Parkin or PTEN were not associated
to high or low expression of PINK1 (Table 6.2). Each of PINK1 variant is associated
with PINK1 expression in 30% of the breast cancer samples, and the two variants are
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associated in 40% of the samples, suggesting a positive regulation of PINK1 function and
its variants in breast cancer.
In conclusion, PINK1 is up-regulated in many breast cancer tumours, and expression of
PINK1 and PINK1-related genes could be linked to progression of breast cancer. Further
analyses need to be done to correlate the expression of PINK1-related genes with breast
cancer prognosis.
Table 6.2: Association of expression of PINK1 and PINK1-related genes in breast
cancer tissues.
Associated mRNAs
Percentage of tumours
with the same expression
Low High
1. PINK1-GBA 2 65
2. PINK1-Htra2/omi 2 60
3. PINK1-LRRK2 2 58
4. PINK1-ATP13A2 2 58
5. PINK1-DJ-1 2 49
6. PINK1-TRAP1 2 44
7. PINK1-MPT18 5 33
8. PINK1-GBA-Htra2-LRRK2-
ATP13A-DJ1-TRAP1-MPT18
2 30
9. PINK1-Parkin 5 23
10. PINK1-PTEN 2 2
11. PINK1-naPINK1 5 33
12. PINK1-svPINK1 2 30
13. naPINK1-svPINK1 5 44
14. PINK1-naPINK1-svPINK1 2 28
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Figure 6.3: Expression of PINK1 and PD-related genes in breast cancer
samples. qPCR analysis of PINK1 (1), LRRK2 (2), DJ-1 (3), Htra2/omi (4),
TRAP1 (5), SNCAIP (6), PTEN (7) and Parkin (8) from 43 breast cancer samples,
normalised to expression in normal breast and HPRT as a reference gene. Fold change
value (∆∆Ct) was calculated and high expression was defined as ≥2, low expression
as ≤0.25, and normal expression between 0.25 and 2. The percentage of each class is
shown.
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SummaryResults
The results obtained with PINK1 wt or mutations in SH-SY5Y cells are summarized in
the Table 6.3, according to four functions: PINK1 localisation, control of mitochondrial
function, oxidative stress production and regulation of CCCP-inducted mitophagy. In
the case of the mitochondrial function analysis, ATP production, ∆Ψm value and mito-
chondrial network is illustrated. Oxidative stress production is shown as ROS production
under basal and rotenone-treated conditions, glutathione levels (MCB), carbonylation of
proteins (protein damage) and mitochondrial DNA content. In the case of mitophagy
function, we compile increase in LC3-II and decrease in damaged mitochondria, PINK1
protein levels and localisation in a time course of CCCP treatment. The symbols shown
are with respect to control cells.
The summary of the results from PINK1 over-expressing MCF-7 cells is shown in Table
6.4, according to seven functions: PINK1 localisation, activation of apoptosis, adhesion,
invasion, colony formation, cell cycle progression and cyclin levels, and proliferation. The
activation of apoptosis via cellular permeability (PI) and mitochondrial membrane depo-
larization (DiOC6(3)) in a H2O2-induced model is shown. The symbols shown are with
respect to control cells.
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7Chapter
Discussion
In this thesis, we have studied the role of PINK1 and several PINK1 mutations (missense:
kinase inactive or PD-linked, or truncated mutations) in the pathogenesis of cancer and
Parkinson’s disease. We have used a human neuroblastoma cell line (SH-SY5Y) as a PD
model and a human breast carcinoma cell line (MCF-7) as a cancer model.
Since its discovery, PINK1 has been associated to both diseases: it is up-regulated in
high tumourigenic tumours and in cells that ectopically over-express PTEN [Unoki and
Nakamura, 2001; Nakajima et al., 2003], and mutations in PINK1 gene have been linked
to early onset Parkinson’s disease [Valente et al., 2004a]. Nevertheless, the molecular
mechanism and the functional role of PINK1 linked to these diseases are not well defined.
Moreover, the association with cancer is weak and not fully clarified.
Our results indicate that PINK1 is an anti-apoptotic protein required to maintain the
correct mitochondrial function and to eliminate damaged mitochondria by mitophagy, and
an anti-proliferative protein which affects tumourigenic processes such as invasion, colony
formation, cell cycle progression and proliferation.
In summary, the results obtained in our study support the notion that PINK1 plays
important roles as a pro-survival protein against stressors and as an anti-proliferative
protein in transformation processes. PINK1 requires an intact C-terminal and kinase
domain to exert its protective mitochondrial function. Also, PINK1 wt, but not a PD-
linked missense mutation, exerts anti-proliferative effects in breast cancer cells.
7.1 PINK1 mutations analysed and functional implications
The crystal structure of PINK1 has not yet been resolved. The analysis of the mutations
chosen in our study in several 3D models [Marongiu et al., 2008; Cardona et al., 2011]
suggests that all of them disrupted important parts of PINK1 kinase domain and may
affect the physiological role of PINK1 diminishing its kinase activity. Most of the PINK1
mutations identified in PD patients are predicted to impair the kinase activity of the
protein, suggesting that loss of PINK1 catalytic function could be one of the causative
mechanism of the disease. However, in vivo and in vitro PINK1 kinase activity is very
low per se, and it has been suggested that PINK1 may be a pseudokinase that does
not phosphorylate substrates directly but facilitate the phosphorylation activity of other
kinases [Pogson et al., 2011]. Further analysis on PINK1 kinase activity and PINK1
potential substrates or regulatory proteins needs to be done [Sim et al., 2012].
Bioinformatic analysis of the PD-linked PINK1 missense mutations used here (A168P,
G309D and L347P) shows that Ala168, Gly309 and Leu347 are conserved between PINK1
orthologues and are within the Ser/Thr kinase domain, as the majority of the PINK1
mutations described from PD patients (Figure 7.1, 7.2 and Appendix 8).
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Figure 7.1: Amino acid sequence of PINK1 protein with the residues mu-
tated in this study. Figure modified from Chapter 1 (Figure 1.7). Amino acids
correspondig to the mutations used are encircled.
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The nonsense W437X mutation truncates the protein at position 436 and produces a
stable protein of about 48 kDa, where the important motifs (AIK, HRD and DFG) for
kinase activity are maintained. The protein portion missing in PINK1 W437X is predicted
to have several residues in contact with the substrate which would disable the substrate
access to the active site, thus increasing the propensity of the truncated protein toward
non-specific protein phosphorylation [Silvestri et al., 2005]. Moreover, the subdomains IX,
X, XI, and the C-terminal PINK1 region are important for folding of the protein [Beilina
et al., 2005; Cardona et al., 2011].
The nonsense W437X mutation truncates the protein at position 436 and produces
a stable protein of about 48 kDa, where the important motifs (AIK, HRD and DFG)
for kinase activity are maintained. The nonsense mutation disrupts the conserved C-
terminal part of the protein, composed of the C-terminal kinase subdomains involved
in substrate recognition (subdomains IX, X and XI) and the C-terminal regulatory tail
(residues 510-581). The protein portion missing in PINK1 W437X is predicted to have
several residues in contact with the substrate which would disable the substrate access to
the active site, thus increasing the propensity of the truncated protein toward non-specific
protein phosphorylation [Silvestri et al., 2005]. Moreover, the subdomains IX, X, XI, and
the C-terminal PINK1 region are important for folding of the protein [Beilina et al., 2005;
Cardona et al., 2011]. The Lys219 has been proposed to bind ATP [Beilina et al., 2005;
Albanese et al., 2005]. In the case of the N- and C-terminal truncated forms, important
parts of the protein that may modulate the kinase activity and localisation are deleted.
Our functional results in SH-SY5Y and MCF-7 cells support the idea that differ-
ent mitochondrial functions are impaired in the different PINK1 mutations [Tan, 2009;
Gru¨newald et al., 2009; Murata et al., 2011b]. It is still unclear how these mutations
affect PINK1 kinase activity under pathologic conditions, and whether other biological
important functions of PINK1 are affected.
7.2 Localisation of PINK1 within the cell and in tissues
Although subcellular distribution of PINK1 is not fully clear, there is a broad agreement
that at least some fraction of PINK1 protein localises to mitochondria, with its kinase
domain facing the inter-membrane space or the cytoplasm [Valente et al., 2004a; Zhou
et al., 2008b]. As most mitochondrial proteins, PINK1 is encoded by the nuclear genome
and synthesised as a precursor polypeptide at cytosolic ribosomes. Thus, PINK1 has to
be targeted to its final mitochondrial localisation in a process that is usually governed
by specific signal sequences and accomplished via the protein translocation machinery
present in the mitochondrial membranes [Pfanner et al., 2001; Chacinska et al., 2009]. At
this regard, it has been proposed that the MLS directs PINK1 to the mitochondria via
TOM20. In addition, the cleavage sites which generate PINK1-∆1 and PINK1-∆2 forms
have been described in the MLS and TM of PINK1 protein [Greene et al., 2012].
The majority of the studies on PINK1 subcellular distribution have been done in
over-expressing systems. This is because the expression of endogenous PINK1 is low and
subjected to a rapid turn-over under basal conditions, and to the lack of sensitive anti-
PINK1 antibodies [Lin and Kang, 2008, 2010; Narendra et al., 2010]. Nevertheless, we
generated a monoclonal anti-PINK1 antibody [Berthier et al., 2011] able to recognise by
immunohistochemistry endogenous human PINK1 in normal and neoplastic tissues.
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7.2. Localisation of PINK1 within the cell and in tissues
In the majority of the tissues analysed, PINK1 showed a cytosolic punctate pattern,
characteristic of a mitocondrial protein. Together with PINK1 protein results, PINK1
mRNA expression studies revealed that PINK1 is widely expressed in normal human
tissues.
In our SH-SY5Y and MCF-7 cell models, PINK1 wt co-localises with mitochondrial
markers such as Mitotracker and TOM-20 (Figure 7.3), as other groups have described
[Silvestri et al., 2005; Gandhi et al., 2006; Muqit et al., 2006; Beilina et al., 2005; Pridgeon
et al., 2007; Weihofen et al., 2008; Marongiu et al., 2009]. In agreement with others sub-
fractionation studies, PINK1 FL and PINK1-∆1 are mostly localised in the mitochondrial
fraction in our SH-SY5Y over-expressing cells. Besides, the three PINK1 protein forms
(FL, ∆1 and ∆2) are also localised in the cytosolic fraction. In favour of the PINK1 par-
tial cytosolic localisation, endogenous protein has been recently localised in the cytosol,
through a mechanism involving cdc37/hsp90 and Parkin [Takatori et al., 2008; Weihofen
et al., 2008]. Also, cytosolic localisation of PINK1 come from its accumulation in the
cytosol under proteasome inhibition, its ubiquitination to be degraded by cytosolic pro-
teasome [Muqit et al., 2006; Tang et al., 2006], and its presence in cytosolic aggresomes
or Lewy bodies in brain samples from PD patients [Gandhi et al., 2006]. The nature and
consequences of this dual localisation is an open question, and suggests the existence of
different PINK1 functions, depending on its subcellular compartmentation and its inter-
action with substrates from mitochondria, such as TRAP1 or Htra2/omi, or from cytosol,
such as Parkin, Rictor or hsp90/cdc37.
The missense mutations analysed (including catalytically inactive and PD-linked mu-
tations) do not show any significant changes in localisation or in protein distribution
either by immunofluorescence or by subcellular fractionation (Figure 7.3), and corrobo-
rate studies done with other PINK1 mutations [Valente et al., 2004a; Silvestri et al., 2005;
Beilina et al., 2005; Petit et al., 2005; Muqit et al., 2006; Pridgeon et al., 2007; Wang et al.,
2007; Zhou et al., 2008b; Becker et al., 2012]. Therefore, the mitochondrial localisation,
import, processing and distribution of PINK1 in the cell do not seem to be affected by
catalytically inactive or PD-linked mutations in the protein, suggesting that changes in
PINK1 distribution alone do not explain PD pathology. Elucidation of how changes in
PINK1 localisation may affect PINK1 physiologic functions requires further studies.
C-terminal truncations of PINK1 localised more at the mitochondria, as we describe
here (Figure 7.3) and others have recently showed, and these mutations displayed higher
kinase activity than PINK1 wt [Becker et al., 2012]. Thus, in addition to the proposed
regulatory role of the C-terminal tail in PINK1 kinase activity [Silvestri et al., 2005;
Sim et al., 2006], it is possible that the compartmentation of PINK1 could modulate its
catalytic activity. In favour of this hypothesis, a study described that PINK1 accumulation
at the OMM upon CCCP treatment enhanced Parkin phosphorylation and PINK1 auto-
phosphorylation [Kondapalli et al., 2012].
Different deletions of the N-terminus of PINK1 are localised almost totally in the cy-
tosolic area, but associated to the mitochondria [Weihofen et al., 2009]. In our analysis, we
confirmed that PINK1 ∆N (without MLS and TM) is mainly in the cytosolic fraction but
it is still associated to the mitochondria (Figure 7.3). We speculate that PINK1 lacking
the N-terminal tail can associate to other proteins and be recruited to the mitochondria
by an MLS-independent import This accounts for the control of mitochondrial antero-
grade transport by complex Miro/Milton, which can bind N-terminal deleted PINK1 and
localises it to the mitochondria [Weihofen et al., 2009; Liu et al., 2012; Wang et al., 2012].
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Figure 7.3: Localisation of PINK1 wt, mutations and truncations under
basal and uncoupling-mitochondrial conditions. PINK1 wt and missense mu-
tations are distributed between mitochondria and cytosol compartments under basal
conditions. Dissipation of mitochondrial membrane potential leads to the mitochon-
drial accumulation of PINK1 wt and, at a lesser extent, missense mutations. The
C-terminal truncations are distributed like PINK1 wt (but more mitochondrial) un-
der basal conditions, while the N-terminal truncations are mostly localised in the
cytosol. Both truncations localise to the mitochondria after long term dissipation of
mitochondrial membrane potential, but with no increase in PINK1 protein levels.
PINK1 full length is processed in its N-terminus to generated PINK1-∆1 [Deas et al.,
2010; Becker et al., 2012; Jin et al., 2010]. Our results demostrate that the ratio and the
existence of PINK1 FL and PINK1-∆1 is unaffected in PINK1 missense and C-terminal
truncated mutations. One point to highlight regarding ∆N and ∆N-C is the detection of
two bands by immunoblot with the same intensity (Figure 4.2, 5.1, contrary to previous
reports showing one band in ∆N [Lin and Kang, 2010; Matsuda et al., 2010; Becker et al.,
2012]. We postulate that the second band (lower migrating band) could be a degradation
product or likely, due to the same intensity, another PINK1 cleavage product. Further
experiments are required to test these hypothesis.
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Recently, it has been reported that PINK1 FL is stabilised at the OMM, facing the cy-
tosol, upon depolarised mitochondria by CCCP or valinomycin treatment [Narendra et al.,
2010]. At this regard, in our SH-SY5Y model, PINK1 FL localised to the mitochondria
at short CCCP treatment times. The missense mutations, which showed mitochondrial
location defects at short CCCP treatment times, localised to the mitochondria at long
CCCP tteatment times. In addition, the deletion of N- or C-terminal parts of PINK1
impaired the mitochondrial localisation induced by CCCP at short times, but not at long
times (Figure 7.3). It is possible that PINK1 kinase activity, and integrity of the N-
and C-terminal portions, are needed to facilitate the import of PINK1 and its location in
the OMM upon uncoupling mitochondrial conditions. Furthermore, PINK1 localisation at
OMM at short times of mitochondrial uncoupling could be important for the downstream
activating pathways, which is disrupted in the PINK1 mutations.
7.3 Role of PINK1 in mitochondrial function and
mitophagy
7.3.1 PINK1 regulates mitochondrial function
Mitochondria are important mediators of generation of ATP and energy to the cell. PINK1
deficiency leads to mitochondrial dysfunction, impairment in complex I function, decrease
in mtDNA, as well as enhanced oxidative stress in neuronal cell, in flies and mice, which
is believed to contribute to PD pathology [Gandhi et al., 2006; Wang et al., 2006; Kitada
et al., 2007; Gegg et al., 2009].
We observed that the expression of PINK1 missense mutations and C-terminal trun-
cated mutations in neuroblastoma SH-SY5Y cells leads to a combined impairment of ATP
generation, decreased mitochondrial membrane potential and mitochondrial DNA, and
increase in ROS production, which is consistent with a deficit in the mitochondrial bioen-
ergetic function. Fibroblasts bearing PINK1 missense and C-terminal truncated mutations
showed decrease activity of complex I and IV [Gru¨newald et al., 2009; Piccoli et al., 2008;
Abramov et al., 2012]. However, our results in SH-SY5Y cells indicated that impairment
of ATP production was due to complexes II/III and IV, but not to complex I. This dis-
crepancy could be due to differences in the bionergetic status of the models used. PINK1
N-terminal deletion did not affect ATP production, supporting the notion that deletion of
PINK1 N-terminal tail does not affect mitochondria function.
The maintenance of ∆Ψm is mainly due to the activity of the mitochondrial elec-
tron transport chain complexes, which pump up protons through the inner mitochondria
membrane generating the proton electrochemical gradient. Indeed, in the majority of the
mutations analysed in this study, the decrease in ATP production is connected to a de-
crease in mitochondrial membrane potential (K219M, A168P, L347P, G309D, W437X and
∆C), as loss of PINK1 studies have already described. Moreover, as a result of the low-
ered activity of the oxidative phosphorylation complexes, the mitochondria switch from
the production of ATP to its consumption by ATP synthase in order to maintain their
mitochondrial membrane potential [Campanella et al., 2008]. This likely occurs in K219M
and C-terminal truncated mutations, where the maintenance of ∆Ψm is mediated by hy-
drolysis of ATP, as PINK1-deficiency studies have previously shown [Gandhi et al., 2006;
Abramov et al., 2012].
Several studies on ∆Ψm in other cell types, where different PINK1 missense PD-
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linked or kinase inactive mutations were over-expressed, showed no significant changes in
∆Ψm under basal conditions, whereas we detected the opposite in SH-SY5Y cells. This
discrepancy can be explained by the type of dye used, its concentration and the type of
analysis done, as saturating concentrations of ∆Ψm dye and FACS analysis can hide the
deleterious defects of ∆Ψm. In favour of this, we do not detect changes in ∆Ψm, analysed
by FACS with DiOC6(3), in MCF-7 cells. However, in our SH-SY5Y model, we study the
distribution of TMRM at low concentration and at single cell level as a more sensitive
method to analyse ∆Ψm [Perry et al., 2011].
The analysis of the mitochondrial morphology revealed that in the mutations with
low ∆Ψm and ATP production, the mitochondrial network was altered and mitochon-
dria were closer to the perinuclear area. Noticeably, PINK1 G309D, which did no show
changes in ∆Ψm, displayed swollen and more fragmented ring-like mitochondria network.
This reinforces the observations from fibroblasts that PINK1 G309D mutation produced
more drastic mitochondrial changes than other PINK1 mutations [Gru¨newald et al., 2009;
Exner et al., 2007]. Together, these data suggest that the PINK1 deficiency firstly caused
impairment in ATP and respiration, and secondly, changes in mitochondrial morphology
and collapsed ∆Ψm. In accordance with this, a study using PINK1-deficient MEFs showed
that the deficit of respiration produced the opening of the mPTP, and subsequently a de-
crease in ∆Ψm and calcium overload, that finally caused changes in the mitochondrial
network [Gautier et al., 2012]. In addition, Gandhi et al. revealed that neurons with
loss of PINK1 display enhanced sensitivity to the toxic effect of dopamine, with increased
mPTP permeability, respiratory chain impairment, and mitochondrial calcium overload
[Gandhi et al., 2012].
The amount and assembly of the respiration chain complexes in PINK1 mutations
seem to be correct [Gru¨newald et al., 2009; Liu et al., 2009]. Therefore, another possible
regulatory role of PINK1 on the oxidative phosphorylation could be the control of the
appropriate phosphorylation of the mitochondrial complex proteins, which is required for
the correct function of the electron transport chain [Liu et al., 2009]. At this regard, it
has been recently shown that the activation of mitochondrial PKA, which phosphorylates
complex I subunits, is sufficient to rescue mitochondrial dysfunction induced by PINK1
deletion [Dagda et al., 2011]. We speculate that PINK1 could be important to maintain
the phosphorylation status of the mitochondrial respiratory complexes.
The impairment in ATP production and the decrease in ∆Ψm favour the generation
of ROS in the cell. In our SH-SY5Y model, the oxidative stress induced by rotenone was
increased in the PINK1 mutations and C-terminal truncations. Furthermore, the genera-
tion of cROS in the mutations was associated to an increase in mitochondrial carbonylated
proteins and a decrease in antioxidant GSH capacity. The decrease in antioxidant capac-
ity of the mutations can be explained by GSH conversion into GS-SG due to increase
in ROS production. One mechanism explaining how PINK1 blocks the ROS production
induced by stress could be the new synthesis of detoxifying enzymes, such as glutathione
transferase and/or MnSOD [Hoepken et al., 2007]. Our study corroborates other reports
showing lipid damage and mtDNA decrease upon PINK1 mutation or silencing conditions
[Gegg et al., 2009; Hoepken et al., 2007], as well as previous studies reporting reduced
∆Ψm and elevated oxidative stress in PINK1 KD human dopaminergic neuron cultures
[Wood-Kaczmar et al., 2008], and reduced mitochondrial respiration and increased sensi-
titvity to oxidative stress in PINK1 KO mice and flies [Wang et al., 2006, 2007; Gautier
et al., 2012].
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Together, these observations reinforce the notion that PINK1 plays an important role
in the integrity of mitochondria function and oxidative metabolism (Figure 7.4).
Figure 7.4: PINK1 wt and ∆N, but not PINK1 missense and C-terminal
truncated mutations, control mitochondrial homeostasis. Over-expression of
PINK1 missense and C-terminal truncated mutations decrease ATP production, mi-
tochondrial membrane potential and mtDNA content, and increase ROS production,
whereas over-expression of PINK1 wt and ∆N maintain the physiologic mitochon-
drial ATP production and mitochondrial membrane potential, and block the ROS
production.
7.3.2 Mitophagy modulation by PINK1
Mitophagy activates selectively the clearance of damaged mitochondria [Twig et al., 2008;
Sandoval et al., 2008; Elmore et al., 2001], and PINK1, together with Parkin, has been
recently described to regulate this process [Narendra et al., 2008]. Several studies have
shown that PINK1 accumulates in the outer membrane of dysfunctional mitochondria,
recruits Parkin and facilitates the activation of its E3 ubiquitin ligase function. Parkin
is able to ubiquitinate other substrates and promotes the triggering of mitophagy [Dagda
et al., 2009; Narendra et al., 2010; Vives-Bauza et al., 2010b; Matsuda et al., 2010; Geisler
et al., 2010; Koh and Chung, 2011]. Moreover, PINK1 FL binds Beclin-1, a protein
involved in the main autophagy pathway [Michiorri et al., 2010].
In our study, we have found that PINK1 wt promotes autophagosome formation and
clearance of damaged mitochondria in SH-SY5Y upon mitochondrial uncoupling by CCCP
or starvation. Moreover, the CCCP treatment induces accumulation and association of
PINK1 FL to the mitochondria, and inhibition of its processing into PINK1-∆1 and
PINK1-∆2. Processing and mitochondrial import of PINK1 is dependent on mitochon-
drial membrane potential, and perhaps the dynamics of PINK1 processing and localisation
could determine its function in different processes and cell compartments. This idea could
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explain why PINK1 and its multiple cleavage forms are regulated and involved in different
functions depending on the cellular status.
Our results show that mutated PINK1 impaired the activation of autophagosome for-
mation and the consequent clearance of damaged mitochondria. The mitochondrial ac-
cumulation of PINK1 missense mutations was impaired only at short times of CCCP
treatment, suggesting a crucial role for PINK1 in early stages of mitophagy. Rapidly
after CCCP treatment, PINK1 FL wt recruits Parkin to the mitochondria and induces
its phosphorylation at Ser63, activating downstream pathways of mitophagy and survival
[Kondapalli et al., 2012]. In the case of the C-terminal truncations, the PINK1 mitochon-
drial accumulation occured at later times of CCCP treatment, and the protein levels were
lower. The N-terminal truncation showed late mitochondrial accumulation and unaffected
protein levels of PINK1 after CCCP treatment. At this regard, it has been documented
that some PINK1 mutations or truncations do not recruit Parkin to the mitochondria,
blocking mitophagy [Narendra et al., 2010; Becker et al., 2012].
The majority of the studies associating PINK1 to mitophagy have been done in an
induced-mitophagy system. However, it has been described that cultured cells silenced
for PINK1 can activate mitophagy under basal conditions to clear up the damaged mi-
tochondria prior to cell death [Chu, 2009]. We and others detect that PINK1 deficiency
or mutations lead to increased oxidative stress and fragmented mitochondria, which acti-
vates mitophagy [Narendra et al., 2008]. Nevertheless, our results show that missense or
truncated mutations of PINK1 do not increase the autophagosome formation at basal con-
ditions, compared to PINK1 wt. Further studies addressing the PINK1 role in autophagy
need to be done.
7.4 Role of PINK1 in apoptosis, tumourigenic and
proliferative processes in breast cancer
7.4.1 PINK1 as an anti-apoptotic protein in breast cancer cells
PINK1 is involved in the protection of the cell from a broad range of mitochondrial insults
and apoptotic inductors, including rotenone, 1-methyl-4-phenylpyridinium (MPP+) and
staurosporine [Valente et al., 2004a; Petit et al., 2005; Muqit et al., 2006; Tang et al., 2006;
Wang et al., 2007; Pridgeon et al., 2007; Chu, 2009; Tan, 2009; Kim and Son, 2010].
In our study using breast cancer cells over-expressing PINK1 wt, we show lack of
dissipation of ∆Ψm (an early event of apoptosis) and inhibition of cell death produced by
H2O2. PINK1 missense mutations and PINK1 deficiency in MCF-7 and MB-MDA-231
cells disrupted this anti-apoptotic role of PINK1, and cells displayed increased cell death
and depolarised mitochondria, as it has been shown in other cell systems [Valente et al.,
2004a; Wood-Kaczmar et al., 2008; Deng et al., 2005; Haque et al., 2012]. It is important
to note that MB-MDA-231 are more resistant to H2O2-induced cell death and induction
of mitochondrial depolarisation than MCF-7, perhaps due to the fact that MB-MDA-231
comes from of a more aggressive breast cancer tumour [Pozo-Guisado et al., 2002].
MCF-7 cells over-expressing the C-terminal truncations, but not those over-expressing
the N-terminal truncation, were more sensitive to cell death, when compared with PINK1
wt over-expressing cells, suggesting an important role for the PINK1 C-terminus in apop-
tosis [Silvestri et al., 2005; Petit et al., 2005]. Interestingly, PINK1 ∆N cells, lacking
the mitochondrial localization sequence, conserved the same anti-apoptotic function than
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PINK1 wt in MCF-7 cells, which has also been observed in other cell types [Haque et al.,
2008; Tan et al., 2009; Tan, 2009]. Nevertheless, Wang et al. reported that PINK1 lacking
the first 35 residues did not protect against apoptosis triggered by proteasome inhibition
[Wang et al., 2007].
Taking together, our results show that the blocking effect of PINK1 in mitochondrial-
induced apoptosis is not cell type-specific, and it is observed in non-neuronal cells. In
breast cancer and neuronal cells, the activation of the MAPKs p38, JNK and ERK1/2
by several mitochondrial stimuli is important for cell death/survival [Ruffels et al., 2004;
Newhouse et al., 2004; Deng et al., 2010]. PINK1 has been related to p38 and JNK
activation upon stress [Pridgeon et al., 2007; Plun-Favreau et al., 2007], and subsequently,
it modulates the activation of Htra2/omi as a cytoprotective role. This makes PINK1
a potential modulator or effector of MAPKs. Also, PINK1 phosphorylates TRAP1 and
Parkin upon stress conditions, and activates downstream pro-survival pathways, such as
the NF-κβ pathway [Sha et al., 2010]. Thus, PINK1 may exert its anti-apoptotic role
acting on different pathways and molecular effectors (Figure 7.6).
7.4.2 PINK1 mediated invasion, colony formation, proliferation and
cell cycle progression
Cancer is a complex disease where cells divide uncontrollably, missing out the cell cycle
checkpoints and invading the surrounding tissue. PINK1 expression is altered in tumours
but PINK1 role in tumourigenicity is unknown [Nakajima et al., 2003; Unoki and Naka-
mura, 2001; Berthier et al., 2011; Fragoso et al., 2011]. In our study, we have characterised
for the first time the role of PINK1 in tumourigenic processes in breast cancer cells, in-
cluding adhesion, invasion, colony formation, proliferation and cell cycle progression.
Our results demonstrate that PINK1 wt does not affect the adhesion capacities of
MCF-7 cells to different matrix substrates, but decrease their invasion and the number
and size of colonies formed in soft agar. This reduction in the number and size of colonies
could indicate inhibition of the most highly proliferating cells and/or presence of more
differentiated cells. At this regard, the morphology of PINK1 wt over-expressing MCF-7
cells is more spread out, differentiated-like, compared to control cells (data not shown).
On the other hand, cell lines over-expressing PINK1 mutations presented higher number
of colonies than control cells, suggesting an increase in tumourigenic properties with more
proliferating and/or less differentiated cells, which could be due to a dominant negative
effect over the endogenous PINK1 [Tan, 2009; Kawajiri et al., 2011]. This suggests a role
for PINK1 in cell differentiation and blockage of cell division. In line with this possibility,
it has been described that PINK1 is up-regulated and required for neuron differentiation
[Wood-Kaczmar et al., 2008] [unpublished data].
The analysis of invasion also suggests that PINK1 wt negatively regulates tumouri-
genic properties, since cell invasion was lower in PINK1 wt over-expressing cells than in
control cells. Consequently, cells over-expressing PINK1 PD-linked mutations (A168P,
G309D and L347P) presented higher increase invasion rate. The PINK1 truncated muta-
tions showed invasion values similar to control cells. PINK1 L347P over-expressing cells
displayed increased invasion and decreased colony formation. This could be explained be-
cause L347P is a destabilising mutation with normal kinase activity [Beilina et al., 2005].
It is possible that the amount of PINK1 could determine differential regulation of these
two processes
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PINK1 wt and PINK1 G309D over-expressing SH-SY5Y cells display increased cell
motility through Matrigel-coated membrane, which dependent on pro-survival Akt/mTOR2
activation [Murata et al., 2011a]. This partial discrepancy with our results could be due
to the differents assays performed in the two studies or to the existence of different PINK1
functions depending on the cell type.
MCF-7 cells over-expressing PINK1 wt showed decreased proliferation, blockage in
cell cycle progression, and diminished expression of cyclins. The inhibition in cell cycle
progression was not due to a complete growth arrest because cells with over-expressing
PINK1 wt still proliferated, although at lower levels. PINK1 could either lengthen G0/G1
transition time or cause arrest in late G0/G1 or S phases. On the other hand, PINK1
G309D over-expressing cells increased cell cycle progression and increase cyclin D and A
expression. The activation of cyclin D is essential for cell cycle progression and increased
levels of cyclin D have been associated to tumourigenic processes in breast cancer [Zwijsen
et al., 1998; Dufourny et al., 2000; Laman et al., 2005; Kehn et al., 2007; Tashiro et al.,
2007]. This points out for a putative role of PINK1 mutations in the progression of cancer.
Further studies will be needed to test this hypothesis.
In other ways, PINK1 can exert its anti-proliferative role through the association
to related proteins like PTEN, which up-regulates PINK1 levels, and it can modulated
the PINK1 function in the cell. It has been described that PTEN prevents spreading,
migration on extracellular matrix proteins and invasion, wchich leads to G1 arrest in
glioma, breast, endometrial and prostate cancer cells [Yamada and Araki, 2001; Kim
et al., 2005; Kim and Mak, 2006]. The mechanism of PTEN cell cycle arrest is dependent
on down-regulating PKB/Akt pathway which increase forkead transcription factors (like
FOXO3a), glycogen synthase kinase and decreased levels of cyclin D [Maehama et al.,
2001]. This process can be link to increase of PINK1 mRNA levels. Moreover, the function
of PTEN is affected by the oncogenic role of cytoplasmic p27 protein and is dependent on
the cellular compartement, nucleus versus cytosol [Andre´s-Pons et al., 2011].
PTEN, apart from its tumour-suppressor role, positively regulates apoptosis, inducing
cell death and inhibit mTOR inducing autophagy. Our results showed that PINK1 plays
as anti-apoptotic and autophagy induction protein so PTEN and PINK1 can have some
linked functions but not other. The relation between them, far from expression is unclear
so further experiments need to be done.
The expression of Parkin is diminished or absent in breast and ovarian cancer [Cesari
et al., 2003]. Recently, Parkin has been proposed as a tumour-suppressor protein that
decreases cancer progression as well as the levels of cyclin E in MCF-7 cells by inducing
the ubiquitination and subsequent degradation [Tay et al., 2010]. Therefore, PINK1 anti-
proliferative or tumour-suppressor activity could be mediated through Parkin. suppression
capacity.
The results reported here suggest that PINK1 functions as an anti-proliferative protein,
blocking the G0/G1-S phases transition and modulating directly or indirectly cyclins and
inhibitors of the cell cycle. It is important to keep in mind that PINK1 is a kinase (or
a pseudokinase) and phosphorylation is very important in controlling cell cycle [Pogson
et al., 2011; Koh and Chung, 2012].
How PINK1 regulates cell cycle and proliferation is only beginning to be unveiled. For
instance, the expression of Parkin is diminished or absent in breast and ovarian cancer
[Cesari et al., 2003]. Recently, Parkin has been proposed as a tumour-suppressor protein
that decreases cancer progression as well as the levels of cyclin E in MCF-7 cells [Tay
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et al., 2010]. Therefore, PINK1 anti-proliferative or tumour-suppressor activity could be
mediated through Parkin. Next frontiers lie in how PINK1 protein and its different binding
partners can exert different functions in several compartments as mitochondria, cytosol,
and, perhaps, nucleus.
7.5 Expression of PD genes/mRNA in breast cancer
tissues
We have found that PINK1 is widely expressed in normal human tissues, suggesting that
its function is not limited to the nervous system [Berthier et al., 2011]. The mRNA levels
of PINK1 have been found to be over-expressed in different cancers with high metastatic
potential, as well as in cells forced to express ectopically the PTEN tumour suppressor,
making possible the involvement of PINK1 in the unbalanced cell growth- or apoptotic-
processes of cancer. In our study, we detected up-regulation of PINK1 mRNA levels
in breast cancer compared to control breast. Moreover, we detected that the subcellu-
lar distribution of PINK1 in breast tumours change from punctate cytoplasmic to more
membranous localisation. This suggests that PINK1 expression levels and subcellular dis-
tribution could be associated to breast cancer progression. Together with PINK1, other
PD-associated genes have been linked to cancer. Our analysis concluded that mRNA
expression of Htra2/omi, ATP13A2, LRRK2, GBA, DJ-1 and TRAP1 is up-regulated
in breast tumours whereas mRNA expression of PTEN and SNCAIP is down-regulated
(Figure 7.5). Moreover, the high expression of PINK1 in some of the tumours was associ-
ated with high expression of Htra2/omi, ATP13A2, GBA, DJ-1 and TRAP1. Interestingly,
it has been described that breast cancer patients have elevated levels of serum DJ-1 and
circulating anti-DJ-1 auto-antibodies, compared to healthy and non-breast cancer patients
[Le Naour et al., 2001]. Together, these findings suggest the existence of a network of PD-
related protein interactions that could be relevant in breast cancer. Further studies are
required to ascertain if over-expression of PINK1 or other PD-related proteins correlates
with breast cancer subtypes or with response to breast cancer therapies.
In favour to the relationship between PD genes expression in cancer progression, it
has been described common determinants to both diseases, such as mitochondrial DNA
mutations and complex I deficiency [Plak et al., 2008]. The mitochondrial bioenergetic
metabolism has been widely linked to both diseases. In addition, mitochondria dysfunction
has been implicated in carcinogenesis since the 1930s where Otto Wanburg suggested that
“respiration damage” is a pivotal feature of cancer cells [Wallace, 2005; Gogvadze et al.,
2008] and in PD pathogenesis [Schapira et al., 1990; Schapira, 2008]. The bioenergetic
metabolism is important for both diseases and our results contributed to this thought
where PD-linked genes could be associated to breast cancer. Furthermore, decrease in
autophagy/mitophagy and fail in ubiquitin-proteasome system have been documented in
both diseases [McNaught et al., 2001; Mitchell, 2003; Cuervo, 2004].
105
Chapter 7. Discussion
Figure 7.5: PINK1, PINK1-related genes and their linkage expression in
breast cancer samples. PINK1-related genes provided by STRING software and
by reported functional association. The up-regulation of PINK1 in breast cancer
samples is associated with up-regulation of Htra2/omi, ATP13A2, DJ-1, GBA and
TRAP1 genes associated to PD and protein quality control. Modified from http:
//string-db.org/.
7.6 PINK1: an anti-apoptotic and anti-proliferative
protein
From our analysis, we propose that PINK1 has several functions and mainly working as an
anti-apoptotic protein under certain stress situations and as an anti-proliferative protein in
breast cancer progression, regulating important processes involved or associated to cancer
and PD pathogenesis Figure 7.6.
PINK1 function is associated to mitochondria homeostasis and integrity. Mitochondria
integrity and mitochondria, play an important role in regulating both apoptosis and cell
proliferation. Small and fragmented mitochondria, together with changes in mitochondrial
density and distribution, have been associated to cancer processes, and inhibition of fission
prevents the cell cycle progression in lung cancer [Olichon et al., 2006; Rehman et al., 2012].
Alterations in oxidative phosphorylation and increase in oxidative stress, resulting from
mitochondrial dysfunction, have long been hypothesised to be involved in tumourigenesis.
Specifically, it has been postulated that the switch in ATP production from mitochon-
drial oxidative phosphorylation to glycolysis is one of the characteristics of cancer cells,
a process known as the “Warburg effect” [Wallace, 2005]. Remarkably. PINK1 KO mice
present increased glycolisis [Yao et al., 2011]. More recently, it has been reported that
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mitochondrial respiratory complex I dysfunction promotes tumourigenesis through ROS
alteration and AKT activation [Sharma et al., 2011]. Our data corroborates that mi-
tochondrial dysfunction and increase in oxidative stress, showed in cells over-expressing
PINK1 PD-linked mutations, could be associated to tumourigenic progression (Figure
7.6).
PINK1 has been associated to Beclin-1-inducted autophagy and Beclin-1 activity is
controlled by Bcl-2 activity. Bcl-2 and Beclin-1 has been associated to proliferation and
cell death. Low levels of Bcl-2 correlates with poor prognosis in patients with breast
cancer [Chang et al., 2003] and increase in cell growth in MCF-7 cells [Oh et al., 2010],
inversely Bcl-2 expression correlates with low proliferation index and favourable prognosis
[Friedrich et al., 1995; Luna-More et al., 1996]. Beclin-1 down-regulation leads to bad
prognosis in cancer [Mutee et al., 2009]. Therefore, PINK1 can mediate its anti-apoptotic
and anti-proliferative functions through Bcl-2 and/or Beclin-1 [Clarke et al., 2011].
Together, all our results prompt PINK1 as a new modulator controlling important
pathways involved in the progression of PD and cancer. PINK1 can control pro-survival
mechanism against mitochondria-mediated apoptosis by keeping the integrity of mitochon-
dria, and can block the uncontrolled division of cancer cells. PINK1 impedes neuronal
cell death, blocks abnormal entry into the cell cycle, and inhibits excessive proliferation.
The analysis of PINK1 mutations can provide new evidences on a positive link between
cancer and PD. In this line, it has been documented that PD patients have increased risk
of breast cancer [Mo¨ller et al., 1995; Minami et al., 2000; Olsen et al., 2004, 2006; Lo
et al., 2010], and we have described here that MCF-7 breast cancer cells over-expressing
a PD-linked PINK1 mutation show increased cell death and apoptosis, proliferation and
abnormal entry into the cell cycle.
The fact that PINK1 functions as an anti-apoptotic and anti-proliferative protein is
not an unique example of a protein with opposite functions (Figure 7.6). The Bcl-2
protein is known to have dual anti-proliferative and anti-apoptotic roles depending upon
cellular and developmental context [Borner, 1996]. Besides, the transcription factor FHL2
exhibits anti-proliferative and anti-apoptotic activities in liver cancer cells [Ng et al., 2011].
Retinoblastome (Rb) regulates tumour suppression and anti-apoptotic function [Ma et al.,
2003]. In these cases, the phosphorylation status, the protein levels, the subcellular local-
isation, as well as the association to other proteins may trigger one function or the other.
Remarkably, PINK1 is a short life Ser/Thr kinase protein which levels are regulated by
uncoupling agents and oxidative stress and is associated to different proteins localised in is
associated to different proteins localised in distinct cellular compartments. Further studies
need to be done to understand how these regulatory processes may drive the dual function
of PINK1 in physiology and human disease (Figure 7.6).
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Figure 7.6: PINK1 as anti-apoptotic and anti-proliferative protein. PINK1
responds to stress signals that activates MAPKs and AKT pathways are activates
the mitochondrial homeostasis. PINK1 inhibits apoptosis and controls the ATP pro-
duction, the ∆Ψm, the ROS production and the mtDNA content. PINK1 exerts
its anti-apoptotic function interacting and controlling the phosphorylation status of
TRAP1, Htra2/omi and Rictor, which subsequently activates pro-survival genes and
controls the protein misfolding. Upon mitochondrial depolarization, PINK1 binds
and phosphorylates Parkin, and together with Beclin-1, activates mitophagy and the
clearance of damaged mitochondria. Black lines: phosphorylation processes; Dash
grey line: associated documented processes; Pink line: PINK1 processes described in
this study.
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Conclusions
1. PINK1 localises between mitochondria and cytosol compartments under basal con-
ditions. PD-linked and catalytic inactive missense mutations do not show changes
in subcellular localisation, whereas PINK1 C-terminal truncations are slightly more
mitochondrial, and PINK1 N-terminal truncations are mainly cytosolic.
2. PINK1 wt, but not missense mutations or truncations, accumulates at the mito-
chondria upon mitochondrial-uncoupling CCCP treatment.
3. PINK1 missense mutations and C-terminal truncations lead to mitochondrial dys-
functions in neuroblastoma cells, with ATP production impairment, decrease in mi-
tochondrial membrane potential, increase oxidative stress and decrease mtDNA con-
tent.
4. PINK1 wt, but not PINK1 missense mutations or truncations, increases the protein
levels of the autophagosome marker LC3-II, and decreases mitochondrial content.
5. PINK1-mediated mitophagy required accumulation and stabilisation of the PINK1
protein at the mitochondria, which is disrupted in PINK1 missense or truncated
mutations.
6. PINK1 wt and N-terminal truncation (∆N), but not PINK1 missense mutations or
C-terminal truncations, protect against mitochondrial-mediated apoptosis trigerred
by H2O2.
7. PINK1 wt and the N-terminal truncation ∆N, but not PINK1 mutations or C-
terminal truncations, inhibit the colony formation capacity and invasion of breast
cancer cells. The PINK1 L347P mutation inhibits colony formation and increases
invasion.
8. PINK1 wt, but not the PD-linked mutation G309D, decreases proliferation and
delays cell cycle progression at G0/G1-S phase of breast cancer cells.
9. PINK1 protein and mRNA are widely expressed in human normal tissue, and PINK1
expression is altered in neoplastic tissues.
10. PINK1 mRNA, together with other PD-linked genes or related partners, is up-
regulated in breast cancer tumours.
11. PINK1 is a pivotal protein controlling mitochondrial homeostasis, as well as survival,
proliferation and cell death. PINK1 mutations impair these processes, which may
be linked to cancer and PD pathogenesis.
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Conclusiones
1. PINK1 se localiza en condiciones basales en la mitocondria y el citosol. PINK1
cataliticamente inactivo y las mutaciones asociadas a PD no muestran cambios en la
localizacio´n subcelular, mientras las formas C-terminales truncadas de PINK1 son
ligeramente ma´s mitocondriales, y las formas N-terminales truncadas de PINK1 son
principalmente citoso´licas.
2. PINK1 wt, pero no las mutaciones con cambio de aminoa´cido o las formas truncadas,
se acumula en la mitocondria tras el tratamiento de desacoplamiento mitocondrial
con CCCP.
3. Las mutaciones de cambio de aminoa´cido y las formas C-terminales truncadas de
PINK1 producen disfuncio´n mitocondrial en ce´lulas de neuroblastoma, con desreg-
ulacio´n en la produccio´n de ATP, disminucio´n del potencial de membrana mitocon-
drial, incremento de estre´s oxidativo y disminucio´n del contenido de mtDNA.
4. PINK1 wt, pero no las mutaciones de cambio de aminoa´cido o las formas truncadas,
aumenta los niveles de la prote´ına marcadora de autofagosomas LC3-II, y disminuye
el contenido mitocondrial.
5. La mitofagia mediada por PINK1 requiere acumulacio´n y estabilizacio´n de la prote´ına
en la mitocondria, lo cual esta´ afectado en las mutaciones y las formas truncadas de
PINK1.
6. PINK1 wt y la forma N-terminal truncada (∆N), pero no las mutaciones de cambio
de aminoa´cido o las formas C-terminales truncadas, protegen de la apoptosis mediada
por la mitocondria inducida por H2O2.
7. PINK1 wt y la truncacio´n N-terminal (∆N), pero no mutaciones de cambio de sen-
tido o truncaciones C-terminal, inhiben la capacidad de formacio´n de colonias y la
invasio´n de ce´lulas de ca´ncer de mama. La mutacio´n L347P inhibe la formacio´n de
colonias e incrementa la invasio´n.
8. PINK1 wt, pero no la mutacio´n asociada a PD G309D, disminuye la proliferacio´n y
retrasa la progresio´n del ciclo celular en fase G0/G1-S en ce´lulas de ca´ncer de mama.
9. El mRNA y la prote´ına de PINK1 esta´n ampliamente expresados en te´jidos normales
humanos, y la expresio´n de PINK1 se encuentra alterada en te´jidos neopla´sicos.
10. La expresio´n del mRNA de PINK1, junto con la expresio´n de otros genes asociados
con PD o prote´ınas relacionadas, esta´ aumentada en tumores de ca´ncer de mama.
111
Chapter 8. Conclusions
11. PINK1 es una prote´ına central que controla la homeostasis mitocondrial, asi como
supervivencia, proliferacio´n y muerte celular. Las mutaciones de PINK1 afectan
estos procesos, lo que podr´ıa estar asociado con la patoge´nesis del ca´ncer y PD.
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Table 8.2: Mutations identified in PINK1 gene.
PINK1
mutation
Exon
Protein
Domain
Mutation
type
Patient
origin
References
Complete gene
delPINK1
1-8
Complete
protein
Deletion Italian Marongiu et al., 2007
Splice variant
affecting exon 7
and 8
7-8
Kinase and
C-terminus
Deletion Italian Marongiu et al., 2007
ex3-8del
(breakpoints
not mapped)
ex3-8del
Kinase and
C-terminus
Deletion Chinese Nuytemans et al., 2010
ex4-8del
(breakpoints
not mapped)
ex4-8del
Kinase and
C-terminus
Deletion Sudanese Cazeneuve et al., 2009
ex6-8del
(breakpoints
not mapped)
ex6-8del
Kinase and
C-terminus
Deletion Japanese
Li et al., 2005; Atsumi
et al., 2006
ex7del (g.170750-
171044del295)
ex7del Kinase Deletion Spanish Samaranch et al., 2010
ex7del
(breakpoints
not mapped)
ex7del Kinase Deletion Brazilian Camargos et al., 2009
c.-82G>A
(g.155274G>A)
5’UTR — Missense Italian Bonifati et al., 2005
c.-21G>A
(g.155335G>A)
5’UTR — Missense Italian Klein et al., 2005
c.-20C>T
(g.155336C>T)
5’UTR — Missense Italian Bonifati et al., 2005
Lys24fs
(g.155425-
155456del32)
EX1
N-terminus
(Transit)
Frameshift French Ibanez et al., 2006
Gly32Arg
(g.155449G>A)
EX1
N-terminus
(Transit)
Missense Korean Choi et al., 2008
Pro52Leu
(g.155510C>T)
EX1
N-terminus
(Transit)
Missense American Brooks et al., 2009
Arg58Val59 ins-
GlyArg
EX1
N-terminus
(Transit)
Frameshift Japanese Funayama et al., 2008
Leu63
(g.155544C>T)
EX1
N-terminus
(Transit)
Synonymous Caucasian
Valente et al., 2004b;
Groen et al., 2004; Schlit-
ter et al., 2005
Leu67Phe
(g.155554C>T)
EX1
N-terminus
(Transit)
Missense Italian Marongiu et al., 2008
Continued on Next Page. . .
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PINK1
mutation
Exon
Protein
Domain
Mutation
type
Patient
origin
References
Arg68Pro
(g.15558-
15559GC>CT)
EX1
N-terminus
(Transit)
Missense Italian
Valente et al., 2004b;
Marongiu et al., 2008
Ala78Val
(g.155588C>T)
EX1
N-terminus
(L1)
Missense Japanese Kumazawa et al., 2008
Cys92Phe
(g.155630G>T)
EX1
N-terminus
(L1)
Missense Italian Valente et al., 2004b
Arg98Trp
(g.155647C>T)
EX1
N-terminus
(TM)
Missense Italian Marongiu et al., 2008
Ile111Ser
(g.155687T>G)
EX1
N-terminus
(L2)
Missense Italian Marongiu et al., 2008
Gln115Leu
(g.155699A>T)
EX1
N-terminus
(L2)
Missense Italian
Bonifati et al., 2005;
Schlitter et al., 2005; Ishi-
hara Paul et al., 2008
Ala124Val
(g.155726C>T)
EX1
N-terminus
(L2)
Missense Italian Marongiu et al., 2008
Cys125Gly
(g.155728T>G)
EX1
N-terminus
(L2)
Missense Italian Ibanez et al., 2006
Gln126Pro
(g.155732A>C)
EX1
N-terminus
(L2)
Missense German Prestel et al., 2008
Gln129fs
(g.155740delC)
EX1
N-terminus
(L2)
Frameshift Tunisian Ishihara Paul et al., 2008
Gln129Stop
(g.155740C>T)
EX1
N-terminus
(L2)
Nonsense Tunisian Ishihara Paul et al., 2008
IVS1+14G>A
(g.155756G>A)
IVS1 — Insertion Indian Biswas et al., 2010
IVS1-7A>G
(g.159642A>G)
IVS1 — Insertion Italian Valente et al., 2004b
Thr145Met
(g.159695C>T)
EX2
N-terminus
(L2)
Missense Italian
Marongiu et al., 2008;
Ishihara Paul et al., 2008
Arg147His
(g.159701G>A)
EX2
N-terminus
(L2)
Missense Irish Healy et al., 2004
Arg152Trp
(g.159715C>T)
EX2
N-terminus
(L2)
Missense Italian Ishihara Paul et al., 2008
Ala168Pro
(g.159763G>C)
EX2 Kinase Missense Italian
Valente et al., 2004b;
Bonifati et al., 2005
Val170Gly
(g.159770T>G)
EX2 Kinase Missense Norwegian Toft et al., 2007
Pro179
(g.159798C>T)
EX2 Kinase Missense Indian Biswas et al., 2010
Lys186Asn
(g.159819G>C)
EX2 Kinase Missense Serbian
Djarmati et al., 2006;
Marongiu et al., 2008
Gly189
(g.159828G>A)
EX2 Kinase Missense American Brooks et al., 2009
Gly193Arg
(g.159838G>A)
EX2 Kinase Missense Taiwanese Weng et al., 2007
Pro196fs
(g.159848delC)
EX2 Kinase Frameshift Japanese Kumazawa et al., 2008
Pro196Leu
(g.159848C>T)
EX2 Kinase Missense Italian Bonifati et al., 2005
Gly197
(g.159852T>C)
EX2 Kinase Missense Indian Biswas et al., 2010
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Pro209Ala
(g.159886C>G)
EX2 Kinase Missense Taiwanese Lee et al., 2009
Pro209Leu
(g.159887G>T)
EX2 Kinase Missense Serbian Djarmati et al., 2006
Pro209Pro
(g.159887G>A)
EX2 Kinase Missense — Devine et al., 2011
Pro215Leu
(g.159904C>T)
EX2 Kinase Missense — Devine et al., 2011
Ala217Asp
(g.159911C>A)
EX2 Kinase Missense Sudanese Leutenegger et al., 2006
Gly227Arg
(g.161702G>C)
EX3 Kinase Missense Tunisian Ishihara Paul et al., 2008
Glu231Gly
(g.161715A>G)
EX3 Kinase Missense
North
American
Rogaeva et al., 2004
Asn235Ile
(g.161727A>T)
EX3 Kinase Missense
North
American
Rogaeva et al., 2004
Thr236
(g.161731A>C)
EX3 Kinase Synonymous
North
American
Rogaeva et al., 2004
Met237Val
(g.161732A>G)
EX3 Kinase Missense Dutch Macedo et al., 2009
Glu239Stop
(g.161738C>T)
EX3 Kinase Nonsense Taiwanese
Hatano et al., 2004; Weng
et al., 2007
Glu240Lys
(g.161741G>A)
EX3 Kinase Missense
North
American
Rogaeva et al., 2004;
Ibanez et al., 2006
Ala244Gly
(g.161754C>G)
EX3 Kinase Missense Italian Gelmetti et al., 2008
Arg246Stop
(g.161759C>T)
EX3 Kinase Nonsense Taiwanese
Hatano et al., 2004; Tan
et al., 2006; Ephraty
et al., 2007
Arg246Gln
(g.161760G>A)
EX3 Kinase Missense Indian Biswas et al., 2010
Thr257Ile
(g.161793C>T)
EX3 Kinase Missense Italian Marongiu et al., 2008
Tyr258Stop
(g.161797C>A)
EX3 Kinase Nonsense Asian
Tan et al., 2006; Keyser
et al., 2010
Arg263Gly
(g.166307A>G)
EX4 Kinase Missense
North
American
Rogaeva et al., 2004
Leu268Val
(g.166322C>G)
EX4 Kinase Missense Asian
Tan et al., 2005;
Marongiu et al., 2008
Leu268
(g.166324A>G)
EX4 Kinase Missense Taiwanese Weng et al., 2007
His271Gln
(g.166333C>A)
EX4 Kinase Missense Japanese Hatano et al., 2004
Arg276Gln
(g.166347G>A)
EX4 Kinase Missense Asian
Marongiu et al., 2008;
Biswas et al., 2010
Leu278Val
(g.166352C>G)
EX4 Kinase Missense Chinese Guo et al., 2010
Arg279His
(g.166356G>A)
EX4 Kinase Missense Italian
Klein et al., 2005; Choi
et al., 2008
Arg279
(g.166357C>T)
EX4 Kinase Synonymous Norwegian Toft et al., 2007
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Ala280Thr
(g.166358G>A)
EX4 Kinase Missense Taiwanese Tan et al., 2006
Thr282
(g.166366C>G)
EX4 Kinase Synonymous Indian Biswas et al., 2010
Ser284
(g.166372C>T)
EX4 Kinase Synonymous Italian Bonifati et al., 2005
Val293
(g.166399C>A)
EX4 Kinase Missense Brazilian
Godeiro-Junior et al.,
2009
Pro296Leu
(g.166407C>T)
EX4 Kinase Missense Italian
Valente et al., 2004b;
Marongiu et al., 2008
Pro296
(g.166408T>G)
EX4 Kinase Synonymous
North
American
Rogaeva et al., 2004
Asp297fs
(g.166409delG)
EX4 Kinase Frameshift Japanese Kumazawa et al., 2008
Pro305Leu
(g.166434C>T)
EX4 Kinase Missense Irish Healy et al., 2004
Gly309Asp
(g.166446G>A)
EX4 Kinase Missense Spanish Valente et al., 2004a
Arg312
(g.166456G>A)
EX4 Kinase Synonymous Italian Valente et al., 2004b
Thr313Met
(g.116458C>T)
EX4 Kinase Missense Asian
Chishti et al., 2006; Ku-
mazawa et al., 2008; Guo
et al., 2008
Leu316
(g.166468C>T)
EX4 Kinase Synonymous
North
American
Rogaeva et al., 2004
Val317Ile
(g.166469G>A)
EX4 Kinase Missense Caucasian
Abou-Sleiman et al.,
2006; Marongiu et al.,
2008; Gelmetti et al.,
2008
Met318Leu
(g.166472A>T)
EX4 Kinase Missense
North
American
Rogaeva et al., 2004;
Djarmati et al., 2006;
Brooks et al., 2009
IVS4-5G>A
(g.167362G>A)
IVS4 — Insertion Italian
Valente et al., 2004a,b;
Schlitter et al., 2005;
Godeiro-Junior et al.,
2009
Pro322Leu
(g.167372C>T)
EX5 Kinase Missense Italian Marongiu et al., 2008
Arg337
(g.167418C>T)
EX5 Kinase Synonymous American Brooks et al., 2009
Ala339Thr
(g.167422G>A)
EX5 Kinase Missense
North
American
Rogaeva et al., 2004;
Abou-Sleiman et al.,
2006; Marongiu et al.,
2008
Ala340Thr
(g.167425G>A)
EX5 Kinase Missense Italian
Valente et al., 2004b;
Groen et al., 2004
Met341Ile
(g.167430G>A)
EX5 Kinase Missense Taiwanese Lee et al., 2009
Met342Val
(g.167431A>G)
EX5 Kinase Missense Japanese Kumazawa et al., 2008
Met342Ile
(g.167433G>A)
EX5 Kinase Missense Chinese Nuytemans et al., 2010
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Leu347Pro
(g.167447T>C)
EX5 Kinase Missense Filipino
Hatano et al., 2004; Ro-
gaeva et al., 2004
Gln355
(g.167472A>G)
EX5 Kinase Synonymous Italian Valente et al., 2004b
Asp362His
(g.167491G>C)
EX5 Kinase Missense
Noth
American
Rogaeva et al., 2004
Ser365
(g.167502C>T)
EX5 Kinase Synonymous Caucasian
Valente et al., 2004b;
Brooks et al., 2009
Asn367Ser
(g.167507A>G)
EX5 Kinase Missense Korean Choi et al., 2008
Leu369Pro
(g.167513T>C)
EX5 Kinase Missense French Ibanez et al., 2006
Ala383Thr
(g.170335G>A)
EX6 Kinase Missense Caucasian
Ibanez et al., 2006;
Abou-Sleiman et al.,
2006; Marongiu et al.,
2008
Phe385Leu
(g.170341T>C)
EX6 Kinase Missense Korean Choi et al., 2008
Gly386Ala
(g.170345G>C)
EX6 Kinase Missense French Ibanez et al., 2006
Cys388Arg
(g.170366T>C)
EX6 Kinase Missense Japanese
Li et al., 2005; Kumazawa
et al., 2008
Gly395Val
(g.170372G>T)
EX6 Kinase Missense Italian Marongiu et al., 2008
Asp391
(g.170377T>C)
EX6 Kinase Synonymous Caucasian
Rogaeva et al., 2004;
Myhre et al., 2008
Pro399Leu
(g.170384C>T)
EX6 Kinase Missense Chinese Tang et al., 2006
Tyr404
(g.170400C>T)
EX6 Kinase Synonymous Taiwanese Weng et al., 2007
Arg407Gln
(g.170408G>A)
EX6 Kinase Missense Asian
Fung et al., 2006; Guo
et al., 2010
Gly409Val
(g.170414G>T)
EX6 Kinase Missense French Ibanez et al., 2006
Asn410
(g.170418C>T)
EX6 Kinase Synonymous Brazilian
Godeiro-Junior et al.,
2009
Gly411Ser
(g.170419G>A)
EX6 Kinase Missense
Irish-
German
Abou-Sleiman et al.,
2006; Toft et al., 2007;
Brooks et al., 2009
Pro416Arg
(g.170435C>G)
EX6 Kinase Missense Jordanian Myhre et al., 2008
Glu417Gly
(g.170438A>G)
EX6 Kinase Missense Japanese Hatano et al., 2004
23bp del ex7
(g.170800-
170822del23)
EX7 Kinase Deletion Italian Marongiu et al., 2007
Ser419Pro
(g.170805T>C)
EX7 Kinase Missense Jordanian Myhre et al., 2008
Thr420
(g.170810G>A)
EX7 Kinase Synonymous American Brooks et al., 2009
Pro425Ser
(g.170823C>T)
EX7 Kinase Missense
North
American
Rogaeva et al., 2004
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Ala427Glu
(g.170830C>A)
EX7 Kinase Missense American Brooks et al., 2009
Tyr431His
(g.170841T>C)
EX7 Kinase Missense Caucasian Abou-Sleiman et al., 2006
Trp437Arg
(g.170859T>C)
EX7 Kinase Missense Turkish Kumazawa et al., 2008
Trp437Stop
(g.170861G>A)
EX7 Kinase Nonsense Italian
Valente et al., 2004a;
Bonifati et al., 2005
Gly440Glu
(g.170869G>A)
EX7 Kinase Missense Tunisian Ishihara Paul et al., 2008
Ile442Thr
(g.170875T>C)
EX7 Kinase Missense Italian Valente et al., 2004b
Asn451Ser
(g.170902A>G)
EX7 Kinase Missense Caucasian Abou-Sleiman et al., 2006
Tyr454
(g.170912C>T)
EX7 Kinase Synonymous Taiwanese Weng et al., 2007
Gln456Stop
(g.170932C>T)
EX7 Kinase Nonsense Italian Bonifati et al., 2005
Arg464His
(g.170941G>A)
EX7 Kinase Missense Italian Valente et al., 2004b
Glu476Lys
(g.170976G>A)
EX7 Kinase Missense Italian Valente et al., 2004b
Val482Met
(g.170994G>A)
EX7 Kinase Missense Japanese Kumazawa et al., 2008
Leu489Pro
(g.171016T>C)
EX7 Kinase Missense
North
American
Rogaeva et al., 2004
Arg492Stop
(g.171024C>T)
EX7 Kinase Nonsense Taiwanese Hatano et al., 2004
IVS7+1G>A
(g.171039G>A)
IVS7 — Insertion Spanish Samaranch et al., 2010
IVS7+14C>G
(g.171052C>G)
IVS7 — Insertion Italian Valente et al., 2004b
Pro498Leu
(g.172245C>T)
EX8 Kinase Missense Norwegian Toft et al., 2007
Lys520fs
(g.172309delG)
EX8 C-terminus Frameshift Korean Choi et al., 2008
Asn521Thr
(g.172314A>C)
EX8 C-terminus Missense Italian Valente et al., 2004b
Asp525Asn
(g.172325G>A)
EX8 C-terminus Missense Italian Valente et al., 2004b
Asp525fs
(g.172325-
172326insTTAG)
EX8 C-terminus Frameshift Italian Bonifati et al., 2005
534-535insQ
(g.172354-
172355insCAA)
EX8 C-terminus Insertion Italian Klein et al., 2005
Asp537Thr
(g.172361G>A)
EX8 C-terminus Missense Italian Marongiu et al., 2008
Asn542Ser
(g.172377A>G)
EX8 C-terminus Missense Japanese Kumazawa et al., 2008
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Cys549fs
(g.172399-
172402delTGTG)
EX8 C-terminus Frameshift French Ibanez et al., 2006
Cys575Arg
(g.172475T>C)
EX8 C-terminus Missense Caucasian Abou-Sleiman et al., 2006
Ser576
(g.172496A>G)
EX8 C-terminus Synonymous
North
American
Rogaeva et al., 2004
Stop582Leu
(g.172497G>T)
EX8 C-terminus Frameshift Norwegian Toft et al., 2007
c.*37T>A
(g.172535T>A)
3’UTR — —
North
American
Rogaeva et al., 2004;
Schlitter et al., 2005
c.*40G>A
(g.172538G>A)
3’UTR — —
North
American
Rogaeva et al., 2004;
Biswas et al., 2010
Data from Deas et al. and http://www.molgen.ua.ac.be Deas et al., 2009; Sobrido et al., 2012.
Putative signal peptide, Transit; N-terminus L1: after signal peptide and before TM;
N-terminus L2: after TM.

Publications
1. A. Berthier, S. Navarro, J. Jimenez-Sainz, I. Rogla, F. Ripoll, J. Cervera, and R. Pulido. Pink1
displays tissue-specific subcellular location and regulates apop- tosis and cell growth in breast cancer
cells. Hum Pathol, 42(1):75–87, 2011.
2. A. Berthier, J. Jime´nez-Sa´inz, and R. Pulido: PINK1 regulates histone H3 trimethylation and
gene expression by interaction with the polycomb protein EED/WAIT1. Submitted.
3. J. Jime´nez-Sa´inz, M. Gegg, A. Berthier, A. Abramov, M. Cooper, J-W. Taanman, R. Pulido,
A. Schapira: PINK1 kinase inactive and C-terminal truncation are important for maintenement of
mitochondrial function and mitophagy processes. Manuscript in preparation.
4. J. Jime´nez-Sa´inz, Berthier, R. Pulido: PINK1 functions as a tumor suppresor protein in breast
carcinoma cells. Manuscript in preparation.
151

Mon ocupation préférée.
Aimer.
Marcel Proust

